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Zusammenfassung
Bei entzu¨ndlichen Darmerkrankungen (inflammatory bowel disease, IBD) handelt es sich um eine Gruppe
chronischer, rezidivierender Krankheiten des Verdauungstraktes, die die Hauptformen Morbus Crohn
(Crohn’s disease, CD) und Colitis ulcerosa (ulcerative colitis, UC) umfasst. Als eine zunehmend ha¨ufige
Diagnose belastet IBD weltweit Gesellschaften und Gesundheitssysteme in erheblichem Maße. Nach wie vor
stellt die Diagnostik von IBD eine klinische Herausforderung dar und schließt die Bewertung zahlreicher
endoskopischer, histologischer, radiologischer und/oder biochemischer Parameter ein. Als Erga¨nzung des
diagnostischen Prozesses wurden zahlreiche Biomarker vorgeschlagen. Fu¨r die routinema¨ßige klinische Praxis
jedoch kann keiner dieser Biomarker empfohlen werden.
Bei microRNAs (miRNAs) handelt es sich um eine Klasse kurzer, nicht-kodierender RNAs, die als post-
transcriptionelle Regulatoren der Genexpression fungieren. Variabilita¨t innerhalb der miRNA-Biogenese
resultiert aus der alternativen Prozessierung unreifer (precursor cropping, precursor dicing), aber auch reifer
miRNAs (sequence editing, sequence trimming, nucleotide addition) und bringt miRNA-Isoformen (isomiRs)
hervor. Aufgrund ihrer bemerkenswerten Widerstandsfa¨higkeit gegenu¨ber physikalischer und enzymatischer
Degradation, wurden im Krankheitsfall deregulierte miRNAs als neuartige Biomarkers fu¨r eine Vielzahl von
Erkrankungen vorgeschlagen. Unter Verwendung globaler Expressionprofile sowie zeitgema¨ßer Methoden
des maschinellen Lernens, wird im Rahmen der vorliegenden Arbeit die Eignung dieser Moleku¨le als nicht-
invasives Werkzeug fu¨r die Diagnose von IBD evaluiert.
In einer ersten Studie verwendeten wir Microarraytechnologie zur Quantifizierung blutbasierter
Expressionslevel von 863 miRNAs, generiert auf Grundlage einer 314 deutsche Individuen umfassenden
Kohorte. Diese resultierenden Expressionsprofile bildeten die Grundlage fu¨r die Etablierung von miRNA-
Signaturen, hilfreich fu¨r die hochgenaue Unterscheidung zwischen CD and UC untereinander, sowie deren
Abgrenzung von gesunden und inflammatorischer Kontrollen. Basierend auf diesen Signaturen generierten
wir binomiale sowie multinomiale Modelle zur Lo¨sung klinisch relevanter Klassifikationsprobleme. Die
Evaluation der Klassifikatoren erfolgte unter Verwendung umfangreichen Samplings und ergab mediane
balanced accuracies von bis zu 91.70% (CD vs. UC) bzw. 98.10% (CD oder UC vs. HC). In
einer weiteren Studie wurde dieser Ansatz um die zusa¨tzliche Beru¨cksichtung von miRNA-Varianten
erweitert. Wir verwendeten Sequenziertechnologie der na¨chsten Generation zur Bestimmung von isomiR-
Expressionsprofilen, generiert auf Grundlage einer Kohorte von 515 Individuen, einschließlich IBD-
Patienten sowie gesunder und symptomatischer Kontrollen. Unter Verwendung charakteristischer isomiR-
Signaturen generierten wir Klassifikatoren, deren Klassifikationgu¨te wir mit medianen balanced accuracies
von 78.57%/78.83% (CD vs. UC, unbehandelt/behandelt) bzw. 100.00%/98.28% (CD oder UC vs.
HC, unbehandelt/behandelt) bewerten konnten. Damit liefern wir statisch belastbare Belege fu¨r eine
U¨berlegenheit unserer Modelle bezu¨glich etablierter Biomarker.
Im Weiteren schlagen wir eine zusa¨tzliche Verbesserung unserer Modelle durch die Beru¨cksichtung von
isomiR-Signaturen, spezifisch fu¨r die zellula¨ren (NK-Zellen, B-Lymphozyten, cytotoxische T-Lymphozyten,
T-Helferzellen, Monozyten, Neutrophile, Erythrozyten) und nicht-zellula¨ren Komponenten peripheren Bluts
(Serum, Exosomen) vor. In einer abschließenden Studie etablierten wir dafu¨r einen umfangreichen Katalog
zelltyp-spezifischer microRNA-Expression. Basierend auf dieser Ressource identifizierten wir Gruppen von
miRNAs/isomiRs, spezifisch differenziell exprimiert in jeder der untersuchten Blutkomponenten. Schließlich
liefern wir Belege fu¨r die Zelllinien-Spezifita¨t bestimmter miRNA-Sequenzvarianten (3’ trimming, 3’ non-
templated nucleotide addition).

Summary
Inflammatory bowel disease (IBD) is a chronic relapsing disorder of the alimentary tract, encompassing
Crohn’s disease (CD) and ulcerative colitis (UC) as its two major subtypes. Recognized as an increasingly
common condition, it renders a significant burden to societies and healthcare systems around the world.
The diagnosis of inflammatory bowel disease remains a clinical challenge and involves the assessment of
numerous endoscopic, histological, radiological and/or biochemical parameters. A multitude of biomarkers
has been proposed to complement the diagnostic process. However, none of them can be recommended for
routine clinical practice.
MicroRNAs (miRNAs) represent a class of short, non-coding RNAs that act as post-transcriptional regu-
lators of gene expression. Variability within the miRNA biogenesis is introduced by alternative precursor
cropping and dicing, sequence editing or trimming as well as addition of nucleotides and gives rise to
miRNA isoforms (isomiRs). Due to their remarkable resistance against physical and enzymatic degradation,
miRNAs exhibiting deregulation in disease have been implicated as novel biomarkers for a variety of clinical
conditions. In the scope of this work we evaluate whether systematic miRNA or miRNA variant expression
profiling, in conjunction with state-of-the-art machine learning techniques, is suitable as a non-invasive tool
for diagnostics of IBD.
In a first study we employed microarray technology to determine expression levels of 863 miRNAs for whole
blood samples drawn from a cohort comprising 314 German individuals, to establish miRNA signature being
informative for the highly accurate distinction of CD and UC among each other as well as from healthy
and inflammatory controls. Utilizing these signatures we generated binomial as well as multinomial models,
solving clinically relevant classification tasks. We evaluated these classifiers employing a comprehensive
sampling strategy, obtaining median balanced accuracies of up to 91.70% (CD vs. UC) and 98.10% (CD
or UC vs. HC), respectively. In another study we extended this approach by additionally incorporating
expression profiles of miRNA variants. We employed next generation sequencing technology to examine
isomiR expression profiles drawn from a cohort of 515 individuals, comprising IBD cases as well as healthy
and symptomatic controls. Incorporating distinctive isomiR signatures, we generated classifiers performing
with median balanced accuracies of 78.57%/78.83% (untreated/treated CD vs. UC) and 100.00%/98.28%
(untreated/treated CD or UC vs. HC), respectively. Hence, we provide sampling-based evidence for our
models’ superiority over established biomarkers.
We propose further improvement of our models by incorporating isomiR signatures dinstinctive for the
cellular (NK cells, B lymphocytes, cytotoxic T lymphocytes, T helper cells, monocytes, neutrophils and
erythrocytes) and non-cellular components of human peripheral blood (serum, exosomes). In a final study
we elaborate on this idea by establishing a comprehensive, cell-type-specific microRNA expression catalogue
required for this purpose. Based on this resource we identified sets of miRNAs being specifically DE in
each of the investigated blood compounds. Furthermore, we provide evidence for cell-lineage-specificity of
particular types of miRNA sequence variation (3’ trimming and 3’ non-templated nucleotide addition).
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1 Introduction
1.1 Inflammatory bowel disease: epidemiology and etiology
Inflammatory bowel disease (IBD) is a chronic relapsing disorder of the alimentary tract. It encompasses
two major subtypes, namely Crohn’s disease (CD) and ulcerative colitis (UC), each showing extensive
heterogeneity in terms of clinical and histological presentation as well as response to treatment.
In the course of the last decades IBD has been recognized as an increasingly common diagnosis in the
industrialized countries. Recent studies of western populations estimate incidence and prevalence of IBD
to be as high as 57.90 per 100,000 person-years and 505.00 per 100,000. However, the estimates vary
considerably with respect to IBD subtype as well as geographic region. Thus, incidence of CD (UC) in
North America, Europe and Oceania is reported with up to 23.82 (23.14), 15.40 (57.90) and 29.30 (17.40)
per 100,000 person-years, respectively. Prevalence of CD (UC) stratified by the afore-mentioned regions is
estimated as up to 318.50 (286.30), 322.00 (505.00) and 197.30 (196.00) per 100,000. This corresponds to
0.32% (0.29%), 0.32% (0.51%) and 0.20% (0.20%) of the respective population size and total numbers of
approximately 1.16 (1.04), 2.39 (3.75) and 0.08 (0.08) million affected individuals. Whereas there is evidence
for the incidence and prevalence to stabilize in the western world, estimates of both epidemiological measures
are on the rise in newly industrialized countries. Currently, incidence of CD (UC) in South America,
Africa and Asia is reported to equal to up to 3.50 (6.76), 5.87 (3.29) and 8.40 (6.50) per 100,000 person-
years. Prevalence of CD (UC) for these regions is estimated as up to 41.40 (44.30), 19.02 (10.57) and
53.10 (106.20) per 100,000. This corresponds to 0.04% (0.04%), 0.02% (0.01%) and 0.05% (0.11%) of the
respective population size and approximate total numbers of 0.18 (0.19), 0.24 (0.14) and 2.41 (4.83) million
affected individuals. This provides evidence for IBD no longer being a problem of western countries alone.
It rather renders a significant burden to societies and healthcare systems around the world. For details see
Ng et al. [1].
A growing body of evidence suggests the disease being a result of dysregulated inflammatory response
to commensal microbes in a genetically susceptible host. In a series of genome-wide association studies
(GWAS, including [2, 3]) 241 genetic loci have been identified to be associated with IBD. While these
GWAS findings added to the understanding of the genetic architecture of the disease, its pathogenesis is still
barely understood and linking SNP associations to functional mechanisms is a major challenge to the field.
Consequently, the different aspects of gene regulation, such as transcription [4], RNA processing [5], mRNA
trafficking and metabolism [6] as well as protein degradation [7], also have been investigated in IBD.
1.2 Clinical presentation and diagnostic features
Inflammatory bowel disease can occur at any age. However, age of onset varies with respect to age group
and exhibits a peak at an age of 20–30. IBD affects males and females to the same extent. Its clinical
features are heterogeneous but typically comprise gastro-intestinal symptoms, such as abdominal pain and
chronic diarrhea or systemic symptoms, such as fever, malaise and anorexia. Notetably, rectal bleeding and
fecal incontinence as well as tenesmus are more common in UC than in CD [8, 9].
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UC is characterized by diffuse, continuous inflammation which extends proximally from the rectum and does
not involve the ileum. Commonly neither granulomas nor fissures or fistulas are observed. Histologically
inflammation is limited to the mucosa [8]. Hallmark of CD is discontinuous inflammation affecting the entire
gastro-intestinal tract. Common features include the involvement of the ileum as well as the development
of granulomas, fissures and fistulas. Histologically the disease is characterized by transmural inflamma-
tion [9]. With a frequency of almost 50%, IBD patients develop both, intestinal and extraintestinal symp-
toms. The most common manifestations include musculoskeletal (peripheral and axial arthropathies) and
mucocutaneous (erythema nodosum, pyoderma gangrenosum, aphthous stomatitis) as well as ophthalmo-
logical (conjunctivitis, scleritis, uveitis) and hepatic diseases (primary sclerosing cholangitis, granulomatous
hepatitis) [10].
According to the current evidence-based consensus published by European (ECCO, European Crohn’s and
colitis organisation) [8, 9] as well as American gastroenterological societies (ACG, American college of
gastroenterology) [11, 12] there is still no gold standard for diagnosing Crohn’s disease and ulcerative colitis,
repectively. Accordingly, the diagnostic procedure for both IBD subtypes involves a combination of clinical,
endoscopic, histological and radiological parameters. At present, neither genetic nor serological testing is
recommended for routine diagnosis.
1.3 Serological biomarkers
A growing body of evidence suggests that IBD results from abberant immune response to commensal
microbes. This hypothesis is supported by the detection of anti-glycan antibodies recognizing glycosy-
lated cell wall components of microbial pathogens. Consequently, anti-glycan antibodies are among the
most extensively investigated serological biomarkers for diagnosis and prognosis of IBD. Examples include
anti-Saccharomyces cerevisiae antibodies (ASCA, targeting mannan), the anti-mannobioside carbohydrate
antibodies (AMCA, targeting mannan), anti-laminaribioside carbohydrate antibodies (ALCA, targeting
laminarin), anti-chitobioside carbohydrate antibodies (ACCA, targeting chitin), anti-chitin carbohydrate
antibodies (anti-C, targeting chitin) as well as anti-laminarin carbohydrate antibodies (anti-L, targeting
laminarin). In addition to anti-carbohydrate antibodies, antibodies targeting protein-based antigens are a
common group of biomarkers, comprising perinuclear atypical neutrophil cytoplasmic antibodies (pANCAs)
as well as antibodies against the bacterial outer membrane porin C (OmpC) and the bacterial flagellin
CBir1 [13, 14]. Differences in the prevalence of the antigens in IBD in comparison to healthy controls or
IBD subtypes among each other have been shown repeatedly. However, performance of derived serological
tests as measured by sensitivity, specificity and balanced accuracy vary considerably (see Table 1.1).
With specificities ranging from 86.0 to 100.0% the distinction between IBD and HC based on these antibodies
appears to perform well. However, all of them show considerably smaller sensitivities (ranging from 6.0 to
45.0%) leading to only modest balanced accuracies (ranging from 52.5 to 72.5%). The distinction between
CD and HC exhibits higher variability with regard to specificities (ranging from 68.0 to 100.0%) as well
as an increase of sensitivities (ranging from 11.0 to 59.0%) leading to only moderately improved balanced
accuracies (ranging from 50.0 to 79.0%). Accordingly, even the best performing serological biomarker
(ASCA) appears to be insufficient to replace standard diagnostic methods, such as endoscopy, histology
and radiology to distinguish between IBD and HC (BAC of 60.5 to 72.5%) as well as between CD and HC
(BAC of 60.5 to 79.0%). Of note, the same biomarkers allow a distinction from symptomatic controls, even
without a drop in accuracy (BAC of 51.0 to 71.5% comparing IBD and SC, BAC of 51.0 to 79.5% comparing
CD and SC). The even more challenging diagnostic problem of distinguishing between the IBD subtypes
among each other also has been addressed by employing the afore-mentioned serological biomarkers. With
balanced accuracies ranging from 46.5 to 86.0% they show comparable diagnostic performance. Due to the
16
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high variability of the performance estimates the current applicability of these biomarkers is clearly limited.
However, they might complement standard diagnostics, particularly in case of diagnostic uncertainty.
problem marker BAC (%) SN (%) SP (%) citation
IBD vs. HC ASCA 60.5–72.5 31–45 90–100 [14, 15]
AMCA 50.5–61.5 9–26 92–97 [14, 15]
anti-OmpC 60.5 27 94 [15]
ACCA 46.0–58.0 6–19 86–97 [14, 15]
pANCA 57.5 17 98 [15]
anti-L 55.5 12 99 [14]
ALCA 54.5 15 94–99 [14, 15]
anti-C 52.5 7 98 [14]
IBD vs. SC ASCA 66.0–71.5 41–45 91–98 [15, 16]
ACCA 51.5–64.5 19–40 84–89 [15, 16]
AMCA 59.5 26 93 [15]
ALCA 54.0–59.5 15–20 93–99 [15]
Anti-OmpC 51.0 27 75 [15]
CD vs. HC ASCA 60.5–79.0 37–59 84–99 [17–20]
AMCA 51.5–63.5 12–27 91–100 [17, 18]
ALCA 51.5–60.0 15–26 88–94 [17, 18]
anti-L 58.0 26 90 [18]
anti-C 56.5 25 88 [18]
ACCA 50.0–56.5 11–17 89–96 [17, 18]
CD vs. SC ASCA 64.0–79.5 51–63 77–96 [16–18]
AMCA 52.0–63.5 12–27 92–100 [17, 18]
ALCA 52.0–62.0 15–26 89–98 [16–18]
anti-L 57.5 26 89 [18]
ACCA 45.5–57.5 11–17 80–98 [16–18]
anti-C 51.0 25 77 [18]
CD vs. UC ASCA+ 59.5–86.0 37–72 82–100 [14–19, 21–26]
ASCA+/ANCA− 72.0–79.0 52–64 92–94 [19, 21–24, 27]
pANCA− 71.5 52 91 [17]
AMCA 47.0–62.5 12–28 82–97 [14, 15, 17, 18]
anti-L 55.5–61.5 18–26 93–97 [14, 18]
anti-C 50.0–61.5 10–25 90–98 [14, 18]
ALCA 53.5–61.0 15–26 92–96 [14–18]
ACCA 46.5–59.0 9–21 84–97 [14–18]
anti-OmpC 55.0 29 81 [15]
Table 1.1: Serological biomarkers in IBD [28, modified from Table 2 and 3]. Stratified by diagnos-
tic problem the table summarizes previously studied serological biomarkers and reports their performance
in terms of balanced accuracy (BAC), sensitivity (SN) and specificity (SP). ASCA = anti-saccharomyces
cerevisiae antibody, ACCA = anti-chitobioside carbohydrate antibody, ALCA = anti-laminaribioside carbo-
hydrate antibody, AMCA = anti-mannobioside carbohydrate antibody, anti-OmpC = anti-outer membrane
porin C antibody, anti-C = anti-chitin carbohydrate antibody, anti-L = anti-laminarin carbohydrate anti-
body, pANCA = atypical perinuclear anti-neutrophil cytoplasmic antibody.
1.4 Fecal biomarkers
Mucosal immune response is associated with the migration of leukocytes (predominantly neutrophils) along
a chemotactic gradient and their subsequent degradation at the site of inflammation, leading to the release of
proteins into the intestinal lumen. Accordingly, fecal levels of those proteins (predominantly calprotectin and
lactoferrin) are assumed to be elevated in response to inflammatory signals and have been extensively studied
17
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as biomarkers distinguishing IBD from functional gastrointestinal disorders (including IBS) and health or
predicting of disease activity. Of note, there is currently no fecal biomarker being able to distinguish between
the substypes of IBD with high sensitivity and sprecificity, respectively.
Calprotectin, a heterodimer of calcium-binding S100 proteins (S100A8 and S100A9), allows a distinction
between IBD and IBS with balanced accuracies ranging from 79.4 to 98.5%. Distinguishing between UC
or CD and IBS, in turn, has been estimated to perform with a balanced accuracy of 91.5%. Lactoferrin, a
monomeric member of the transferrin family of iron-binding glycoproteins, allows a discrimination between
IBD and IBS with a balanced accuracy of 93.0%. Discriminating active IBD (or CD and UC, respectively)
from inactive IBD (or CD and UC, respectively), functional bowel disorders or health, however, has been
estimated to perform with balanced accuracies ranging from 70.9 to 82.0%. Accordingly, fecal calprotectin as
well as lactoferrin serve as reliable indicators for intestinal inflammation (see Table 1.2). Nonetheless, neither
the European Crohn’s and Colitis Organisation (ECCO) [9] nor the American College of Gastroenterology
(ACG) [11] recommend sole reliance of IBD diagnosis on these fecal biomarkers.
problem marker BAC (%) SN (%) SP (%) citation
IBD vs. IBS calprotectin 98.5 100.0 97.0 [29]
IBD vs. IBS calprotectin 97.3 94.5 100.0 [30]
IBD vs. IBS calprotectin 96.5 93.0 100.0 [31]
IBD vs. IBS calprotectin 91.5 83.0 100.0 [32]
IBD vs. IBS calprotectin 79.4 94.4 64.3 [33]
CD vs. IBS calprotectin 91.5 83.0 100.0 [32]
UC vs. IBS calprotectin 91.5 83.0 100.0 [32]
IBD vs. IBS lactoferrin 93.0 86.0 100.0 [34]
active IBD vs. inactive IBD/IBS lactoferrin 82.0 86.7 77.2 [35]
active CD vs. inactive CD/IBS/BIBD/HC lactoferrin 86.0 92.0 80.0 [36]
active CD vs. inactive CD/IBS lactoferrin 70.9 81.8 60.0 [35]
active UC vs. inactive UC/IBS/BIBD/HC lactoferrin 89,0 90.0 88.0 [36]
active UC vs. inactive UC/IBS lactoferrin 79.7 92.6 66.7 [35]
Table 1.2: Fecal biomarkers in IBD [37, modified from Table 1 and 2]. Stratified by diagnostic
problem the table summarizes previously studied fecal biomarkers and reports their performance in terms of
balanced accuracy (BAC), sensitivity (SN) and specificity (SP). BIBD = bacteria infectious bowel disease.
1.5 MicroRNAs
MicroRNAs (miRNAs) represent a class of short, non-coding RNAs that act as post-transcriptional regula-
tors of gene expression. Individual miRNAs regulate specific mRNA targets recognized by the RNA-induced
silencing complex (RISC), whose formation corresponds to the end point of a multi-step biogenesis [38].
Variability in the biogenerative process is introduced by alternative precursor cropping and dicing, sequence
editing or trimming as well as addition of nucleotides and gives rise to miRNA isoforms (isomiRs) [39].
miRNAs first have been described in Caenorhabditis elegans. Originally referred to as small temporal RNAs
(stRNAs) due their role as key regulators of developmental timing [40, 41], they later have been recognized as
a general class of post-transcriptional regulators being evolutionary conserved in a multitude of species [42–
44]. In the course of the last years, thousands of miRNAs have been identified. Accordingly, miRBase, the
primary miRNA sequence repository, now lists 48885 mature miRNAs (3982 with high confidence) from
271 species (20 with high confidence), including nematodes, insects, plants and mammals. At present, 2656
miRNAs have been identified in humans (1198 with high confidence) [45].
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miRNAs have been recognized as important determinants of innate as well as adaptive immunity. They are
involved in several steps of myelopoiesis, such as the development of MEPs (megakaryocyte-erythroid progen-
itors) and GMPs (granulocyte-macrophage progenitors) from CMPs (common myeloid progenitors) as well
as their differentiation into terminal myeloid cells (dendritic cells, macrophages, platelets and erythrocytes).
In the latter, miRNAs regulate innate immune response, e.g. via PAMP-dependent activation of NF-κB and
MAPKs and subsequent induction of pro-inflammatory cytokines and antigen presentation genes. Moreover,
miRNAs are associated with a multitude of developmental steps being part of lymphopoiesis, comprising the
differentiation of B cells as well as different types of T cells from CLPs (common lymphoid progenitors). B
cells further differentiate into plasma cells (mediating humoral immune response by producing high-affinity
antibodies). CD4+ T cells differentiate into T helper cells (TH, regulating cellular response to pathogens
and tumors) or regulatory T cells (Treg, mediating immune tolerance by interference with the activity of
TH cells). Driven by antigen exposure and inflammation, CD8+ T cells in turn, differentiate into cytotoxic
T cells (TC, inducing apoptosis via the caspase or perforin/granzyme pathway). Development, activation
and function of all lymphoid cell types depend on complex regulatory networks comprising a multitude of
miRNAs [46].
In accordance to their regulatory role in immune cell development and response, miRNAs are critical mod-
ulators of intestinal homeostasis. In line with this, they regulate autophagy (lysosomal degradation of
cytoplasmic content) by direct or indirect impairment of the process of vesicle elongation [47]. Moreover,
they interfere with the formation of tight junctions (affecting paracellular permeability), adherent junctions
(affecting calcium-dependent adhesion of adjacent epithelial cells and spatial organization actin filaments)
as well as desmosomes (affecting calcium-independent hyperadhesion of adjacent epithelial cells) and are
therefore likewise contributing to intestinal homeostasis by regulation of epithelial integrity and barrier
function [48].
Due to their remarkable resistance against physical and enzymatic degradation, miRNAs exhibiting dereg-
ulation in disease have been implicated as putative biomarkers [49]. Accordingly, a multitude of studies has
been conducted to assess the utility of miRNAs with respect to the distinction of IBD from functional gas-
trointestinal disorders and health, or in the prediction of disease activity. As a result numerous candidates
have been proposed to complement traditional serological and fecal biomarkers such as ASCAs, pANCAs
and lactoferrin. However, the translatability of these findings into routine clinical practice remains to be
proven [50].
The evident relationship between dysregulation of miRNAs and human diseases suggests a therapeutic ap-
plication of these molecules. Accordingly, numerous (pre-)clinical studies have been conducted to investigate
the directed manipulation of miRNA expression utilizing miRNA mimics or miRNA inhibitors [51]. Exem-
plary, MesomiR-1 (EnGeneIC), a miR-16 mimic encapsulated in an EGFR-targeted delivery vehicle, has been
shown to induce substantial dose-dependent inhibition of tumor growth in human mesothelioma xenograft. A
first clinical trial suggested comparable effects in patients with pleural mesothelioma (NCT02369198). Fur-
thermore, MRG-201 (miRagen Therapeutics), a cholesterol-conjugated miR-29 mimic, has been reported to
induce reversal of bleomycin-induced pulmonary fibrosis in mice. Likewise, a clinical study confirmed the
reduction of scar tissue in patients with systemic sclerosis (NCT02603224). The treatment of Hepatitis C by
Mirvirasen (Roche), a LNA-modified antimiR-122 represents one of the currently most promising applica-
tions of miRNA inhibitors. By impairing the mir-122-induced replication of HCV, the drug has been shown
to reduce viral titres in mice and primates. With recent clinical trails this effect likewise could be confirmed
in humans (NCT01872936). Finally, MRG-106 (miRagen Therapeutics), a LNA-modified antimiR-155, has
been reported to induce tumor regression and apoptosis in mouse models of lymphoid malignancies. An
ongoing clinical study in patients with various lymphomas and leukemia aims for the evaluation of safety,
tolerability, pharmacokinetics and potential efficacy of the investigational drug (NCT02580552).
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1.6 Summary of Article I
M. Hu¨benthal, S. Lipinski, A. Franke et al. “Molecular Genetics of Inflammatory Bowel Disease”. In: ed.
by M. D’Amato, C. Hedin, and J. D. Rioux. Springer Science+Business Media New York, 2019. Chap.
MiRNAs in inflammatory bowel disease. (in press).
With this article we provide an in-depth review of current knowledge about miRNAs in the context of IBD.
We describe the pivotal role of these molecules for the maintenance of intestinal homeostasis, focusing on
their regulatory impact on mucosal immunity as well as epithelial autophagy and barrier integrity. We
review recent biomarker research proposing candidate miRNAs as diagnostic tools predicting IBD-related
traits. Ultimately, we report estimates of these candidates’ performance as a foundation for qualitative
classification of biomarkers and models being proposed in the course of this thesis.
1.7 Summary of Article II and related patents
M. Hu¨benthal, G. Hemmrich-Stanisak, F. Degenhardt et al. “Sparse Modeling Reveals miRNA Signatures
for Diagnostics of Inflammatory Bowel Disease”. In: PLOS ONE 10.10 (2015), e0140155.
In the course of this study we evaluated whether systematic miRNA expression profiling, in conjunction
with machine learning techniques, is suitable as a non-invasive test for the major IBD phenotypes (Crohn’s
disease (CD) and ulcerative colitis (UC)). Based on microarray technology, expression levels of 863 miRNAs
were determined for whole blood samples from 40 CD and 36 UC patients and compared to data from
38 healthy controls (HC). To further discriminate between disease-specific and general inflammation we
included miRNA expression data from other inflammatory diseases (inflammation controls (IC): 24 chronic
obstructive pulmonary disease (COPD), 23 multiple sclerosis, 38 pancreatitis and 45 sarcoidosis cases) as
well as 70 healthy controls from previous studies. Multiclass classification problems considering 2, 3 or 4
of the afore-mentioned groups were solved employing different types of state-of-the-art machine learning
methods (support vector machines, SVMs). The resulting models were assessed regarding sparsity and
performance and a subset was selected for further investigation. Measured by the area under the ROC
curve (AUC) the corresponding median holdout-validated accuracy was estimated as ranging from 0.75 to
1.00 (including IC) and 0.89 to 0.98 (excluding IC), respectively. In combination, the corresponding models
provide tools for the distinction of CD and UC as well as CD, UC and HC with expected classification
error rates of 3.1 and 3.3%, respectively. These results were obtained by incorporating not more than 16
distinct miRNAs. Validated target genes of these miRNAs have been previously described as being related
to IBD. For others we observed significant enrichment for IBD susceptibility loci identified in earlier GWAS,
suggesting that the proposed miRNA signature is of relevance for the etiology of IBD.
T. Brefort, A. Franke, G. Hemmrich-Stanisak et al. “MiRNAs as non-invasive biomarkers for inflammatory
bowel disease”. EP Patent 3212803B1 (granted). 2018.
T. Brefort, A. Franke, G. Hemmrich-Stanisak et al. “MiRNAs as non-invasive biomarkers for inflammatory
bowel disease”. US Patent 20170306407A1 (published). 2017.
T. Brefort, A. Franke, G. Hemmrich-Stanisak et al. “MiRNAs as non-invasive biomarkers for inflammatory
bowel disease”. WO Patent 2016066288A1 (published). 2016.
The miRNA signatures defined in the course of the afore-mentioned microarray study were utilized to com-
plement/extend a set of patents filed at the European Patent Office (EPO), USPTO (United States Patent
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and Trademark Office) and World Intellectual Property Organization (WIPO) to protect the application
of miRNAs as non-invasive biomarkers for inflammatory bowel disease. The described inventions relate to
the whole workflow of sampling/purifying miRNAs, quantifying their expression (employing hybridisation-,
amplification-, sequencing-, cytometry- and/or spectroscopy-based approaches), deriving a mathematical
model (employing regression, clustering and/or classification techniques) and applying this model to obtain
a diagnostic prediction.
1.8 Summary of Article III
M. Hu¨benthal, S. Juze˙nas, S. Nikolaus et al. “Comprehensive discriminative analysis of sequencing-based
isomiR expression profiles reveals highly accurate tools for diagnostics of inflammatory bowel disease”. (in
submission).
With this study we provide the to-date most comprehensive discriminative analysis of sequencing-based
isomiR expression profiles from whole blood, contributing to a more comprehensive understanding of in-
flammatory bowel disease. We examined isomiR expression profiles of 515 individuals, including 75 cases of
untreated IBD (denoted as CD− and UC−, respectively), 271 cases of treated IBD (denoted as CD+ and
UC+, respectively), 124 healthy and 45 symptomatic controls (denoted as HC and SC, respectively). We
identified specific signatures of differentially expressed isomiRs, providing the foundation to derive mathe-
matical classification models for discrimination of arbitrary combinations of these traits. For the first time,
we do not only focus on 2-nomial classifiers ( UC− vs. CD−, SC vs. CD−, SC vs. UC−, HC vs. CD−, HC
vs. UC− and SC vs. HC as well as UC+ vs. CD+, HC vs. CD+ and HC vs. UC+) but likewise provide
tools to solve 3-nomial (CD+ vs. UC+ vs. HC, CD− vs. UC− vs. HC and CD− vs. UC− vs. SC) as well
as 4-nomial classification problems (CD− vs. UC− vs. SC vs. HC). To ensure biological interpretability
we thereby account for unwanted variability of both biological and technical origin. Extensive sampling has
been performed to obtain generalizable models but also a reliable evaluation of their clinical utility. In this
way we do not only provide strong evidence for sequencing-based isomiR expression profiles being a valuable
tools for diagnosing IBD but also for their superiority over established biomarkers. We furthermore detect
treatment-dependent changes of the isomiR expression profiles, leading to improved classifier performance
for treated patients. However, the translatability of the findings into routine clinical practice remains to be
proven.
1.9 Summary of Article IV
S. Juze˙nas, G. Venkatesh, M. Hu¨benthal et al. “A comprehensive, cell specific microRNA catalogue of
human peripheral blood”. In: Nucleic Acids Research 45.16 (2017), pp. 9290–9301.
In the course of this study we investigated the transcriptional profiles of miRNAs from seven distinct periph-
eral blood cell populations of 43 healthy donors employing next generation sequencing. These measurements
were complemented by profiles of circulating miRNAs from whole blood (n = 77) as well as serum (n = 38)
and blood-borne exosomes (n = 38). The resulting dataset represents our (still non-exhaustive, but sub-
stantial) contribution towards a reference of miRNA and isomiR expression in the cellular and non-cellular
components of human peripheral blood. Pairwise differential expression analysis between the different cell
types revealed 224 miRNA arms being significantly differentially expressed between the two major blood
cell lineages (lymphoid versus myeloid). Furthermore, by focusing on the subtypes of lymphoid and myeloid
cells, we found that 149 miRNAs were significantly deregulated between natural killer cells (CD56+) and
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small lymphocytes (CD4+, CD8+ and CD19+), 119 miRNAs between T-lymphocytes (CD4+ and CD8+)
and B-lymphocytes (CD19+) and 193 between CD14+ and CD15+ cells. Furthermore, we showed that cell
type specificity of miRNA profiles can even be increased by considering miRNA variants (isomiRs). Thus,
a comparison between lymphoid and myeloid lineages revealed 1862 differentially expressed isomiRs (from
281 miRNA arms). Analogous comparisons of the subtypes of lymphoid and myeloid cells displayed 1204
differentially expressed isomiRs (derived from 211 arms) between natural killer cells (CD56+) and small
lymphocytes (CD4+, CD8+ and CD19+), 773 isomiRs (from 179 arms) between T-lymphocytes (CD4+
and CD8+) and B-lymphocytes (CD19+) and 1420 (from 246 arms) between CD14+ and CD15+ cells.
With this work we provide the most comprehensive contribution to date toward a complete miRNA inventory
of healthy human blood. We identified blood cell specific transcription signatures at both the miRNA as well
as the isomiR level. It might be reasonably assumed that these signatures are altered in the diseased state
and that this alteration represents a valuable discriminative tool. Its impact on the predictive performance
of IBD biomarkers might be investigated in the course of future studies.
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Introduction 
 
MicroRNAs (miRNAs; non-coding RNAs, approximately 22 nucleotides in 
length) represent a class of post-transcriptional regulators of gene expression. 
Individual miRNAs regulate specific mRNA targets recognized by the RNA-induced 
silencing complex (RISC). The formation of this complex corresponds to the end 
point of a multi-step biogenerative process [1]. Variability in miRNA biogenesis 
introduced by alternative precursor cropping and dicing, sequence editing or 
trimming as well as addition of nucleotides, gives rise to miRNA isoforms (isomiRs) 
[2]. Being implicated in numerous physiologic processes such as immune cell 
development and regulatory circuits of cell functions, miRNAs (and their variants) 
are also believed to play a critical role in the etiology of a variety of diseases [3, 4]. 
Imbalance of the regulatory processes within immune system development and 
function lead to an increased production of cytokines being involved in the 
development of inflammation. Relapsing as well as persisting inflammation, in 
turn, is a characteristic feature of  inflammatory bowel disease (IBD), including its 
subtypes Crohn's disease (CD) and ulcerative colitis (UC) [5]. The pivotal role of 
miRNAs in regard to the development of the involved innate and adaptive immune 
cells as well as their response to inflammatory signals are further key points of this 
chapter. 
Recent studies provide evidence for miRNAs modulating intestinal 
homeostasis by calibrating immune cell responses, and also regulating autophagy 
(lysosomal degradation of cytoplasmic content) by direct or indirect impairment 
of the process of vesicle elongation [6]. Furthermore, they interfere with the 
formation of tight junctions (affecting paracellular permeability), adherent 
junctions (affecting calcium-dependent adhesion of adjacent epithelial cells and 
spatial organization actin filaments) as well as desmosomes (affecting calcium-
2 Publications
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independent hyperadhesion of adjacent epithelial cells) and are therefore critical 
for maintaining epithelial integrity and barrier function [7]. 
Establishing IBD diagnostics according to the current consensus of the 
European Crohn’s and Colitis Organization (ECCO) [8, 9] or the American College 
of Gastroenterology (ACG) [10, 11] incorporates the assessment of numerous 
endoscopic, histological, radiological and/or biochemical parameters. 
Nonetheless, a definite differential diagnosis cannot be established in 
approximately 10%–17% of colitis patients [12], and more than 10% of IBD patients 
change diagnosis during the first two years of the disease course [13]. In recent 
past, miRNAs emerged as a new class of putative biomarkers detectable in a wide 
range of tissues and body fluids [14]. In the context of IBD, a multitude of studies 
has been conducted to assess the utility of miRNAs with respect to the distinction 
of IBD from functional gastrointestinal disorders and health, or in the prediction of 
disease activity. Numerous candidates have been proposed to complement 
traditional serological and fecal biomarkers such as ASCAs, pANCAs and lactoferrin. 
However, further research is needed to validate these findings and translate them 
into clinical practice [15]. 
MicroRNA biogenesis and regulatory roles 
 
The canonical miRNA biogenesis is a multi-step process initiated by RNA 
polymerase II (Pol II)-mediated transcription, which are encoded as individual 
genes (monocistronic), as gene clusters (polycistronic) or in introns of host genes 
(intronic) [16]. In mammals, canonical miRNAs are transcribed as a part of much 
longer RNAs called primary miRNA (pri-miRNA) transcripts which typically contain 
5′ cap, poly-A tail and hairpins wherein miRNA sequences are embedded [1, 17]. 
The pri-miRNA transcripts are recognized by a nuclear protein complex referred to 
as microprocessor, which processes the latter into single hairpins called precursor 
miRNAs (pre-miRNAs). The microprocessor is a heterotrimeric complex containing 
one Drosha endonuclease and two DGCR8 subunits [1, 16]. The DGCR8 subunits 
recognize the hairpin of pri-miRNA, while Drosha cuts the stem with a two-
nucleotide 3′ overhang and releases approximately 60 nucleotide-long, stem-loop 
shaped pre-miRNA. After export to the cytoplasm by Exportin 5, the pre-miRNA is 
further processed by the Dicer nuclease, which in co-operation with TARBP or 
PACT, based on distance from 5′ end terminus of dsRNA, cleaves the hairpin loop 
to liberate the 21–24 base pair miRNA duplex. After the cleavage, the duplex has 
a two-nucleotide-long 3′ overhang on each end, resulting from the offset cuts 
made by both Drosha and Dicer nucleases [1, 17]. Once generated, the small RNA 
duplex is subsequently loaded onto an Argonaute protein (AGO), where it is 
unwound to form a RNA-induced silencing complex (RISC), the effector unit that 
recognizes target mRNA molecules. The unwinding of the miRNA duplex is 
promoted by mismatches in the guide strand at nucleotide positions 2–8 and 12–
15. The guide strand is selected based on relative thermodynamic stability of the 
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two ends of the small RNA duplex. Accordingly, the strand with the least stable 5′ 
terminus is typically selected as the guide strand [17]. Crystal structures of the 
human RISC with and without target RNAs suggest a stepwise mechanism, in which 
AGO2 primarily exposes guide bases 2–5 for initial target pairing, which then 
promotes conformational changes that expose not only the seed sequence (2–8), 
but also bases 13–16 for further target recognition [2]. 
Since the final maturation of miRNAs takes place in the cytoplasmic space, 
where miRNAs silence gene expression via translational repression of targeted 
mRNAs, cytosol contains the highest abundance of functional RISCs. However, 
mature miRNAs also reside in multiple subcellular locations, such as nucleus and 
mitochondria, and can be secreted out of cells via exosomes into various types of 
body fluids and even into the gut lumen [18, 19]. Recent studies have shown that 
mature miRNAs localized within the nucleus can be involved in epigenetic 
regulation, whereas miRNAs localized in mitochondria can directly enhance 
translation of mitochondrial transcripts [20, 21]. Interestingly, as in the case of 
mitochondria, a recent study reported that host miRNAs can directly modulate gut 
microbiome composition by selectively promoting bacterial growth [19]. 
Although public databases catalogue miRNAs as single sequences, an 
individual miRNA hairpin arm can give rise to multiple distinct isoforms (isomiRs) 
which are referred to as the mature miRNA transcripts, and which can differ in 
sequence length and composition [22]. Such sequence divergence occurs due to 
alternative precursor cropping and dicing, sequence editing, end trimming or the 
addition of non-templated nucleotides [23]. Depending on the type of variation, 
isomiRs are categorized into three main classes: 5′, 3′ and polymorphic (internal) 
isomiRs. Additionally, 5′ and 3′ isomiRs are sub-classified into templated 
(trimming) or non-templated (tailing) variants [2, 24]. The primary source of 
templated isomiRs is alternative cleavage during the Drosha and Dicer processing 
steps. Cleavage by Dicer is regulated by a mechanism based on binding 
competition between TARBP and PACT which, in the end, tune the length of 
miRNAs [25]. The alternative cleavage by Dicer directly modulates the seed 
sequence of the 3p miRNA arm, whereas alternative cleavage by Drosha shifts the 
seed site of the 5p arm [2]. Due to the altered seed sequence, 5′ templated variants 
can broaden the binding site repertoire of the respective reference miRNA and 
often together regulate distinct or shared targets involved in the same biological 
pathways [4]. Polymorphic isomiRs are usually formed via sequence editing by RNA 
editing enzymes such as ADARs, which catalyze hydrolytic conversion of adenosine 
(A) to inosine (I) in pre-miRNA molecule [23]. Templated 3′ isomiRs can also be 
formed after maturation by exoribonucleases, which trim nucleotides from the 3′ 
end and produce shorter isoforms [26]. Another post-maturation sequence 
modification of 3′ isomiRs is the non-templated nucleotide addition by terminal 
nucleotidyl transferases (TUTs), which extend mature sequences by one or more 
nucleotides. 3′ isomiRs are the most frequently observed types of isomiRs and 
potentially have an effect on miRNA cellular or extracellular localization and 
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turnover [2]. Very often these variants are expressed in a cell type specific manner 
[27, 28]. 
 
Role of miRNAs in immune system  
 
miRNAs are important for cell fate decisions in the immune system. By 
providing positive or negative feedback of gene expression, miRNAs also regulate 
cell signaling pathways during innate and adaptive immune responses [3]. 
Imbalance within these regulatory processes may lead to increased pro-
inflammatory cytokine production and T cell proliferation and/or recruitment in 
the affected tissue. This in turn may lead to a relapsing and remitting course and 
persisting low-grade inflammation, which characterizes chronic inflammatory 
disorders, including IBD [5]. In this section, we will describe and summarize recent 
findings about the involvement of miRNAs in the regulation of innate and adaptive 
immunity. 
 
Innate Immunity and miRNAs 
 
The innate immune system is predominantly composed of myeloid 
lineage cells and it represents the first line of defense against infection by external 
pathogens such as bacteria, fungi and viruses [3]. These pathogens are mainly 
recognized by tissue-residing macrophages and dendritic cells (DCs) via pattern 
recognition receptors (PRRs), which bind to pathogen-associated molecular 
patterns (PAMPs) [29]. The innate immune system is maintained by extensive 
regulatory networks, in which miRNAs play an important role as regulatory 
elements in the development and function of immune cells (Figure 1) [3].  
 
Innate cell development 
 
Myeloid lineage development begins with common myeloid progenitor 
(CMP) cells, which give rise to megakaryocyte-erythroid progenitors (MEPs) and 
granulocyte-macrophage progenitors (GMPs). In mammals, CMP transition to 
GMP or MEP depends on miR-29a, which negatively regulates Dnmt3a translation 
[30]. The decision whether the GMPs will become granulocytes or monocytes also 
remarkably relies on miRNAs, i.e. during the granulocyte differentiation highly 
expressed miR-223 inhibits MEF2C (myocyte-specific enhancer factor 2C), which is 
a suppressor of granulocyte differentiation [3]. Additional miRNAs such as miR-21 
and miR-196b also influence GMP fate. Enforced expression of these two 
molecules blocks granulocyte differentiation, whereas enforced expression of miR-
424 promotes monocytic differentiation [3, 31]. Monocytes can differentiate into 
DCs or into macrophages and this transition is influenced by miR-34a-5p and miR-
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21-5p, which repress the mRNAs encoding WNT1 (Wnt Family Member 1) and 
JAG1 (Jagged 1), respectively, to promote DC differentiation [31].  
In another myeloid branch, progenitors (MEPs) give rise to anucleate 
erythrocytes and megakaryocytes, the latter of which produce anucleate platelets. 
The core transcription factor of erythropoiesis GATA1 directly targets promoters 
of miR-451a and miR-486 genes, and initiates their Pol II-mediated transcription 
[32, 33]. A recent study utilizing knockout mouse strains showed that these two 
miRNAs are necessary for erythroid development and maturation [34]. The fate of 
megakaryocytes, in turn, depends on several miRNAs, including miR-130a, miR-
150, miR-34a and miR-10a [3, 35, 36]. For example, miR-10a-5p and miR-150-5p 
drive MEP differentiation to the megakaryocyte lineage by suppressing transcripts 
of HOXA1 [37] and MYB [38] genes, respectively. Although megakaryocyte-derived 
platelets are anucleate, like erythrocytes, they contain a substantial number of 
miRNA species and some of those, including miR-96-5p, miR-200b-3p, miR-495-3p, 
miR-107 and miR-223-3p are highly abundant and critically involved in platelet 
reactivity, aggregation, secretion and adhesion. [39].  
 
Innate cell response  
 
The activation of innate immune response starts once PAMPs bind to DC 
or macrophage PRRs such as Toll-like receptors (TLRs) and Nod-like receptors 
(NLRs), which bind extracellular and intracellular microbial molecules, 
respectively. These receptors, in turn, recruit adaptor proteins that activate NF- B 
(nuclear factor kappa-light-chain-enhancer of activated B-cells) and MAPKs 
(mitogen-activated protein kinases) for the induction of inflammatory cytokine 
and antigen presentation (MHC; major histocompatibility complex) genes [40, 41]. 
The regulation of the aforementioned biological cascade highly relies on miR-155 
and miR-146a molecules, which are two of the most relevant and most studied 
miRNAs in the field [42, 43]. Both miRNAs are induced in DCs and macrophages by 
NF- B in response to TLR or pro-inflammatory cytokine signals [3]. In monocytes, 
miR-146a-5p functions as an anti-inflammatory regulator by providing a negative 
feedback loop to decrease NF- B via suppression of TRAF (TNF receptor associated 
factor 1) and IRAK (interleukin 1 receptor associated kinase) translation [44]. On 
the other hand, miR-155-5p acts as pro-inflammatory regulator by repressing the 
production of SHIP1 (SH-2 containing inositol 5’ polyphosphatase 1) and SOCS1 
(suppressor of cytokine signaling-1), which leads to the increase of NF- B activity 
and promotion of macrophage transition to the pro-inflammatory M1 phenotype 
[45, 46]. During macrophage activation, there is a temporal imbalance between 
miR-155 and miR-146a gene expression. Activated by inflammatory stimulus, NF-
B immediately induces miR-155 expression, which leads to even stronger NF- B 
activity. At the same time, miR-146a levels rise to negatively regulate NF- B 
activity, leading to inhibition of miR-155 expression and resolution of the 
inflammatory response [46]. Besides these two molecules, there are several other 
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miRNAs, which increase or decrease during macrophage polarization from anti-
inflammatory M2 to pro-inflammatory M1 phenotype. More specifically, miR-
26a/b, miR-27a/b, miR-127, miR-101, let-7e and miR-125b have been shown to 
promote M1 polarization while miR-21, miR-124, miR-223, let-7c, miR-34a, miR-
146b and miR-125a have been shown to induce M2 polarization in macrophages 
by targeting various transcription factors and adaptor proteins [45, 47–50]. As in 
macrophages, miR-155 is also involved in DC TLR-evoked polarization to a pro-
inflammatory milieu. Other miRNAs such as miR-146a and miR-21 are involved in 
the negative regulation of DC activation [51]. After activation of the NOD2 
(nucleotide-binding oligomerization domain-containing protein 2) pathway DCs 
upregulate miR-29 expression, which in turn acts as an anti-inflammatory miRNA 
by directly suppressing the production of the cytokine IL-23 [52]. Interestingly, 
miRNA let-7c which has been shown to promote the resting M2 phenotype of 
macrophages, was reported to act as a positive regulator of DC activation [53]. 
 
Adaptive immunity and microRNAs 
 
The adaptive immune system is comprised of lymphoid lineage cells, 
including T and B lymphocytes. These cells provide a second line of immune 
defense against specific pathogens after priming from the innate immune system 
(in case of T cells) or from the primary pathogen-derived molecules (in case of B 
cells) [3]. PRRs of innate immune cells determine the origin of antigens recognized 
by T cell receptor (TCR), as well as resolve the type of detected infection, and guide 
T-lymphocytes to induce the proper effector class of the immune response [54]. B 
Cell Receptor (BCR)-activated B cells, on the other hand, provide humoral 
immunity against extracellular pathogens themselves, through antibody 
production [55]. Similar to the innate immune system, the adaptive immune 
system is under tight control by complex regulatory networks including a number 
of transcriptional factors, cytokines and miRNAs, the latter of which are regulating 
gene-expression programs during development and function of the adaptive 
immune cells (Figure 2). 
 
Adaptive cell development 
 
Adaptive immune system development is a hierarchical and lineage-
restricted differentiation process starting with the common lymphoid progenitor 
(CLP), which resides in bone marrow and can give rise either to precursor-
progenitors of B cells (pre-pro-B cells) or to progenitors of T cells called double 
negative (DN) cells [3, 31]. The fate determination whether the CLP will become 
pre-pro-B cell or DN involves of miR-181a and miR-126 molecules. The increased 
expression of these two miRNAs drive CLPs toward B-lymphopoiesis [56, 57]. The 
further development of B lymphocytes is a rather linear and stepwise process, 
which ensures that each B lymphocyte acquires a single, unique B cell antigen 
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receptor (BCR) [58]. The process involves multiple transitional stages, such as 
progenitor B (pro-B), precursor B (pre-B) and mature B cells, in which miRNAs have 
a remarkable impact. Lineage specification from pre-pro-B to pro-B cells is 
controlled by miR-212-3p and miR-132-3p through the suppression of SOX4 (SRY-
box 4) translation [59]. Another checkpoint of quality control is introduced by miR-
34a, miR-150 and the miR-17~92 cluster. Both miR-34a-5p and miR-150-5p act to 
inhibit pro-B cell to pre-B cell transition by targeting FOXP1 (forkhead box P1) and 
MYB, respectively, whereas the miR-17~92 cluster acts to promote the pro-B to 
pre-B cell conversion by negatively regulating the pro-apoptotic protein BIM (Bcl-
2 interacting protein) [3]. A recent study has shown that epigenetic silencing of 
miR-125b is required for normal B-cell development and that the overexpression 
of this miRNA leads to inefficient appearance of immature B cells in peripheral 
blood and also induces pre-B-cell leukemia [60]. In contrast, miR-148a, which is 
highly expressed in pro- and pre-B cells, is gradually down-regulated following 
their transition into immature and then into mature B cells [61]. A study in mice 
has shown that miR-148a might be critical for the regulation of B cell apoptosis 
and survival by targeting Gadd45a (growth arrest and DNA damage inducible 
alpha), Bim, and Pten (phosphatase and tensin homolog) proteins [62]. 
As introduced above, T-lymphopoiesis starts when bone marrow-residing 
CLPs differentiate into early stage DN cells, which then migrate to the thymus, 
where they undergo multiple stages of differentiation, T cell receptor (TCR) gene 
rearrangement and selection. The different stages include double positive (DP) and 
single positive (SP), the latter of which give rise to naïve CD4+ or naïve CD8+ cells 
[63]. To make the transition from DN cells to DP cells happen, the miR-17~92 
cluster has to be expressed above a certain threshold, because the loss of its 
expression leads to reduced surface expression of IL-7R, resulting in decreased DN 
to DP transition [64]. Another miRNA having an influence on this transition is miR-
150-5p, which inhibits early T-lymphopoiesis by downregulating NOTCH3 [65]. Of 
note, these miRNAs were already described as being involved in B-lymphopoiesis, 
where they positively affect cell differentiation as in T-lymphopoiesis. However, 
this effect is achieved by targeting different mRNAs. A further step in the 
thymocyte differentiation is the transition from DP to SP cells, where miR-181a 
plays an important role by regulating TCR sensitivity in DP cells during positive and 
negative selection in the thymus [66]. 
 
Adaptive cell response 
 
Once exposed to an antigen, mature B cells become activated and further 
proliferate in germinal centers and finally differentiate into plasma cells [58]. The 
plasma cells, in turn, are critical for mediating humoral immune responses through 
the production of high-affinity antibodies [67]. During the activation of mature B 
cells, miR-155 is upregulated and promotes further proliferation via direct 
regulation of PU.1 (hematopoietic transcription factor), which has an important 
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role in antigen-driven B-cell maturation [68]. Besides that, miR-155 together with 
miR-181b, miR-210 and miR-217 are involved in the regulation of BCR signaling, 
antibody production and proliferation of the activated B cells. miR-146a-5p, 
together with miR-142-3p, prevents uncontrolled B cell activation trough 
repression of NF- B and BAFF-R (B-cell activating factor receptor), respectively [3]. 
During the terminal stage of B cell differentiation, in an incoherent feed-forward 
loop regulated by STAT3 (signal transducer and activator of transcription 3) and 
BLIMP-1 (PR domain zinc finger protein 1), miR-21 provides a temporally delayed 
repression of plasma cell differentiation to prevent dysregulated proliferation [69]. 
miR-155 also plays a role in plasma cell fate commitment, where it acts on BSAP 
(B-cell-specific activator protein) via the miR-155/PU.1 axis, thus promoting 
efficient terminal B cell differentiation [70].  
The function of CD8+ T cells is to destroy cells presenting exogenous 
antigens on MHC I class molecules; for example, cytotoxic T (TC) cells kill virally 
infected cells, preventing them from being the source of more viral pathogen [71]. 
Differentiation of naïve CD8+ T cells into TC cells is driven by antigen exposure and 
inflammation, which leads to the induction of specific gene-expression programs 
that also include miRNAs [66]. One example is the IL-2 signaling network, which is 
induced during the differentiation of TC cells. The IL-2 pathway induces the 
expression of perforin, granzymes, and effector cytokines, while down-regulating 
miR-139-5p and miR-150-5p, which target perforin and IL-2R, respectively [72]. In 
contrast, miR-155-5p is induced in effector CD8+ T cells and promotes cell 
proliferation and differentiation through the repression of SOCS1 [73].  
After activation, CD4+ T cells can differentiate into different subsets of T 
helper (TH) cells, such as TH1, TH2 and TH17 cells, regulatory T (Treg) cells and T 
follicular helper (TFH) cells. Each of the subsets has specific functions and distinctive 
gene expression programs, and interestingly, they possess a fair amount of 
plasticity to differentiate into different TH cell subsets [66]. TH1 cells are 
responsible for immune responses against intracellular viral and bacterial 
pathogens and tumors. TH2 cells target helminths and facilitate tissue repair, and 
their deregulated response can cause allergy or asthma. TH17 cells mediate 
immune responses against extracellular bacteria and fungi, and their dysregulated 
response can induce many organ-specific autoimmune diseases [74]. TFH  are 
involved in the elimination of numerous pathogens such as viruses, bacteria and 
fungi, by forming immunological memory and providing help to B cells [75]. Treg 
cells, in turn, comprise a distinct anti-inflammatory lineage subpopulation of T 
CD4+ cells. They are essential mediators of immune tolerance, which actively 
suppress the function of conventional TH cells and limit inappropriate or excessive 
responses of the immune system [76]. The differentiation of IL-17-producing TH17 
cells is promoted by numerous miRNAs, including miR-155, miR-21, miR-181c, miR-
301a, miR-326 as well as clusters miR-183~96~182 and miR-212~132 [77–83]. For 
example, the pro-inflammatory miR-155-5p together with miR-326 play an 
important role in the TH17 commitment by targeting ETS1 [77, 84]. Likewise, miR-
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155-5p alone regulates the TH17/Treg ratio by targeting SOCS1 [85]. T cell-specific 
miR-17~92 cluster deficiency reduces TH17 differentiation and ameliorates 
symptoms of experimental autoimmune encephalomyelitis (EAE), thus showing 
the importance of the cluster in promoting TH17 responses [86], even though 
individual miRNAs of the cluster might have opposing effects on TH17 
differentiation [87]. On the other hand, miR-146a has been reported as a negative 
regulator of TH17 differentiation. A study of miR-146a-dificient mice has shown 
that 2D2 T cells produce higher levels of autocrine IL-6 and IL-21, contributing to 
enhanced TH17 responses and development of severe EAE [88]. The transition 
towards TH1 cells is also endorsed by miR-155 and miR-17~92 cluster [89, 90]. As 
in TH17 cells, miR-155 promotes the commitment of TH1 cells by repression of 
SOCS1 transcripts [90]. Similarly, the miR-17~92 cluster promotes TH1 
commitment by blocking apoptosis, increasing IFN-γ (interferon gamma) 
production, and obstructing inducible Treg cell differentiation [89]. In contrast, miR-
29 acts as a negative regulator of TH1 cell differentiation by suppressing IFN-γ 
production [66]. The differentiation of IL-4-producing TH2 cells is also promoted by 
the miR-17~92 cluster. It has been shown that one of the members, miR-19a, 
endorses TH2 cytokine production by direct targeting of PTEN, SOCS1, and TNFAIP3 
(TNF-alpha-induced protein 3) [91]. Conversely, miR-24 and miR-27a limit TH2 cell 
differentiation through inhibition of IL-4 production [92]. The development and 
function of Treg cells is highly supported by miR-155, miR-10a, miR-146a, miR-146b 
and the miR-17~92 cluster [93–97]. Highly expressed in Treg cells, miR-155 has been 
reported to be involved in the differentiation of these cells [98], as well as in the 
maintenance of competitive fitness [93]. Another highly abundant molecule, miR-
146a, has been shown to be critical for Treg suppressor function [94]. Its family 
member, miR-146b, which is a part of TRAF6-NF- B-FoxP3 signaling pathway, has 
been demonstrated to repress Treg cell survival, proliferation, and suppressor 
function [95]. miR-17, a member of the miR-17~92 cluster, has been reported to 
obstruct the differentiation of Treg cells [89]. However, another study showed that 
Treg-specific loss of miR-17~92 expression results in a failure of Treg accumulation 
and function during an acute EAE in vivo [97], thus confirming its importance for 
the function of Treg cells. The TGF-β (transforming growth factor beta) and retinoic 
acid inducible miR-10a plays a role in positively maintaining the stability of 
inducible Treg cells and preventing their phenotypic conversion into follicular helper 
T cells [96]. TFH cells themselves are also highly regulated by miRNAs, including the 
well-described miR-155, miR-146a and miR-17~92 cluster [99]. The miR-17∼92 
cluster is a critical regulator of T cell-dependent antibody responses, TFH cell 
differentiation and the fidelity of the TFH cell gene-expression program [100]. Pro-
inflammatory miR-155 is required for the development and expansion of TFH cells. 
In contrast to this, miR-146a has an opposing function to TFH cell development 
and restricts spontaneous expansion of TFH cells [99]. 
Interestingly, upon naïve CD4 T-cell activation, besides up- or down-
regulation of particular miRNAs, all miRNA sequences bearing 3’-terminal uridines 
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are specifically degraded and this decrease is accompanied by the down-regulation 
of uridyltransferases, including TUT4 and TUT7 [101], thus again highlighting the 
importance of miRNA regulation in T cell development and function.  
 
Role of miRNAs in Inflammatory Bowel Disease 
 
IBD belongs to the group of multifactorial chronic inflammatory disorders 
and affects the gastrointestinal tract. Its main types CD and UC are associated with 
various pathogenic phenotypes, including broadly dysregulated immune 
responses, disturbed autophagy and increased permeability of the epithelial 
barrier [102]. In the following section, we summarize the available evidence 
regarding miRNA involvement in the aforementioned pathological processes. 
 
Role of miRNAs in Disruption of Gut Immune Homeostasis 
 
The human gut immune system consists of innate and adaptive immune 
cells as well as non-immune cells scattered all over the intestinal layers. These cells 
sustain a balance between immune tolerance and rapid activation [5]. Immune 
balance is maintained through the combination of activating and inhibitory 
signaling pathways, including secretion of cytokines and activation of signal 
transducers, where miRNAs play an important regulatory role [43]. Dysregulation 
of these processes leads to inappropriate host immune responses to commensal 
bacteria. This, in turn, causes a continuous inflammation in genetically susceptible 
[103, 104] and environmentally conditioned individuals [105], which is a hallmark 
of multiple complex diseases, including IBD (Figure 3). 
In genetically predisposed individuals, environmental factors such as diet 
or smoking can alter the composition of the gut microbiota, reduce the mucus 
layer and change the permeability of the intestinal epithelium, resulting in the 
increased uptake of luminal antigens [105, 106]. Once exposed to these antigens, 
DCs or macrophages convert from a tolerogenic state to an activated phenotype. 
In addition to producing pro-inflammatory cytokines (such as TNF, IL-6, IL-12 and 
IL-23) [107], TLR-NF- B pathway activated cells also induce the expression of miR-
155 and miR-146a, which, as described in the previous section, create a combined 
positive and negative feedback loop to control NF- B activity itself [46]. The up-
regulation of miR-155 in macrophages and DCs leads to increased production of 
the aforementioned pro-inflammatory cytokines [108, 109], which are usually 
found to be elevated in these cells during IBD pathogenesis [107]. Recent studies 
report the up-regulation of miR-155 in the IBD-affected tissues [110, 111] and 
support its functional importance in macrophages under IBD conditions [112, 113]. 
Another TLR-induced miRNA, anti-inflammatory miR-146a is also commonly found 
to be up-regulated during active colon inflammation [110, 114], and, in contrast to 
miR-155, it acts as a suppressor of inflammation and conditions DCs as well as 
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macrophages towards tolerogenic phenotype by suppressing NF- B activity [44]. 
However, it has been shown that enforced miR-155 expression overrides miR-
146a-mediated repression of NF- B activation, thus emphasizing the dominant 
pro-inflammatory function of miR-155 and possibly explaining why the active state 
of macrophages persists after stimulation, even in the presence of large quantities 
of miR-146a [46]. Importantly, mouse studies have shown that deletion of miR-
146a leads to aberrant myeloproliferation [115–117], autoimmunity [116] and 
even chronic inflammatory stress-related tumorigenesis [115, 117], thus 
suggesting the miRNA’s critical role in TNF signaling regulation. The evidence on 
miR-146a down-regulation in peripheral blood mononuclear cells during lupus 
erythematosus additionally supports these findings [118]. TLR-activated NF- B 
also prompts the expression of another anti-inflammatory miRNA, miR-9, which in 
a negative feedback loop via NF- B1 (nuclear factor kappa B subunit 1) suppresses 
NF- B dependent inflammatory responses [119], and inhibits activation of the 
NLRP3 inflammasome, most likely through the JAK1/STAT1 signaling pathway 
[120]. Although miR-9 has been reported to be up-regulated under active CD and 
UC conditions [121, 122] (most likely because of TLR stimulation), its methylation 
levels have been shown to be increased in the rectal mucosa of UC patients and 
even more increased in CRC patients when compared with healthy individuals 
[123], thus showing its importance in the maintenance of inflammation and 
tumorigenesis. Another TLR-induced miRNA in macrophages, miR-124, negatively 
modulates TLR inflammatory activity itself, by targeting multiple components of 
the TLR signaling cascade [124]. Interestingly, miR-124 has been reported to be 
down-regulated in the tissues of pediatric UC due to promoter hypermethylation, 
but not in the cohort of adult UC patients, reflecting the mechanistic differences 
between adult and pediatric UC [125]. The stimulation of intestinal DCs through 
TLR signaling also leads to decreased expression of miR-10a, which was observed 
in the IBD inflamed mucosa [126]. In human DCs, anti-inflammatory miR-10a 
reduces the production of IL-12 and IL-23, which in turn suppress IBD TH1 and TH17 
cell immune responses. Moreover, miR-10a directly targets NOD2, which has a 
central role in intracellular pathogen sensing [127], and is highly relevant for IBD 
pathogenesis [128]. The genetic association between CD and NOD2 has been 
consistently replicated at the genome-wide level [129]. It has been shown that in 
human DCs, NOD2 induces miR-29 expression to limit IL-23 release, and that DSS-
induced colitis was more severe due to the elevated IL-23 and TH17 cell signature 
cytokines in the intestinal mucosa of miR-29-deficient mice. Moreover, CD patient 
DCs expressing NOD2 polymorphisms failed to induce miR-29 upon PRR 
stimulation and showed enhanced release of IL-12p40 [52]. The differentiation and 
function of intestinal macrophages and DCs is also calibrated by anti-inflammatory 
miR-223, which directly targets pro-inflammatory transcription factor C/EBPß 
[130]. Another study has shown that in addition to miR-9, miR-223 plays an 
important role in regulation of the myeloid-specific NLRP3 inflammasome during 
intestinal inflammation [131]. Although miR-223 has been repeatedly reported to 
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be elevated in active IBD conditions [131, 132], its deficiency results in severe DSS-
colitis in mice [130, 131]. 
After processing of antigens, macrophages and DCs present them to naïve 
CD4+ T-cells, promoting differentiation into effector T cells, including TH1, TH2, 
TH17 and Treg cells. The intestinal inflammatory infiltrate of CD patients contains 
elevated numbers of TH1 and TH17 cells, whereas the mucosa of UC patients 
exhibits disturbed homoeostatic balance towards TH2 and TH17 cells [133, 134]. 
The increase of TH1 and TH17 cells during CD pathogenesis might be affected by 
miR-155, miR-29, miR-326 as well as the miR-17~92 cluster. Overexpression of 
miR-155 forces naïve CD4+ T cells to differentiate into TH1 and TH17 cells [90]. The 
role of miR-155 in the IBD TH1/TH17 pathway has been investigated in more detail 
using knockout, indicating that the loss of miR-155 leads to protection from 
advanced DSS‐induced colitis development, and results in decreased TH1/TH17, 
CD11b+, and CD11c+ cells. This decrease, in turn, correlated with reduced clinical 
scores and severity of disease [135]. Besides the function in DCs, miR-29 has been 
shown to inhibit IFN-γ production and TH1 differentiation via direct repression of 
T-bet and Eomes [136, 137]. Therefore, the down-regulation of miR-29 in T cells 
might likewise play a role in the IBD pathogenesis via the TH1/TH17 axis, even 
though the expression data in the IBD affected mucosa and serum shows up-
regulation in the active disease state [122, 138, 139]. The TH17 cell-promoting 
miRNA, miR-326 was found to be up-regulated in inflamed mucosa, thus 
suggesting its possible role in IBD pathogenesis [140]. Other TH1/TH17 response-
promoting and Treg differentiation-preventing miRNAs include members of the 
miR-17~92 cluster, which are found to be commonly deregulated in IBD [122, 138], 
and might be involved in the pathogenesis via TH1/TH17 or TH17/Treg pathways. 
However, to date, there are no functional studies that provide direct evidence for 
miR-17~92 modulating the IBD TH1/TH17 response pathway. 
The increase of TH2 cells during UC pathogenesis might be affected by 
miR-21, which has been repeatedly shown to be up-regulated in IBD, especially in 
UC [122, 141, 142]. Interestingly, in the colonic T cells during the recovery stages 
of UC, the expression of miR-21 has been found to be down-regulated, thus 
suggesting that miR-21 may play a role in limiting pathogenic T-cell responses 
[143].  
During the pathogenesis of IBD, intestinal Treg/TH17 cell balance is altered 
and shifted towards pro-inflammatory TH17 cells [144]. A recent study employing 
a murine IBD model, showed that TNFα-mediated loss of Treg suppressive function 
coincides with induction of miR-106a via NF- B promoter-binding to suppress 
post-transcriptional regulation of IL-10 release, and that selective inhibition of 
miR-106a leads to enhanced Treg function in vitro [145]. Another miRNA that might 
play a role in IBD Treg/TH17 balance regulation is miR-31, which was found to be up-
regulated in IBD [146]. A recent study that investigated knockout mice in the EAE 
model has shown that miR-31 targets RAI3 (retinoic acid-inducible protein 3) and 
conditional deletion of this miRNA results in enhanced induction of peripheral Treg 
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cells [147], thus showing its importance in Treg cell regulation. Treg suppressor 
function is likewise controlled by miR-146a. As shown in a study by Lu et al., miR-
146a contributes to Treg-mediated control of TH1 responses via suppression of Stat1 
activation [94]. To date, there is no direct evidence that miR-146a might play a role 
in IBD Treg function. However, findings supporting this role have been described in 
the context of rheumatoid arthritis [148]. 
The elevated number of TH1, TH2, TH17 and reduced number of Treg cells 
leads to an increased production of various pro-inflammatory cytokines, which in 
turn leads to activation of innate immune cells such as macrophages, and to the 
loss of immune tolerance to commensal bacteria, reflecting the typical phenotype 
of IBD [107]. Processes described in this section are summarized and visualized in 
the Figure 3. 
 
miRNAs and dysregulation of cellular autophagy 
 
Recent studies provide evidence for dysfunctional autophagy in the 
intestinal epithelial cells (IECs) being a factor contributing to the development of 
IBD. Autophagy thereby refers to a degradative pathway contributing to cellular 
homeostasis. It involves the delivery of cytoplasmic components being enclosed 
by the autophagosome to the lysosome. The biogenesis of the autophagy 
machinery is a multi-stage process comprising the formation of a double-
membrane structure (phagophore) and its expansion to a vesicle 
(autophagosome). miRNAs have been shown to be involved in various stages of 
autophagy [6]. However, current knowledge suggests that IBD-related miRNAs 
mainly interfere with vesicle elongation [40, 149, 150]. TLR (toll-like receptor)-
dependent activation of the NF- B pathway leads to increased expression of miR-
30c and miR-130a [151]. These miRNAs suppress the transcription of ATG5 as well 
as ATG16L, thereby inducing a direct impairment of autophagy. Indirect autophagy 
impairment, in turn, involves NOD2 [152, 153]. For this intracellular PRR, inhibitory 
effects on TLR-based recognition of PAMPs as well as inductive effects on the 
assembly of the autophagy elongation complex have been shown. By 
transcriptionally inhibiting NOD2, miR-192, miR-495, miR-512 and miR-671 
interfere with both pathways, leading to a disruption of autophagy [154] (see 
Figure 4A). 
 
miRNAs and disruption of epithelial barrier integrity 
 
Functional maintenance of the healthy gastrointestinal tract is provided 
by the intestinal epithelium, a physical barrier spatially segregating the 
environment and the host. Being selectively permeable, it allows protection 
against intraluminal antigens, microorganisms and their toxins, as well as the 
passage of dietary nutrients, electrolytes and water. Dysfunction of the intestinal 
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barrier has been reported to be associated with a variety of diseases, including IBD 
[7]. 
The intestinal epithelium consists of a continuous, polarized layer of IECs, 
adjoining to the mucus layer (apical, biochemical barrier) and the lamina propria 
(basolateral, immunological barrier) [155] . To maintain homeostasis of the 
epithelial barrier, adjacent IECs are interconnected by different types of junctional 
protein complexes. Tight junctions (TJs) are composed of a multitude of 
transmembrane proteins (including claudins, tricellulin, occulin, as well as 
junctional adhesion molecules) polymerized into strands. Extracellular domains of 
these strands establish close contact between adjacent cells. Intracellular domains 
of the strands are associated to a cytoplasmic plaque (formed by peripheral PDZ 
proteins, including ZO-1, ZO-2, ZO-3 as well as the Par3-Par6-aPKC polarity 
complex), which, in turn, is linked to the cytoskeleton [156]. Adherens junctions 
(AJs) establish cell adhesion by interaction of transmembrane cadherins (E-, N and 
P-cadherin) of neighboring cells. Catenins (such as plakoglobin, p120-catenin) link 
cadherins to the cytoskeleton incorporating adapter proteins (such as α-catenin 
and ß-catenin). Desmosomes, finally, show structural similarities to adherens 
junctions but are formed by distinct proteins. Thus, cell adhesion of neighboring 
cells is established by interaction of desmosomal cadherins (desmogleins 1–4 and 
desmocollins 1–3). Members of the catenin family of proteins (plakoglobin, p120-
catenin) link these cadherins to the cytoskeleton by incorporating adapter proteins 
(such as desmoplakin 1/2) [157]. 
miRNAs have been shown to interfere with the maintenance of the 
gastrointestinal epithelial barrier employing different regulatory mechanisms (see 
Figure 4B). For example, miR-122, miR-155 and miR-223 have been shown to 
target occludin, claudin-1 and claudin-8, respectively, leading to the depletion of 
these transmembrane proteins and therewith to the impairment of intestinal 
barrier function [158]. Other mechanisms leading to the destabilization of the 
junctional complex involve scaffolding proteins of the ZO family. According to their 
pivotal role for cross-linking the tight junction strands to the actin cytoskeleton, 
these proteins are targets of a multitude of regulatory pathways. Hence, for 
example, miR-21 (via RhoB, ras homolog family member B; F-actin), miR-146a (via 
beta-catenin), miR-155 (via RhoA, ras homolog family member A) as well as miR-
200b and miR-221 (via PTEN, phosphatase and tensin homolog; beta-catenin) have 
been shown to disrupt junctional complexes by impairment of ZO-1 [159, 160]. A 
last mechanism incorporates JAM-A (junctional adhesion molecule A). By 
recruiting Par3, this protein induces the formation of the Par3-Par6-aPKC polarity 
complex and therewith regulates permeability, assembly, and stabilization of tight 
junctions. This process is regulated through inhibition of aPKC (atypical protein 
kinase C, maintaining phosphorylation of JAM-A) by miR-155, or of PP2A (protein 
phosphatase 2A, antagonizing phosphorylation of JAM-A) by miR-221 [161]. 
Although not yet shown for human IECs, studies in various cell lines suggest that 
miRNAs are likewise important for regulating the function of adherent junction 
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and desmosomes. Thus, miR-200b induces E-cadherin expression by inhibiting its 
transcriptional repressor ZEB1. In this way, this miRNA promotes the formation of 
adherent junctions as shown in rat [162] and mouse [163] studies. By inhibiting a 
major desmosomal component (desmocollin-2), in turn, miR-29 controls 
desmosome function by impairing its hyperadhesiveness in human keratinocytes 
[164]. 
 
Role of microRNAs in Diagnosis of IBD  
 
miRNAs have been implicated in numerous physiologic and pathologic 
processes and their expression has been shown to be deregulated in a multitude 
of diseases, including several types of cancer [165] as well as inflammatory 
diseases (such as multiple sclerosis, psoriasis, rheumatic arthritis and systemic 
lupus erythematosus) [166]. These features, along with their remarkable 
resistance against physical and enzymatic degradation implicate miRNAs being 
putative biomarkers [14]. Accordingly, recent studies report candidate biomarkers 
for diagnosis and prognosis of a multitude of clinical conditions. However, so far 
none of these candidates have been translated into routine clinical practice [15].  
In recent years, deregulation of miRNA expression has also been 
investigated in the context of IBD. Notably, current literature often solely reports 
differential expression. Accordingly, studies evaluating the predictive performance 
of IBD-specific miRNA deregulation are underrepresented. Tables 1 and 2 list 
miRNAs that have been repeatedly detected to be differentially expressed in 
intestinal biopsies, peripheral blood, serum and/or saliva comparing IBD to healthy 
controls, and report point or range estimates of clinical performance as measured 
by sensitivity (SN), specificity (SP) and balanced accuracy (BAC). miRNAs being 
specifically deregulated in CD include miR-30e-5p, miR-484, miR-106a-5p, miR-
195-5p, miR-140-5p, miR-20a-5p, let-7b-5p, miR-192-5p and miR-93-5p. 
Conducting receiver-operating characteristics (ROC) analysis, the distinction 
between CD and HC based on these miRNAs has been reported to perform with 
SN and SP ranging from 69.57 to 82.61% and 75.00 to 96.88%, respectively, and 
BAC ranging from 78.06 to 85.40% [167, 168]. Additional miRNAs, such as miR-19b-
3p, miR-29a-3p, miR-107, miR-126-3p, miR-191-5p and miR-200c-3p, exhibit 
differential expression in CD but estimates of their clinical utility remain to be 
reported. miRNAs specifically deregulated in UC comprise miR-28-5p, miR-103a-2-
5p, miR-142-3p, miR-151a-5p, miR-155-5p, miR-188-5p, miR-340-3p, miR-345-5p, 
miR-378a-3p, miR-422a, miR-500a-5p, miR-501-5p, miR-532-5p, miR-769-5p and 
miR-874-3p. The distinction of UC from HC based on these miRNAs shows SN and 
SP ranging from 75.86 to 89.50% and 66.67 to 96.20%, respectively, and BAC 
ranging from 71.27 to 92.85%. The studies reporting these estimates employed 
analyses based on ROC [132, 167] or (penalized) support vector machines (SVM) 
[169, 170]. Additional miRNAs, including miR-142-5p and miR-505-5p exhibit 
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differential expression in UC but have not yet been evaluated with respect to their 
clinical utility [168, 171–173].  
Remarkably, the more interesting task of distinguishing the subtypes of 
IBD using miRNAs has not been extensively studied so far. However, Wu et al. [173] 
and Hübenthal et al. [170] report sets of miRNAs being differentially expressed in 
CD with respect to UC. Although not replicating each other, both studies indicate 
that miRNAs may serve as a diagnostic tool complementing classical serological 
markers such as ASCAs (anti-Saccharomyces cerevisiae antibodies) or pANCAs 
(perinuclear atypical neutrophil cytoplasmic antibodies). Estimated SN, SP and BAC 
of 100.00, 83.30 and 91.70%, respectively, suggest that miRNAs even may 
supersede currently used biomarkers in terms of clinical performance. Beyond 
diagnosis, miRNAs may be a valuable tool to assess and predict disease activity in 
IBD. In line with this assumption, Polytarchou et al. [132] and Wang et al. [174] 
report serum levels of miR-223-3p to be significantly correlated with the activity 
of CD (as measured by Crohn’s disease activity index (CDAI)) as well as UC (as 
measured by (partial) Mayo score) and therefore allow prediction of an IBD 
patient’s disease state. How the performance of these predictions compares to 
traditional fecal markers, such as lactoferrin [175, 176], still needs to be evaluated. 
Despite these promising findings miRNAs have not been recognized as an 
emerging tool for IBD diagnosis by neither the European Crohn’s and Colitis 
Organisation (ECCO) [8, 9] nor the American College of Gastroenterology (ACG) 
[10, 11] so far. Further research is needed to translate the findings into clinical 
practice. 
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Figure 1: miRNAs in development and response of innate immune system cells. The common myeloid 
progenitor (CMP) gives rise to the main two myeloid lineage branches, megakaryocyte-erythroid progenitor 
(MEP) and granulocyte-monocyte progenitor (GMP) cells, which in turn differentiate into terminal myeloid cells, 
responsible for the innate immune response. The figure depicts miRNAs involved in the regulation of 
myelopoiesis as well as in the innate immune response. The color gradient indicates relative time scale of 
developmental and functional stages of myeloid lineage cells. The figure has been adapted and updated 
from Mehta et al. [3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Publications Hu¨benthal, Franke, Lipinski et al. (in press)
42
18  Hübenthal, Franke, Lipinski, Juzėnas 
Figure 2: miRNAs in development and response of adaptive immune system cells. The common 
lymphoid progenitor (CLP) gives rise to the two main lymphoid lineage branches, T cell 
progenitors double negative (DN) cells and precursor progenitor B-cells (Pre-pro-B), which in turn 
differentiate into terminal effector cells, responsible for the adaptive immune response. The 
figure depicts miRNAs which are involved in the regulation of lymphoesis as well as in the 
adaptive immune response. The color gradient indicates relative time scale of developmental and 
functional stages of lymphoid lineage cells. DP, double positive; SP, single positive; Pro-B cell, 
progenitor B cell; Pre-B cell, precursor B cell; TC cell, cytotoxic T cell; TH1 cell, T helper 1 cell; TH2, 
T helper 2 cell; TH17, T helper 17 cell; Treg, T regulatory cell. The figure has been modified and 
updated from Mehta et al. [3]. 
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Figure 3: The pathophysiology of inflammatory bowel disease (IBD) in relation to miRNAs. The 
characteristic immunological features of IBD-affected mucosa are over-reaction of the innate 
immune cells, defective functionality of intestinal regulatory T (Treg) cells, increased recruitment 
of T helper 17 (TH17), T helper 1 (TH1; in Crohn’s disease) and T helper 2 (TH2; in ulcerative colitis) 
cells in the gut. These features lead to an increased production of pro-inflammatory cytokines, 
including TNF, IL-6, IL-17, IL-12, IL-23, etc., which in turn lead to the failure of immune tolerance 
to commensal bacteria. The elevated expression of pro-inflammatory miRNAs (i.e. miR-155, miR-
31, miR-17~92 cluster, etc.), as well as decreased expression of anti-inflammatory miRNAs (i.e. 
miR-146a, miR-10a, miR-29a/b, miR-124, etc.) may disturb gut homeostasis and might cause the 
aforementioned alterations. However, the increased expression of anti-inflammatory miRNAs 
(i.e. miR-146a, miR-223, miR-21, etc.), a common event in active IBD conditions, is more likely a 
consequence of the upstream inflammatory processes (such as TLR stimulation) rather than the 
cause of tolerance disruption. The figure (excluding miRNAs) has been adapted from Lutter et al. 
[5] with the additional information from Khalili et al. [105] and Neurath [107]. 
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Figure 4: (A) IBD-related miRNAs affecting cellular autophagy. This figure illustrates how miRNAs 
interfere with vesicle elongation. Direct impairment of the Atg12-Atg5-Atg16-complex depending 
on TLR and the resulting elevated expression of miR-30c and miR-130a. Indirect impairment by 
inhibition of NOD2 results from elevated expression of miR-192, miR-495, miR-512 and miR-671. 
The figure has been modified from Füllgrabe et al. [6] with additions from [40, 149, 150]. (B) IBD-
related miRNA affecting epithelial barrier integrity. This figure illustrates how transmembrane 
proteins (claudins CLDN; occludin, OCLN; JAM-A) forming tight junctions between adjacent 
intestinal epithelial cells (IEC, pink) are affected by miRNAs. Furthermore, adherent junctions 
(formed by cadherin, CDH; catenin, CAT; vinculin, VCL) as well as desmosomes (formed by 
desmocollin, DSC; desmoglein, DSG; plakoglobin, PKG; plakophilin, PKP; desmoplakin, DSP). The 
arrow head indicates the miRNA's mode of action (bar=inhibition, arrow=induction), the line style 
indicates whether the affection is of direct (solid line) or indirect type (dotted line). For further 
detail reference is made to the literature (miRNA and autophagy in general [155, 177–179] and 
specific to IBD [180]) 
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Table 1: miRNAs as biomarkers distinguishing CD from HC. The table summarizes miRNAs 
(named in accordance to miRBase 22) being repeatedly reported to be deregulated in CD with 
regard to health (direction of effect indicated by ↓ or ↑, respectively) as measured given 
different types of sample tissue (blood, serum, biopsy and/or saliva, data availability indicated by 
•). miRNAs for which inconsistent data has been reported are not shown. If available, point or 
range estimates of clinical performance in term of sensitivity (SN), specificity (SP) and balanced 
accuracy (BAC) are given. miRNAs whose deregulation in regard to HC is not specific to CD but 
observed both IBD subtypes are highlighted with a gray background (see Table 2). 
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miR-16-5p↑ • • •  73.91 100.00 86.96 [138, 139, 172], [168]1 
miR-21-5p↑ •    75.86–76.09 66.67–84.38 71.27–80.24 [138], [168]1 
miR-106a-5p↑ • • •  76.09 90.62 83.36 [122, 138, 139], [168]1 
miR-192-5p↑ • •   78.26–79.31 77.78–78.12 78.19–78.55 [138], [167, 168]1 
let-7b-5p↑ •    82.61 75.00 78.81 [138], [168]1 
miR-20a-5p↑ •    73.91 87.50 80.71 [138], [168]1 
miR-23a-3p↑ • •   79.00 68.00 73.50 [138], [168]1 
miR-93-5p↑ •    71.74 84.38 78.06 [138], [168]1 
miR-140-5p↑ •    73.91 87.50 80.71 [138], [168]1 
miR-195-5p↑ •    69.57 96.88 83.23 [138, 172], [168]1 
miR-30e-5p↑ •    73.91 96.88 85.40 [138], [168]1 
miR-484↑ •    82.61 84.38 83.50 [138], [168]1 
miR-199a-5p↑ • •   — — — [138, 168, 173] 
miR-223-3p↑ • • •  — — — [139, 174, 181] 
miR-362-3p↑ • •   — — — [138, 168, 173] 
miR-532-3p↑ • •   — — — [138, 168, 173] 
miR-19b-3p↓ • • •  — — — [182, 183] 
miR-29a-3p↑ • •   — — — [138, 168] 
miR-107↑ • •   — — — [138, 168] 
miR-191-5p↑ • •   — — — [138, 168] 
miR-126-3p↑ • •   — — — [138, 168] 
miR-200c-3p↑ • •   — — — [138, 168] 
1study reporting estimates of clinical performance 
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Table 2: miRNAs as biomarkers distinguishing UC from HC. The table summarizes miRNAs 
(named in accordance to miRBase 22) being repeatedly reported to be deregulated in UC with 
regard to health (direction of effect indicated by ↓ or ↑, respectively) as measured given 
different types of sample tissue (blood, serum, biopsy and/or saliva, data availability indicated by 
•). miRNAs for which inconsistent data has been reported are not shown. If available, point or 
range estimates of clinical performance in term of sensitivity (SN), specificity (SP) and balanced 
accuracy (BAC) are given. miRNAs whose deregulation in regard to HC is not specific to UC but 
observed both IBD subtypes are highlighted with a grey background (see Table 1). 
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miR-21-5p↑ • • • • 75.86–89.50 66.67–96.20 71.27–92.85 [138, 141, 171, 173, 184–187], [167, 169]1,2 
miR-223-3p↑ • •   79.00 72.00 75.50 [171, 172, 174, 188], [132]1 
miR-16-5p↑ •    89.50–100.00 90.00–96.20 92.86–95.00 [138, 173], [169, 170]1,2 
miR-199a-5p↑ • •   89.50 96.20 92.85 [138, 173, 189], [169]1,2 
miR-362-3p↑ •    89.50 96.20 92.85 [138, 168, 173], [169]1,2 
miR-532-3p↑ •    89.50 96.20 92.85 [138, 168, 173], [169]1,2 
miR-155-5p↑ • • •  89.50 96.20 92.85 [110, 111, 138, 141, 173], [169]1,2 
miR-28-5p↑ • •   89.50 96.20 92.85 [138, 173], [169]1,2 
miR-188-5p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-378a-3p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-340-3p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-422a↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-501-5p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-769-5p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-151a-5p↑ • •   89.50 96.20 92.85 [138, 173], [169]1,2 
miR-500a-5p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-874-3p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-103a-2-5p↑ •    89.50 96.20 92.85 [138, 173], [169]1,2 
miR-142-3p↑ • • • • 75.86 66.67 71.27 [171], [167]1 
miR-345-5p↑ •    89.50 96.20 92.85 [172], [169]1,2 
miR-532-5p↑ •    89.50 96.20 92.85 [172], [169]1,2 
miR-142-5p↑ • •   — — — [171, 172] 
miR-505-5p↓ •    — — — [168, 173] 
1study reporting estimates of clinical performance, 2performance estimates based on combinations of miRNAs 
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Abstract
The diagnosis of inflammatory bowel disease (IBD) still remains a clinical challenge and the
most accurate diagnostic procedure is a combination of clinical tests including invasive endos-
copy. In this study we evaluated whether systematic miRNA expression profiling, in conjunc-
tion with machine learning techniques, is suitable as a non-invasive test for themajor IBD
phenotypes (Crohn's disease (CD) and ulcerative colitis (UC)). Based on microarray technol-
ogy, expression levels of 863miRNAs were determined for whole blood samples from 40 CD
and 36 UC patients and compared to data from 38 healthy controls (HC). To further discrimi-
nate between disease-specific and general inflammation we includedmiRNA expression data
from other inflammatory diseases (inflammation controls (IC): 24 chronic obstructive pulmo-
nary disease (COPD), 23 multiple sclerosis, 38 pancreatitis and 45 sarcoidosis cases) as well
as 70 healthy controls from previous studies. Classification problems considering 2, 3 or 4
groups were solved using different types of penalized support vector machines (SVMs). The
resulting models were assessed regarding sparsity and performance and a subset was
selected for further investigation. Measured by the area under the ROC curve (AUC) the corre-
sponding median holdout-validated accuracy was estimated as ranging from 0.75 to 1.00
(including IC) and 0.89 to 0.98 (excluding IC), respectively. In combination, the corresponding
models provide tools for the distinction of CD and UC aswell as CD, UC andHCwith expected
classification error rates of 3.1 and 3.3%, respectively. These results were obtained by incor-
porating not more than 16 distinct miRNAs. Validated target genes of thesemiRNAs have
been previously described as being related to IBD. For others we observed significant enrich-
ment for IBD susceptibility loci identified in earlier GWAS. These results suggest that the pro-
posed miRNA signature is of relevance for the etiology of IBD. Its diagnostic value, however,
should be further evaluated in large, independent, clinically well characterized cohorts.
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Introduction
Inflammatory bowel disease (IBD) is a complex, polygenic, chronic intestinal disorder of
unknown etiology, comprising two major types: Crohn’s disease (CD) and ulcerative colitis
(UC). IBD is believed to evolve through a dysregulated response of the immune system to the
commensal microbiota associated with intestinal tissues in a genetically susceptible host. The
diagnosis of IBD is often achieved only months or years after the first onset of symptoms and
still requires a multitude of information from clinical, radiological, endoscopic and histological
tests. Extensive heterogeneity is observed in terms of disease presentation, behavior, and
response to treatment. However, a definite diagnosis of CD or UC cannot be established in
approximately 10%–17% of colitis patients (known as “indeterminate colitis” (IC)) [1] and
more than 10% of IBD patients change diagnosis (CD or UC) during the first year of the dis-
ease course [2]. Fecal and serological diagnostic tests, e.g. for calprotectin, lactoferrin or CRP
(C-reactive protein) as well as serum antibodies like pANCAs (perinuclear antineutrophil cyto-
plasmic antibody) and ASCAs (anti-S.cerevisiae antibody), supplement invasive endoscopic/
colonoscopic methods to verify IBD-diagnosis, to differentiate between the major subtypes or
to evaluate disease progression [3,4]. In the last 10 years, several genome-wide association stud-
ies (GWAS) were carried out to identify common susceptibility variants for IBD. In a large
meta-analysis of previous IBD GWAS, including more than 75,000 cases and controls, Jostins
et al. identified 71 additional loci, increasing the total number of known IBD susceptibility loci
with association of genome-wide significance to more than 163 [5]. While GWAS findings
have added tremendously to the understanding of disease etiology and the genetic architecture,
common genetic variants have low diagnostic value as shown for IBD [6] and other diseases
[7]. Other studies, employing mRNA-based measurements of differential gene expression in
tissue or peripheral blood of IBD patients of varying disease state, revealed distinct expression
patterns [8–11]. Limitations of these studies were reported when comparing cases and healthy
controls or trying to classify disease subphenotypes [12]. Non-coding, regulatory microRNAs
(miRNAs) have been studied in the context of their function in IBD [13] but especially because
of their ability to serve as diagnostic markers, as recently summarized by Chen et al. [14]. As
miRNA expression levels are more stable in tissues and body fluids, such as peripheral blood,
and as miRNAs act as master-regulators of mRNAs, differential signatures of miRNAs could
serve as superior, non-invasive diagnostic markers to verify IBD diagnosis, discriminate
between major IBD subphenotypes and to predict prognosis. A core set of deregulated miRNAs
has been identified in a series of studies investigating differential miRNA expression in biopsies
and peripheral blood of IBD patients [15–22]. Functional links gained from the analysis of
IBD-associated miRNA target genes implicate an involvement of cellular pathways of the
immune system (NF-κB, IL-23/IL-23R, IL-6/STAT3) [23–29], autophagy [13,30,31], epithelial
barrier function [32,33], IBD-associated dysplasia and colorectal cancer [34–36] in IBD disease
etiology. Besides these mechanistic insights into the disease, highly accurate predictive sets of
miRNAs suitable for diagnostic purposes have not yet been reported. Interestingly, most of the
afore-described studies, investigating deregulation of miRNAs, follow the classic approach of
statistical hypothesis testing for significant differential expression of single candidate miRNAs.
Some publications, however, point out an alternative way of employing large miRNA datasets
and machine-learning techniques, such as support vector machines (SVMs) [37] or random
forests (RFs) [38]. Keller and colleagues successfully applied SVM-based approaches to identify
diagnostic miRNA-profiles for several different diseases [39], such as multiple sclerosis [40,41],
lung cancer [42] or male infertility [43]. Others used similar analysis strategies to generate
miRNA expression signatures for pharyngeal squamous cell carcinomas [44], thyroid lesions
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[45], lung adenocarcinoma [46] or pulmonary tuberculosis [47]. Even ulcerative colitis has
been investigated using SVMs, leading to a signature of platelet-derived miRNAs [48].
Here we investigate microarray-based miRNA expression profiles from peripheral blood of
IBD patients, using penalized SVMs [49] and random forests for distinction of CD and UC
from healthy controls and other complex inflammatory diseases (chronic obstructive pulmo-
nary disease (COPD), multiple sclerosis, pancreatitis and sarcoidosis). The promising results of
our pilot study show, that machine-learning techniques and miRNA signatures should be fur-
ther investigated for IBD diagnostics. Moreover, the miRNA profiles identified yield further
insight into the disease-relevant signaling pathways.
Material and Methods
Patient recruitment and sampling
Clinical data and sample material used in this study were obtained under written informed
consent of patients as well as healthy donors, and under approvals of the local ethics commit-
tees (Biobank Popgen & Ethik-Komission der Medizinischen Fakultät, Universitätsklinikum
Schleswig-Holstein, Kiel). We randomly selected blood samples of 40 CD, 36 UC patients and
included 38 healthy controls (HC) from our biobank. Patients were collected at the UKSH ter-
tiary referral center. Diagnoses were verified by a clinician after reviewing the respective medi-
cal health records. As shown in Table 1, patients of every group were matched regarding
demographic parameters (mean age at diagnosis of 27.3 and 28.1 years for CD and UC cases,
respectively; mean age at sampling of 46.0 and 43.8 years for CD and UC cases, respectively;
fraction of males of 54.1% in CD and 53.1% in UC patients, respectively). The majority of the
patients was treated with anti-TNF-α inhibitors, such as Infliximab or Mesalazine (67.6% of
CD and 90.6% of UC cases) and is therefore assumed to be stable regarding the clinical presen-
tation. The activity of immune cells is assumed to be altered partially since a fraction of the
patients additionally was treated with immunosuppressive drugs, such as Azathioprine, Cyclo-
sporine, 6-Mercaptopurine or Tacrolimus (48.6% of CD and 31.3% of UC cases). Furthermore
a substantial fraction of the patients underwent the clinically common treatment with SAIDs
(steroidal anti-inflammatory drugs; 29.7% of CD and 56.3% of the UC cases, respectively) and/
or NSAIDs (non-steroidal anti-inflammatory drugs; 2.7% of CD and 6.3% of the UC cases,
respectively). However, based on the available data exacerbation of IBD at sampling was ruled
out for 51.4% of CD and 56.3% of UC cases.
Table 1. Characterization of the study subjects. Grouped by CD, UC and HC frequency information (in percent) on demographics (gender and smoking
status), medication (anti-TNF-α, immunosuppressant, SAIDs and NSAIDs) as well as symptoms (disease attack at sampling, stenosis, fistula and surgery) is
shown.
demographics medication symptoms
male smoker anti-TNF-alpha immunosuppressant said nsaid disease attack at sampling stenosis ﬁstula surgery
CD no 45.9 35.1 32.4 51.4 70.3 97.3 51.4 27.0 48.6 29.7
yes 54.1 64.9 67.6 48.6 29.7 2.7 0.0 62.2 48.6 70.3
NA 0.0 0.0 0.0 0.0 0.0 0.0 48.6 10.8 2.7 0.0
UC no 46.9 68.8 9.4 68.8 43.8 93.8 56.3 78.1 84.4 90.6
yes 53.1 31.3 90.6 31.3 56.3 6.3 0.0 3.1 3.1 3.1
NA 0.0 0.0 0.0 0.0 0.0 0.0 43.8 18.8 12.5 6.3
HC no 46.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
yes 53.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
NA 0.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
doi:10.1371/journal.pone.0140155.t001
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miRNA extraction and microarray measurement
After sampling, peripheral blood was anticoagulated using ethylenediaminetetraacetic acid
(EDTA) and immediately processed for RNA isolation. Total RNA, including miRNAs, was
extracted using the miRNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) and stored at
-80°C. All samples were analyzed on the automated Geniom Real Time Analyzer (GRTA, febit
biomed GmbH, Heidelberg, Germany) using the Geniom miRNA Biochip for Homo sapiens,
covering 866 human miRNA species [50]. Since miRBase has been updated from version 12 to
14 during the time course of the study, we used 863 miRNAs that were consistently present in
all three versions for the final data analysis. Biotin labeling was conducted by microfluidic
enzymatic on-chip labeling of miRNAs as described previously [51]. Hybridization was carried
out for 16 hours at 42°C followed by signal enhancement processing with GRTA. Detection
images were analyzed using the GeniomWizard Software.
Data preprocessing
Sample data for other inflammatory diseases, representing the inflammation control panel for
the current investigation, was taken from a previously published study [39]. This dataset com-
prised 24 COPD, 23 multiple sclerosis, 38 pancreatitis and 45 sarcoidosis cases as well as
another 70 healthy controls. Raw data of these samples was downloaded from Gene Expression
Omnibus (GEO, Accession code: GSE31568) and analyzed jointly with raw data of samples
generated for this study. Samples with median background-subtracted intensity exceeding
1.5IQR where removed as outliers resulting in 273 samples, including 37 CD, 32 UC, 92 HC,
23 COPD, 23 multiple sclerosis, 35 pancreatitis and 32 sarcoidosis cases. To account for batch
effects arising from differences in the source of data the background-subtracted intensity values
were centered with regard to the medians of the healthy controls. Normalization then was per-
formed using the R package vsn [52] for robust calibration and variance stabilization.
Classification with penalized support vector machines
To obtain mathematical models that allow diagnostic applications as well as the elucidation
of the role of miRNAs in the development of IBD, different types of classification problems
were investigated. Aiming for the distinction between CD, UC and HC initially a set of mod-
els considering 2 groups was examined (CD vs. HC, UC vs. HC, CD vs. UC). Classification
problems additionally incorporating IC (CD vs. IC, UC vs. IC, IC vs. HC) were carried out to
differentiate CD, UC and HC from general inflammation. Models aiming for the distinction
of combinations of groups were examined by jointly considering 3 groups (CD vs. UC+HC,
UC vs. CD+HC, HC vs. CD+UC as well as CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC).
Finally, also a set of models allowing for 4 groups was investigated (CD vs. UC+HC+IC, UC
vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Each of the 16 classification prob-
lems was solved using different types of linear penalized support vector machines, namely
LASSO SVM, elastic net SVM, SCAD SVM and elastic SCAD SVM. Additionally, the linear
standard SVM not performing feature selection was used as a reference. It is worth noting
that not every classification problem considered has a diagnostic meaning. However, for the
subsequent construction of combined classifiers, none of these can be neglected.
Support vector machines (SVMs) are widely used for solving supervised classification prob-
lems. However, SVMs do not allow for the selection of important variables (feature selection).
Applying the mathematical idea of regularization abolishes this limitation [49]. Accordingly,
regularized incarnations of the standard SVM along with efficient algorithms for optimizing
their objective functions have been proposed. All these methods share the use of penalties for
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model complexity to provide sparse solutions, i.e. small sets of features that enable good
classification.
For data D 2 fðxi; yiÞjxi 2 Rm; yi 2 f1; 1ggni¼1 with input vectors xi and class labels yi for
i = 1, . . ., n the SVM optimization problem corresponds to the minimization of kbk22 with
respect to the decision rule yiðb  xi  b0Þ  1. As shown by Hastie [49] this also can be written
as a regularization problem minb0 ;b
Pn
i¼1 Lðyi; fðxiÞÞ þ plðbÞ where Lðyi; fðxiÞÞ ¼ maxð0; 1
yiðβ  xi  b0ÞÞ is a loss (or cost) function and plðbÞ a penalty function with parameter λ. The
classic choices of plðbÞ include the ridge penalty [49] (standard SVM, plðbÞ ¼ lkbk22) and the
LASSO [53] (least absolute shrinkage and selection operator, plðbÞ ¼ lkbk1) as well as their
combination known as the elastic net [54] (plðbÞ ¼ l1kbk1 þ l2kbk22; l1; l1  0). More
recently a penalty function improving the properties of the LASSO was published. The SCAD
(smoothly clipped absolute deviation) penalty [55] is given by the quadratic spline
pSCADl ðbÞ ¼
Xm
j¼1
ljbjjIðjbjj  lÞ þ
jbjj2  2aljbjj þ l2
2ða 1Þ Iðl < jbjj  alÞ þ
ðaþ 1Þl2
2
Iðjbjj > alÞ
 !
for a> 2 and λ> 0 and indicator function I(). Similar to the LASSO this function provides feature
selection by shrinking small coefﬁcients |βj| λ to zero (resulting in a sparse model). However, in
contrast to the LASSO it applies a constant penalty to large coefﬁcients |βj|> aλ (resulting in an
approximately unbiased model). Combining SCAD with the ridge penalty ﬁnally results in the elas-
tic SCAD penalty [56] deﬁned as pðbÞ ¼ pSCADl1 ðbÞ þ l2kbk
2
2 with tuning parameters λ1, λ2 0.
Efﬁcient implementations of SVMs regularized using the penalty functions mentioned before are
available in the R package penalizedSVM (version 1.1) [57].
The normalized miRNA expression data were randomly split at a ratio of 5:3, preserving the
proportion of samples per group. The first partition was used to construct the respective
model, whereas the second was used for evaluation. To estimate the distribution of each mod-
el’s predictive performance, the partitioning was conducted repeatedly applying 500-fold hold-
out sampling (random choice of samples without replacement). The tuning parameters
thereby were trained using 5-fold cross validation and fixed grid search based on the respective
training datasets. The final SVMs then were obtained by selecting the sparsest median perform-
ing model for each investigated classification task. A classifier’s performance thereby was mea-
sured by the area under the receiver operating characteristic (ROC) curve (AUC, sensitivity as
a function of 1-specificity). For illustrative purpose, additional performance measures of vary-
ing informational content were determined, e.g. balanced accuracy (BAC), sensitivity (SN),
specificity (SP). For each classification problem the sets of miRNAs (miRNA signatures) con-
sidered by the sparsest median performing model were selected for further investigation,
including validation with random forests and target enrichment analysis.
According to the principal of majority voting [58], the selected models were used to con-
struct combined classifiers for exemplary diagnostic problems (CD vs. UC, CD vs. UC vs. HC,
CD vs. UC vs. IC and CD vs. UC vs. HC vs. IC). The diagnoses provided by these models were
evaluated using the classification error rate estimated based on the complete dataset. Finally,
the risk of observing small combined error rates by chance was assessed using the Z-statistic
with parameters estimated based on 1,000-fold permutation of the class labels. Corresponding
p-values were calculated using the normal cumulative distribution function and tested for sig-
nificance using the standard significance level of 0.05.
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Validation with random forests
A second machine-learning approach, random forest (RF), was used to analyze the reported
miRNA dataset. RF is an ensemble tree method that was first introduced by Breiman et al. in
2001 [38], and has been shown to be accurate in both classification and regression problems.
Randomization is introduced by constructing each decision tree with a randomly chosen boot-
strap sample. Additionally, at each node the optimal splitting variable is selected among a ran-
dom subset of variables (predictors). Variables selected in RF classification trees are assigned
an importance score that is a measure of how much the particular predictor contributes to clas-
sifying the respective data. In this study relative recurrency variable importance metric
(r2VIM), recently proposed as a measure of variable importance, was used. Based on the per-
mutation importance scheme this measure reduces noisy signal selection [59]. For further
details on the concept of RF refer to Strobl et al. [60]).
To evaluate the validity of the feature selection employed by the penalized SVMs, two ran-
dom forests were built for each classification problem. While the first model incorporated vari-
ables per holdout selected by the RF, the second contained variables per holdout selected by the
SVM (holdout signature). To further validate the meaningfulness of the proposed miRNA sig-
nature, another two random forests were built. This time the variable set was constant across
the training datasets for each classification problem. For the third model all variables selected
in at least one training dataset were ranked by the number of times they were selected and the
50% most frequently selected variables (top signature) were used for training of the RF. Finally,
for the fourth model the variables incorporated by the sparsest median performing SVM
(median signature) were used.
For comparability, model training, as well as evaluation, incorporated the randomly selected
datasets (500-fold holdout partitioning) previously used to construct the SVM classifier. As a
measure of model performance again the area under the ROC curve (AUC) was used. All RF
analyses were performed in R (version 3.0.1) using the packages parallelRandomForest (version
4.6–7) and ROCR (version 1.0–5) [61]. For each forest, 500 trees (ntree) were built with a ter-
minal node size (nodesize) of 10% of the sample size. The number of randomly selected vari-
ables at each node (mtry) was set to the square root of the total number of predictors. For each
analysis a random seed was set to a randomly chosen number between 1 and 100,000.
miRNA target gene enrichment analysis
Experimentally validated miRNA target genes were extracted from miRTarBase [62] version
4.5 and tested for significant enrichment within the previously published IBD susceptibility
loci [5]. In total more than 163 genetic risk loci have been previously identified as being associ-
ated with inflammatory bowel disease (CD: 30, UC: 23, IBD: 110) [5]. 49 out of 1332 experi-
mentally validated miRNA target genes, as listed in miRTarBase, overlap with these loci. To
test for overrepresentation of risk loci among the targets of the miRNAs selected for distin-
guishing CD, UC and HC, Fisher’s exact test was applied (see also S7 Table). Enrichment was
considered as being significant in case p-values were smaller than 0.05. Adjustment for multi-
ple testing was conducted using Bonferroni correction.
Results
Differential expression analysis of peripheral blood miRNAs
To examine potential deregulation, we analyzed expression levels of 863 miRNAs in 40 Crohn’s
disease patients, 36 ulcerative colitis patients as well as 70 healthy control individuals. After
RNA isolation from freshly drawn peripheral blood, miRNA expression data were generated
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utilizing the Geniom Biochip miRNA (Homo sapiens). After batch-correction and normaliza-
tion the background-subtracted microarray intensity values did not show considerable sample-
based mean-variance dependencies or sample-based variability of dispersion estimates. As
illustrated using multidimensional scaling based on Spearman’s rank correlation distance (S1
Fig), the groups of interest are visually hardly distinguishable.
In the differential expression analysis (summarized in S1 Table) we were able to identify
292 and 353 miRNAs as being significantly deregulated in CD and UC, respectively, when
compared to healthy controls (Student's t-test with significance threshold of 0.05 applied to p-
values adjusted for multiple testing according to Holm’s sequential Bonferroni method). In
terms of miRNA expression level differences these results correspond well to previously pub-
lished findings (see S2 Fig and S2 Table). The degree of consistency, thereby, increases with
the sample size of the reference study. The correspondence to expression levels of the core set
of altered miRNAs involved in IBD [14] was estimated to be 75.0%. Additional 20 miRNAs
investigated by Wu et al. (14 cases of active CD, 10 cases of active UC, 13 HC) agree with our
data in 45.0% of the cases [16]. Evaluation of another 7 miRNAs identified in a study employ-
ing 20 UC and 20 HC samples shows a correspondence of 71.4% [48]. Finally, the studies con-
ducted by Zahm et al. [18] (11 deregulated miRNAs identified in 46 cases of active CD and 32
HC) and Paraskevi et al. [22] (17 miRNAs, 128 cases of active CD, 88 cases of active UC, 162
HC) completely overlap with our results (correspondence of 100.0%). Interestingly, a large pro-
portion of miRNAs that have previously been reported as being differentially expressed only
for a certain group (CD or UC) appear to be deregulated similarly in both subtypes in our data
and thus may be general IBD miRNAs. This effect may be explained due to the smaller sample
size and/or higher variability in previous studies.
Classification with penalized support vector machines
Since there are various ways to construct complex classifiers for the distinction between CD,
UC and HC (and IC, respectively), we assessed different types of penalized SVMs as well as the
corresponding sets of miRNAs based on model performance and sparsity. Considering models
incorporating 2 groups, differences in holdout-based median classifier performance of the
penalization methods were small. However, due to its theoretic properties, the elastic SCAD
SVM (median AUC = 0.97) was chosen for further investigation. Plots and tables illustrating
the performance of the LASSO SVM (median AUC = 0.96), elastic net SVM (median
AUC = 0.94) and SCAD SVM (median AUC = 0.95) are shown in S4–S6 Figs and S3–S5
Tables.
Fig 1 summarizes the elastic SCAD SVM’s performance in solving the 16 different diagnos-
tic problems measured by the area under the curve (AUC). The models incorporating 2 groups
show stable superiority (median AUC = 0.97; 0.98 including vs. 0.95 excluding IC) in compari-
son to the models considering 3 groups (median AUC = 0.92; 0.93 including vs. 0.92 excluding
IC) or 4 groups (median AUC = 0.85). In addition, these models provide remarkable sparsity
(median percentage of miRNAs removed = 99.3%, 99.4% including vs. 99.2% excluding IC)
and only marginal loss of performance compared to the standard SVM. As shown in Table 2,
in terms of median sensitivity and specificity, the performance of the selected models can be
estimated as 1.00 and 0.90, respectively (1.00 and 0.91 including IC, 1.00 and 0.90 excluding
IC). The median balanced accuracy (BAC) was 0.95 (0.96 including IC, 0.95 excluding IC).
Additional performance measures (e.g. median Matthews correlation coefficient (MCC) and
Youden’s index (YOUDEN)) are listed in S3 Table for each particular classifier.
The final set of markers selected for diagnostic application is shown in Fig 2. It includes 16
distinct miRNAs originating from elastic SCAD SVMs incorporating 2 groups: hsa-miR-34b-
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Fig 1. SVM classification results.Measured by the area under the ROC curve (AUC), classification performance is shown for models considering (A) 2
groups (CD vs. HC, UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC vs. CD+HC, HC vs. CD+UC, CD vs. UC+IC,
UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups (CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Performance of linear
standard SVMs (considering every miRNAmeasured, white boxes) is compared to linear elastic SCAD SVMs (considering subsets of miRNAs measured,
red boxes). In addition, as a measure of model complexity the percentage of miRNAs neglected for constructing the respective penalized SVMs are plotted
(blue boxes).
doi:10.1371/journal.pone.0140155.g001
Table 2. Performance measures for the different classification models. Corresponding to the classification accuracy of the sparsest median performing
penalized SVM (see Fig 1) for each classifier area under the ROC curve (AUC), sensitivity (SN = TPR, true positive rate), specificity (SP = TNR, true negative
rate) and balanced accuracy (BAC = (SN+SP)/2) are shown.
#groups classiﬁer AUC SN SP BAC
CD/HC 0.950 0.963 1.000 0.981
UC/HC 0.981 1.000 0.900 0.950
CD/UC 0.889 1.000 0.833 0.917
2 median 0.950 1.000 0.900 0.950
CD/IC 0.984 1.000 0.909 0.955
UC/IC 1.000 1.000 1.000 1.000
IC/HC 0.752 0.750 0.765 0.757
median 0.984 1.000 0.909 0.955
CD/UC+HC 0.893 0.969 0.692 0.831
UC/CD+HC 0.917 0.971 0.800 0.886
HC/CD+UC 0.974 1.000 0.963 0.981
3 median 0.917 0.971 0.800 0.886
CD/UC+IC 0.876 0.951 0.800 0.876
UC/CD+IC 0.933 0.976 0.889 0.933
IC/CD+UC 0.984 0.950 1.000 0.975
median 0.933 0.951 0.889 0.933
CD/UC+HC+IC 0.885 0.970 0.800 0.885
UC/CD+HC+IC 0.930 0.985 0.800 0.893
4 HC/CD+UC+IC 0.758 0.830 0.708 0.769
IC/CD+UC+HC 0.817 0.860 0.765 0.813
median 0.851 0.915 0.783 0.849
doi:10.1371/journal.pone.0140155.t002
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3p, hsa-miR-142-5p, hsa-miR-205-5p, hsa-miR-424-5p, hsa-miR-570-3p, hsa-miR-885-5p,
hsa-miR-1301-3p (CD vs. HC), hsa-miR-16-5p, hsa-miR-34b-3p, hsa-miR-99b-5p (UC vs.
Fig 2. Expression profile of signature miRNAs.Median normalized expression levels for miRNAs considered by the final models (sparsest median
performing elastic SCAD SVMs) used to distinguish CD, UC and HC are shown. The heat map was generated using a distance function based on
Spearman’s rank correlation coefficient and agglomerative hierarchical clustering using complete-linkage. Low and high expression levels are plotted using
red and blue, respectively.
doi:10.1371/journal.pone.0140155.g002
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HC) and hsa-miR-34b-3p, hsa-miR-377-3p, hsa-miR-484, hsa-miR-574-5p, hsa-miR-656-3p,
hsa-miR-744-5p, hsa-miR-1247-5p, hsa-miR-1908-5p (CD vs. UC, miRBase version 21
nomenclature). The corresponding models provide tools for the distinction of CD and UC as
well as CD, UC and HC with remarkable small classification error rates of 3.1 and 3.3%, respec-
tively (i.e. applying the proposed models will result in approximately 3 incorrect diagnoses per
100 tests). Notably, these estimates are not based on an independent dataset. Therefore, they
are potentially optimistic but still provide a measure for the combined classifier’s diagnostic
value. This is confirmed by permutation tests showing significant deviation of the classification
error from its random expectation. For further examples of classifier combinations and the cor-
responding size of miRNA signatures see S6 Table.
Validation using random forests
A second, independent machine learning approach, random forest analysis (RFs), was
employed to validate our SVM-based miRNA signatures. As shown in Table 3, random forest
analyses confirmed our SVM results. In the case of models considering 2 groups, the perfor-
mance differences were small (AUC = 0.990 for the SVM using the entirety of the miRNAs,
AUC = 0.992 for the RF per holdout sample using miRNAs selected by the RF and
AUC = 0.996 for the RF using the top 50% of the miRNAs most frequently selected by the RF
across all runs). When using the miRNAs selected by the elastic SCAD SVM for training the
RF in the same way, highly accurate models were obtained: AUC = 0.965 for the elastic SCAD
SVM, AUC = 0.992 for the RF per holdout sample using miRNAs selected by the elastic SCAD
SVM and AUC = 0.994 for the RF using the miRNAs considered by the median performing
elastic SCAD SVM. These results strongly support the validity of the miRNA combinations
chosen as putative diagnostic markers by the SVM approach.
Target genes of the diagnostic miRNA signature correlate with
susceptibility genes
To assess the potential biological significance of miRNAs within the signatures revealed by the
machine-learning approaches we correlated previous knowledge about disease relevance of
IBD-related genes to the experimentally validated target genes of the miRNA signatures
(results summarized in Table 4 and S7 Table). Irrespective of the miRNA signature tested (CD
vs. HC, UC vs. HC or CD vs. UC), we observed an overlap of miRNA target genes and pub-
lished IBD-related genes or, on the other hand, genes within known IBD susceptibility loci.
Thus, target genes of signature miRNAs used for the distinction of CD and HC are significantly
enriched for loci known to be associated with CD (p = 3.2210−3), UC (p = 1.0910−3) and sug-
gestive for IBD (p = 4.3710−2). Targets of signature miRNAs used for the distinction of UC
and HC show suggestive enrichment for loci associated with CD (p = 3.3410−2). Considering
Table 3. Comparison of classification approaches. The table shows the median classifier performance (AUC) of the classification problems considering
different numbers of groups (2, 3 and 4) and models (SVM and RF). Performance of the standard SVM is compared to the elastic SCAD SVM (a). Perfor-
mance of the RF per holdout sample using the miRNAs selected by the RF is compared to the RF per holdout sample using the miRNAs selected by the elas-
tic SCAD SVM (b). Performance of the RF using the top 50% of the miRNAs most frequently selected by the RF across all runs is compared to the RF using
the miRNAs selected by the median performing elastic SCAD SVM (c). For each comparison performance estimates based on miRNAs selected by the elas-
tic SCAD SVM are enclosed in parentheses.
classiﬁcation signature 2 groups 2 groups, no IC 3 groups 3 groups, no IC 4 groups
(a) SVM 0.990 (0.965) 0.981 (0.950) 0.938 (0.925) 0.931 (0.917) 0.858 (0.851)
(b) RF, holdout signature 0.992 (0.992) 0.985 (0.985) 0.978 (0.980) 0.969 (0.974) 0.919 (0.910)
(c) RF, top/median signature 0.996 (0.994) 0.992 (0.988) 0.982 (0.989) 0.977 (0.992) 0.941 (0.940)
doi:10.1371/journal.pone.0140155.t003
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the targets of the complete set of miRNAs used for the distinction of CD, UC and HC sugges-
tive enrichment is observed for previously published susceptibility loci of CD (p = 4.8010−3)
and UC (p = 4.8010−3).
In a next step we investigated whether previously identified genetic variation in the IBD sus-
ceptibility genes could directly play a role in miRNA-target gene interaction. We used dbSNP
annotations of the human genome provided by the UCSC genome browser to identify SNPs
that could interfere with miRNA binding sites. As a result we found that most 3’-UTRs of the
analyzed IBD-risk genes indeed exhibit genetic variation (SNPs and small InDels) but mostly
not in the respective signature-miRNA binding site regions. Only for hsa-miR-99b, which is
part of the UC signature, we were able to identify potentially interesting SNPs located in the
essential miRNA binding site seed regions of RAVER2 (rs183861354, chr1:64831085, G>A)
and mTOR (rs375505566, chr1:11107188, G>A). Strikingly, both SNPs change the same
nucleotide position within the seed region of the miRNA binding site. Whether this single
nucleotide variant affects the binding behavior and as a consequence the gene functions in IBD
cases compared to healthy controls, remains to be shown.
Discussion
In this study we compared miRNA expression profiles of whole peripheral blood samples from
patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis) to healthy
controls and “disease controls”. We were able to confirm significantly deregulated miRNAs in
blood that were previously reported by others and could further add new candidates to the cat-
alogue of IBD-associated miRNAs. To our knowledge this study represents the largest (both in
terms of samples and measured miRNAs) blood-based miRNA-expression study for IBD pub-
lished to date. Our analysis, however, was focused on the identification of disease specific,
Table 4. Signature miRNAs regulate target genes previously identified as IBD-risk genes. Both CD and UC diagnostic signatures contain several miR-
NAs that regulate experimentally validated target genes known to be involved in IBD-related phenotypes in humans and/or mice. Genes marked with * have
even been reported as candidate genes in susceptibility loci identified in recent IBD GWAS.
signature miRNA target gene function/disease implication reference
CD/HC hsa-miR-205 LRRK2 * susceptibility gene for CD [63]
SHIP2/INPPL1 regulator of PI3K, therapeutical target in inﬂammation [64]
ZEB1 regulates intestinal cell growth [65]
E2F1 activation promoted by chronic inﬂammation [66]
ERBB3 inhibits treatment of IBD [67]
hsa-miR-142-5p NFE2L2/NRF2 susceptibility for DSS-induced colitis [68]
hsa-miR-424 MYB colonic epithelial disruption by mir-150 [69]
CUL2 * susceptibility gene for CD [70]
PU.1 role in T-cell mediated colitis [71]
hsa-miR-34b HNF4A * susceptibility gene for early onset CD [72]
CREB1 diverse implications in CD [73]
UC/HC hsa-miR-34b HNF4A * susceptibility gene for UC [74]
NOTCH1 regulator of intestinal epithelial barrier [75]
c-MET/HGFR upregulated in UC [76]
CAV1 upregulated in UC inﬂamed tissue [77]
hsa-miR-99b RAVER2 * susceptibility gene for UC [78]
mTOR inhibition depletes mouse colitis [79]
hsa-miR-16 HMGA1/2 P-ANCA autoantigens [80]
ACVR2a associated with IBD-related CRC [81]
doi:10.1371/journal.pone.0140155.t004
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diagnostic classification signatures derived from the overall miRNA expression profiles irre-
spective of single miRNA deregulation.
miRNAs are often referred to as “blood-based biomarkers” for diagnosing disease or moni-
toring disease progression. As it has been shown for several types of cancer this holds true as
long as a relatively stable condition, such as a recurrent aberrant gene expression in certain tis-
sues or exosomal miRNA content can be measured repeatedly. Concerning blood-based
miRNA expression in inflammatory or auto-immune diseases, however, the assumption of sta-
ble conditions is often violated. Numerous known comorbidities as well as environmental and
life-style factors, treatment and disease activity may influence miRNA levels in the blood
stream and lead to intra- and interindividual miRNA-expression variability. Also general fac-
tors like blood cell composition, depending on the type of disease may vary significantly, and
hence impact miRNA levels in peripheral blood. Thus, instead of aiming to identify single
miRNA “biomarkers”, to enhance predictive power it appears more promising to investigate
complex predictors that are based on larger numbers of miRNAs. In this way, besides simple
deregulation, also certain combinations of regulatory effects are taken into account for diagnos-
tic or predictive models.
In this work we demonstrated the use of machine-learning techniques to construct IBD-spe-
cific miRNA signatures and we were able to reveal highly accurate classification models that
distinguish healthy and diseased individuals as well as the two main IBD subtypes and other
inflammatory conditions from each other. Furthermore, a minimal set of not more than 16
miRNAs, being sufficient for sensitive and specific classification, holds great promises and
should be further evaluated in independent sample panels.
The here-investigated models represent solutions to construct classifiers for miRNA expres-
sion data but they also exhibit some limitations, most notably the limited generalizability of the
models to other technologies. All models are trained based on the same type of data that origi-
nate from a certain technology (here the Geniom Array). Application of these models to inde-
pendent samples in a clinical or diagnostic setting would always require to remove technology
biases. In addition to that, the here-presented classifiers remain restricted to the set of miRNAs
that are present on the microarray used to detect differential expression. Future studies utiliz-
ing next generation sequencing (NGS) will presumably overcome this limitation as all present
miRNAs in a sample are theoretically detectable by this technology. Furthermore, implement-
ing approaches that include more levels of available information e.g. genetic variants, micro-
biome data or clinical data from electronic health records (that include information on
differential diagnoses, medication, disease activity, etc.) will potentially add to the predictive
power needed for highly sensitive and specific classification.
Regularized instances of support vector machines incorporate penalties for model complex-
ity to prevent overfitting and to provide sparse solutions. In the here-presented study this prop-
erty is used to obtain small sets of miRNAs suitable for diagnostic application. It is expected
that miRNAs essential for solving a particular classification problem likewise are selected by
random forests using the recurrent relative variable importance. However, this approach does
not aim at selecting a minimal set of features so that one does not expect miRNA signatures to
be fully overlapping. To obtain more comparable results, future studies might consider regular-
ized random forests as introduced by Deng and Runger [82]. In this work the miRNA signature
selected using the elastic SCAD SVM was confirmed by comparably high classification perfor-
mance of random forests as an independent classification approach. For this purpose afore-
mentioned limitations can be neglected.
To obtain a model applicable with high accuracy to independent data we chose the sparsest
median performing elastic SCAD SVM along with the corresponding miRNA signature. Both,
the regularization approach and the comprehensive holdout sampling decrease the model’s
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probability of being overfitted to the dataset generated for this study. However, due to correlat-
ing expression profiles it is expected that models with matching accuracy potentially incorpo-
rate differing miRNAs. For the same reason more complex signatures may exist which merely
incoporate additional highly correlated miRNAs.
Classifiers for complex diagnostic problems were constructed by majority voting of simpler
models. As shown in this study, this approach results in remarkable low classification error
rates. However, follow-up studies could potentially incorporate the estimation of class proba-
bilities to enhance the interpretability of the classification results.
To get insights into functional implications of the miRNAs contained in the revealed IBD
signature, we screened current databases for experimentally validated miRNA-target gene
interactions. Notably, a considerable fraction of the target genes within the IBD miRNA signa-
tures has been implicated in intestinal diseases (see Table 4). Many of those targets were identi-
fied in recent IBD GWAS but most of the genetic variation detected does not correlate (and
thus not interfere) with miRNA regulatory binding sites. Only the hsa-mir-99b binding sites in
the 3’-UTRs of the IBD susceptibility gene RAVER2, a ribonucleoprotein (hnRNP) involved in
regulation of splicing and mTOR, a serine/threonine proteine kinase, shown to be involved in
activation of autophagy, represent good candidates for further experimental investigation. In
the future, more complete data on genetic varation in 3’-UTRs of IBD related genes will sup-
posedly come from whole genome sequencing approaches and will thus enable for more com-
plete analyses of miRNA target genes. In a recent review on genetic studies in IBD Liu and
Anderson [83] conclude that most of the identified GWAS loci actually reside in noncoding
regions of the genome and that a vast number of these noncoding variants will likely play a role
in gene regulation. miRNAs are certainly an important part of the regulatory machinery of the
genome, but besides their utility in diagnostics, miRNA signatures might also give valuable
insights into disease development and progression.
Supporting Information
S1 Fig. MDS (multidimensional scaling) plots for visualization of background-subtracted
intensity values. Background-subtracted intensity values normalized using variance stabiliza-
tion (A) before and (B) after median centering based on the batches observed for healthy con-
trols. The corresponding medians are indicated by black circles. MDS was performed using a
distance function based on Spearman’s rank correlation coefficient. Data points of each group
are represented by their α-shape (generalized convex hull). The second plot visualizes the
batch-corrected normalized data used for diagnostic classification.
(TIFF)
S2 Fig. Median expression levels of miRNAs previously published as being deregulated in
CD, UC and HC. The horizontal side bar indicates the correspondence between the literature
and the dataset used for this study. Measurements with directions of effect deviating from the
literature are marked using black bars. The heat map was generated using a distance function
based on Spearman’s rank correlation coefficient and agglomerative hierarchical clustering
using complete-linkage. Low and high expression levels are plotted using red and blue, respec-
tively.
(TIFF)
S3 Fig. Median expression profiles of significantly deregulated miRNAs in CD, UC and
HC. For each pair of groups two-sample t-tests were applied. Deregulation was considered as
being significant for Holm-corrected p-values<0.05. Not significantly differentially expressed
miRNAs were neglected. 667 out of 863 miRNAs were differentially deregulated in any of the
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comparisons.
(TIFF)
S4 Fig. Classification results for LASSO SVM.Measured by the area under the ROC curve
(AUC) classification performance is shown for models considering (A) 2 groups (CD vs. HC,
UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC vs.
CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups
(CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Perfor-
mance of linear standard SVMs (considering every miRNA measured, white boxes) is com-
pared to linear LASSO SVMs (considering subsets of miRNAs measured, red boxes). In
addition, as a measure of model complexity the percentage of miRNAs neglected for construct-
ing the respective penalized SVMs are plotted (blue boxes).
(TIFF)
S5 Fig. Classification results for elastic net SVM.Measured by the area under the ROC curve
(AUC) classification performance is shown for models considering (A) 2 groups (CD vs. HC,
UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC vs.
CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups
(CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Perfor-
mance of linear standard SVMs (considering every miRNA measured, white boxes) is com-
pared to linear elastic net SVMs (considering subsets of miRNAs measured, red boxes). In
addition, as a measure of model complexity the percentage of miRNAs neglected for construct-
ing the respective penalized SVMs are plotted (blue boxes).
(TIFF)
S6 Fig. Classification results for SCAD SVM.Measured by the area under the ROC curve
(AUC) classification performance is shown for models considering (A) 2 groups (CD vs. HC,
UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC vs.
CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups
(CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Perfor-
mance of linear standard SVMs (considering every miRNA measured, white boxes) is com-
pared to linear SCAD SVMs (considering subsets of miRNAs measured, red boxes). In
addition, as a measure of model complexity the percentage of miRNAs neglected for construct-
ing the respective penalized SVMs are plotted (blue boxes).
(TIFF)
S7 Fig. Comparison of SVM and random forest.Measured by the area under the ROC curve
(AUC) classification performance is shown for models considering (A) 2 groups (CD vs. HC,
UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC vs.
CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups
(CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Classifi-
cation performance of the linear elastic SCAD SVM (white box) is compared to a Random for-
ests per holdout sample considering variables selected using the SVM (red box) and the
Random forest itself (blue box), respectively.
(TIFF)
S8 Fig. Comparison of SVM and random forest.Measured by the area under the ROC curve
(AUC) classification performance is shown for models considering (A) 2 groups (CD vs. HC,
UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC vs.
CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups
(CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC).
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Classification performance of the linear elastic SCAD SVM (white box) is compared to a Ran-
dom forests considering variables selected using the median performing SVM (red box).
Additionally, Random forests were trained with the top 50% of the variables ranked by their
frequency of selection (blue box).
(TIFF)
S1 Table. Differential expression analysis. For each binary combination of groups t-tests for
differential miRNA expression were conducted. The test results are summarized by the fold
change (fc), the t-statistic (t), the p-value (p) and the p-values adjusted for multiple testing
using Holm-correction (padj).
(XLSX)
S2 Table. miRNAs previously described to be deregulated in IBD. Tables were adapted from
Chen et al. (A) and Coscun et al. (B), respectively. For binary comparisons (CD vs. HC, UC vs.
HC, IBD vs. HC and CD vs. UC). Directions of effect known from the literature as well as mea-
sured by the microarray used for this study are summarized.
(XLSX)
S3 Table. Performance measures for LASSO SVM. Corresponding to the classification accu-
racy of the sparsest median performing penalized SVM (see S4 Fig) for each classification task
area under the ROC curve (AUC), Matthews correlation coefficient (MCC), balanced accuracy
(BAC), Youden’s index (YOUDEN), sensitivity (SN = TPR), specificity (SP = TNR), positive
predictive value (PPV), false discovery rate (FDR), negative predictive value (NPV) and false
omission rate (FOR) are shown.
(XLSX)
S4 Table. Performance measures for elastic net SVM. Corresponding to the classification
accuracy of the sparsest median performing penalized SVM (see S5 Fig) for each classification
task area under the ROC curve (AUC), Matthews correlation coefficient (MCC), balanced
accuracy (BAC), Youden’s index (YOUDEN), sensitivity (SN = TPR), specificity (SP = TNR),
positive predictive value (PPV), false discovery rate (FDR), negative predictive value (NPV)
and false omission rate (FOR) are shown.
(XLSX)
S5 Table. Performance measures for SCAD SVM. Corresponding to the classification accu-
racy of the sparsest median performing penalized SVM (see S6 Fig) for each classification task
area under the ROC curve (AUC), Matthews correlation coefficient (MCC), balanced accuracy
(BAC), Youden’s index (YOUDEN), sensitivity (SN = TPR), specificity (SP = TNR), positive
predictive value (PPV), false discovery rate (FDR), negative predictive value (NPV) and false
omission rate (FOR) are shown.
(XLSX)
S6 Table. Exemplary diagnostic application. The final median performing models were used
to predict the disease status based on each individual’s miRNA expression data. For each com-
bined classifier, constructed using majority voting, the number of groups, n(groups), consid-
ered by the atomic models as well as the respective number of miRNAs, n(mirnas), and unique
miRNAs, n(unique), are shown. In addition the classification errors per individual’s group (ε
(CD), ε(UC), ε(HC) and ε(IC)) were estimated. Furthermore, for each classifier the mean clas-
sification error (mean) as well as the corresponding permutation based Z-score (Z(mean))
were calculated. Z-scores corresponding to p-values lower than the significance threshold of
0.05 are marked using .
(XLSX)
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S7 Table. Enrichment analysis for validated signature miRNA targets. The proportion of
validated targets of the miRNAs selected for diagnostic prediction (CD vs. HC, UC vs. HC, CD
vs. UC and CD vs. UC vs. HC) known to be coded at risk loci (CD, UC and IBD) is compared
to the proportion of general miRNA targets known to be coded at risk loci (CD, UC and IBD).
Targets of signature miRNA coded at risk and non-risk loci are denoted as C_r and C, repec-
tively. miRNA targets excluding signature targets coded at risk and non-risk loci are denoted as
R_r and R, repectively. The total number of validated miRNA targets is denoted as N. Enrich-
ment analysis was performed using Fisher’s exact test, resulting p-values are marked as being
nominal significant (, p<0.05) and significant after Bonferroni correction for multiple testing
(; padj<0.05).
(XLSX)
S8 Table. Raw miRNA expression data. Background subtracted microarray intensities from
GeniomWizard Software that were used to infer miRNA expression levels.
(XLSX)
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Supplementary Figure S2.1: MDS (multidimensional scaling) plots for visualization of
background-subtracted intensity values. Background-subtracted intensity values normalized using
variance stabilization (A) before and (B) after median centering based on the batches observed for healthy
controls. The corresponding medians are indicated by black circles. MDS was performed using a distance
function based on Spearman’s rank correlation coefficient. Data points of each group are represented by
their α-shape (generalized convex hull). The second plot visualizes the batch-corrected normalized data
used for diagnostic classification.
Supplementary Figure S2.2: Median expression levels of miRNAs previously published as
being deregulated in CD, UC and HC. The horizontal side bar indicates the correspondence between
the literature and the dataset used for this study. Measurements with directions of effect deviating from
the literature are marked using black bars. The heat map was generated using a distance function based
on Spearman’s rank correlation coefficient and agglomerative hierarchical clustering using complete-linkage.
Low and high expression levels are plotted using red and blue, respectively.
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Supplementary Figure S2.3: Median expression profiles of significantly deregulated miRNAs
in CD, UC and HC. For each pair of groups two-sample t-tests were applied. Deregulation was considered
as being significant for Holm-corrected p-values < 0.05. Not significantly differentially expressed miRNAs
were neglected. 667 out of 863 miRNAs were differentially deregulated in any of the comparisons.
Supplementary Figure S2.4: Classification results for LASSO SVM. Measured by the area under
the ROC curve (AUC) classification performance is shown for models considering (A) 2 groups (CD vs.
HC, UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC
vs. CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups (CD
vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Performance of linear
standard SVMs (considering every miRNA measured, white boxes) is compared to linear LASSO SVMs
(considering subsets of miRNAs measured, red boxes). In addition, as a measure of model complexity the
percentage of miRNAs neglected for constructing the respective penalized SVMs are plotted (blue boxes).
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Supplementary Figure S2.5: Classification results for elastic net SVM. Measured by the area
under the ROC curve (AUC) classification performance is shown for models considering (A) 2 groups (CD
vs. HC, UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC
vs. CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups (CD
vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Performance of linear
standard SVMs (considering every miRNA measured, white boxes) is compared to linear elastic net SVMs
(considering subsets of miRNAs measured, red boxes). In addition, as a measure of model complexity the
percentage of miRNAs neglected for constructing the respective penalized SVMs are plotted (blue boxes).
Supplementary Figure S2.6: Classification results for SCAD SVM. Measured by the area under
the ROC curve (AUC) classification performance is shown for models considering (A) 2 groups (CD vs.
HC, UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC
vs. CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups
(CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Performance of
linear standard SVMs (considering every miRNA measured, white boxes) is compared to linear SCAD SVMs
(considering subsets of miRNAs measured, red boxes). In addition, as a measure of model complexity the
percentage of miRNAs neglected for constructing the respective penalized SVMs are plotted (blue boxes).
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Supplementary Figure S2.7: Comparison of SVM and random forest. Measured by the area
under the ROC curve (AUC) classification performance is shown for models considering (A) 2 groups (CD
vs. HC, UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC,
UC vs. CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups
(CD vs. UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Classification
performance of the linear elastic SCAD SVM (white box) is compared to a Random forests per holdout
sample considering variables selected using the SVM (red box) and the Random forest itself (blue box),
respectively.
Supplementary Figure S2.8: Comparison of SVM and random forest. Measured by the area
under the ROC curve (AUC) classification performance is shown for models considering (A) 2 groups (CD
vs. HC, UC vs. HC, CD vs. UC, CD vs. IC, UC vs. IC, IC vs. HC), (B) 3 groups (CD vs. UC+HC, UC
vs. CD+HC, HC vs. CD+UC, CD vs. UC+IC, UC vs. CD+IC, IC vs. CD+UC) and (C) 4 groups (CD vs.
UC+HC+IC, UC vs. CD+HC+IC, HC vs. CD+UC+IC, IC vs. CD+UC+HC). Classification performance
of the linear elastic SCAD SVM (white box) is compared to a Random forests considering variables selected
using the median performing SVM (red box). Additionally, Random forests were trained with the top 50%
of the variables ranked by their frequency of selection (blue box).
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Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing disorder of the alimentary tract, encompassing two
clinical entities, namely Crohn’s disease (CD) and ulcerative colitis (UC). In the course of the last decades
IBD has been recognized as an increasingly common diagnosis, rendering a significant burden to societies and
healthcare systems around the world. The diagnostic procedure for both IBD subtypes involves a combination
of clinical, endoscopic, histological and radiological parameters. Numerous biomarkers have been proposed to
complement IBD diagnosis. However, due to insufficient accuracy none of them can be recommended for clinical
diagnostic practice. With this study we present the first-time evaluation of the clinical utility of miRNA variants
(isomiRs) in the context of IBD.
Global profiling of isomiRs expression has been conducted by next generation sequencing based on whole-
blood samples drawn from a cohort of 515 individuals (346 cases of untreated/treated IBD as well as 124 healthy
and 45 symptomatic controls). The resulting profiles have been used to identify trait-specific signatures of isomiR
expression, providing the foundation to derive binomial as well as multinomial classification models for IBD-
related diagnostic problems. For pairs of untreated phenotypes (CD−, UC−, including HC) we estimated these
models to perform with a median BAC of 0.9286. Models distinguishing pairs of treated phenotypes (CD+,
UC+, including HC), in turn, we estimated to perform with a median BAC of 0.9655. According to the principal
of majority voting, binomial models have been used to construct combined classifiers, solving 3-nomial (CD+
vs. UC+ vs. HC, CD− vs. UC− vs. HC and CD− vs. UC− vs. SC) as well as 4-nomial diagnostic problems
(CD− vs. UC− vs. SC vs. HC). With mean BACs of up to 0.9000 and 0.8667, respectively, the performance of
the models likewise has been estimated to be remarkably high.
Overall, we do not only provide evidence for sequencing-based isomiR expression profiles being a valuable
tools for diagnosing IBD but also for their superiority over established biomarkers. However, the translatability
of these findings into routine clinical practice remains to be proven.
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1 Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing disorder of the alimentary tract. It encompasses two
major subtypes, namely Crohn’s disease (CD) and ulcerative colitis (UC), each showing extensive heterogeneity
in terms of clinical and histological presentation as well as response to treatment. A growing body of evidence
suggests the disease being a results of dysregulated inflammatory response to commensal microbes in a genetically
susceptible host. In a series of genome-wide association studies (GWAS, including [11, 25]) 241 genetic loci have
been identified to be associated with IBD. While these GWAS findings added tremendously to the understanding
of the genetic architecture of the disease, the exact mechanisms of its pathogenesis is barely understood and
linking SNP associations to functional mechanisms is a major challenge to the field. Consequently, the different
aspects of gene regulation also have been investigated in IBD.
microRNAs (miRNAs) represent a class of short endogenous, non-coding ribonucleic acids (RNAs), acting
as master post-transcriptional regulators of a wide range of physiological and pathological processes. Thus, the
molecules modulate the activity of specific messenger RNAs (mRNAs) by predominantly targeting their 3’ UTR
region [2]. As evident from a growing number of studies each single miRNA hairpin arm (3’ and 5’, respectively)
can give rise to numerous variants, referred to as isomiRs, which differ in length and sequence composition [16,
36, 49]. These variants can be classified into (templated or non-templated) 3’ and 5’ isomiRs, respectively, as
well as polymorphic isomiRs. Their abundance is shown to vary depending on gender, ethnicity [29], tissue, cell
type [21] and state of health [49]. It has been shown that 5’ isomiRs extend target repertoire of their corresponding
reference miRNAs [7], whereas 3’ isomiRs seem to be involved in modulation of miRNA targeting effectiveness [5]
and even in subcellular and extracellular miRNA trafficking [23, 53]. However, their biological significance still
needs to be investigated.
Due to their short length miRNAs are considered to be more stable than mRNAs [22], even in tissues and body
fluids, such as peripheral blood [35]. Furthermore, they are shown to be deregulated in a variety of conditions,
including cancer [6, 31] and autoimmune disorders [1, 13, 46], and signatures of differentially expressed miRNAs
have been intensively studied as biomarkers for the prediction of diseases. Noteworthy, in the context of IBD
the number of blood-based studies of differential miRNA expression is limited. Thus, for instance, Paraskevi
et al. [39] as well as Schaefer et al. [45] reported distinct expression patterns for a small number of candidate
miRNAs comparing CD, UC with the healthy state (HC) based on real-time quantitative PCR (RT-qPCR). To-
date, the only miRNome-wide analyses of IBD have been performed by Wu et al. [52] and Hu¨benthal et al. [17].
Employing microarray technology these studies revealed putative biomarkers (along with mathematical models)
for the distinction of CD, UC and HC.
Relying on predefined annealing probes, microarray technology solely allows the detection of annotated miRNAs
and isomiRs, respectively. Next generation sequencing (NGS) technology, instead, enables the quantification of
the entire set of isomiRs being expressed in a given sample. Recent studies of colonic/ileal miRNAs/isomiRs em-
ployed NGS for the distinction between CD, UC and healthy controls [4, 27, 28] or between CD subtypes among
each other [40]. However, global NGS-based profiles of miRNAs/isomiRs circulating in whole blood so far have
not been investigated in the context of IBD.
This study now examines isomiR expression profiles of 515 individuals (346 cases of IBD as well as 124 healthy
and 45 symptomatic controls) and state-of-the-art machine learning methods to identify trait-specific signatures.
Therewith, we provide the to-date most comprehensive discriminative analysis of sequencing-based isomiR ex-
pression profiles from whole blood, contributing to a more comprehensive understanding of inflammatory bowel
disease. Ultimately, we present classification models for highly accurate sequencing-based isomiR-guided diag-
nostics of IBD and a multitude of other diagnostically relevant problems. These models serve as exemplary
applications of signatures of differentially expressed isomiRs and represent the first-time evaluation of the discrim-
inative power of these molecules in the context of IBD. Our data clearly shows that isomiR expressions profiles are
2
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a powerful tool for the distinction of CD and UC in both, treated and untreated patients. However, the signature
enabling the distinction varies depending on the treatment status.
2 Materials and methods
2.1 Patients and samples
For study participants recruited in Germany and Sweden biological samples as well as clinical meta-data was
collected. The study has been approved by the respective local ethics committees (PopGen 2.0 Netzwerk (P2N) and
ethics committee of the medical faculty, University Hospital Schleswig-Holstein, Kiel, Germany; ethics committee
of the Karolinska Institutet, Stockholm, Sweden). All participants provided written informed consent.
The German cohort comprises 94 healthy individuals as well as 271 patients diagnosed with inflammatory
conditions. The diagnoses include Crohn’s disease (treated CD denoted as CD+, n=146) and ulcerative colitis
(treated UC denoted as UC+, n=125). The Swedish cohort (Swedish Inception Cohort in IBD, SIC IBD) in turn,
includes 30 healthy individuals as well as 120 patients diagnosed with inflammatory conditions. The diagnoses
comprise Crohn’s disease (untreated CD denoted as CD−, n=27) and ulcerative colitis (untreated UC denoted as
UC−, n=48). Patients with gastro-intestinal symptoms not being diagnosed with IBD have been considered as
symptomatic controls (SC, n=45). For a summary reference is made to Table S1.
A major difference between the German and Swedish cohort is their treatment status. Swedish samples were
included in the SIC IBD cohort at first diagnosis of IBD. This implies their na¨ıvety with regard to any IBD med-
ication. More precisely, criteria for excluding patients were systemic treatment with immunosuppressants, such
as Infliximab (Remicade, Remsima, Inflectra), Adalimumab (Humira, Exemptia), Methotrexat (Trexall, Rheuma-
trex), Azathioprine (Azasan, Imuran), Tacrolimus (Prograf, Advagraf) and Ciclosporin (Neoral, Sandimmune).
Furthermore, topical treatment (by suppository or enema) with Mesalazine (Azacol, Lialda), systemic treatment
with corticosteroids, such as budesonide (Entocort) as well as with sulfasalazine (Azulfidine, Salazopyrin), 6-
Mercaptopurine (Purinethol), Vedolizumab (Entyvio) or Certolizumab (Cimzia), respectively, lead to exclusion of
participants. In contrast German samples are assumed to be treated with one or more of the drugs mentioned
before. For further details see Table 1.
CD and UC cases of both cohorts have been evaluated with regard to disease activity the Harvey-Bradshaw
index (HBI), the clinical activity index according to Rachmilewitz (CAI) as well as the partial Mayo score,
respectively [8, 43, 44]. In addition to medication and disease activity, patients have been evaluated with regard
to common clinical parameters, such as gender and smoking status. Furthermore, information on disease location,
behavior, extent (Montreal classification) as well as serological (C-reactive protein, CRP; albumin) and fecal
markers (calprotectin) has been collected. For details including parameter’s distributional information reference
is made to Table 1.
2.2 RNA isolation and sequencing
Stabilization and purification of total RNA (including miRNA) from whole blood samples was conducted employing
the PAXgene Blood miRNA System (Qiagen) in accordance to the manufacturers’ instructions. The products
were subjected to Illumina’s TruSeq Small RNA Sample Preparation protocol to generate small RNA libraries
for each sample. Subsequently, sequencing was conducted on Illumina HiSeq 2500 machines (24 samples per lane,
single-end reads of 50bp length, TruSeq sequencing chemistry v2.5, 3.0 or 4.0).
Raw sequencing reads as well as quantified read-count data will be deposited at NCBI Gene Expression
Omnibus (GEO) [10].
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2.3 Processing of small RNA-seq data
Raw small RNA sequencing reads were processed using cutadapt v1.3 [33] to remove adapters, low-quality bases
(<Q20) and reads shorter than 18bp. Processed reads which mapped to viral genomes, viral miRNA precursors
and human non-miRNA short RNAs were filtered out. The remaining reads were mapped to miRNA sequences
from miRBase release 22 [24] using mirAligner [37] with default parameters. The R package isomiRs [38] then
was used to generate read count data. Thereby for a given reference miRNA mismatches observed in < 20%
of the reads were considered as sequencing errors. The corresponding reads have been removed accordingly.
Furthermore requiring the sum of counts to be ≥ 106 for each sample and the number of samples to be ≥ 10 for
each technical batch under consideration we obtained count matrices of 14874 isomiRs for the German (comprising
365 samples) as well well as the Swedish cohort (comprising 150 samples). By considering only reads with counts
exceeding 5 in a fraction of samples of >10% per batch, sex and trait the number of isomiRs reduced to 2895
for the German and 1954 for the Swedish cohort. We only incorporate isomiRs featuring canonical nucleotide
substitutions (cytidine (C) to uridine (U) and (A) to inosine (I) deamination) as well as canonical nucleotide
additions (poly(A) and poly(T) tailing), further reducing dimensionality to 2426/1565 for the German/Swedish
cohort. Besides 282/213 reference miRNAs, the final datasets comprise 1739/1100 3’ trimming modifications,
723/405 5’ trimming modifications, 737/460 3’ end additions as well as 8/6 nucleotide substitutions (including
3/2 seed alterations).
This dataset was normalized by performing variance stabilizing transformation (VST) based on parametric
dispersion estimates as implemented in the R package DESeq2 [30]. Samples for which normalized counts x met
x ≷ |median(x)± 3 · ICQ(x)| (with respect to batch and trait) were considered as being outliers and removed.
Subsequently, the same criterion was applied to exclude outliers with regard to relative log expression (RLE).
After renormalization adjustment for biological (gender) as well as experimental batches (sequencing technician,
chemistry and run) has been performed, employing the empirical Bayesian framework implemented by the R
function sva::ComBat [20, 26]. Explorative plots then were generated based on a multidimensional scaling (MDS)
of the data employing Spearman dissimilarities.
2.4 Differential expression analysis
Subsequent to the preprocessing of the isomiR read count data differential expression analysis has been performed
to facilitate the identification of trait-specific isomiR expression patterns. The analysis is based on generalized
linear models (GLMs) allowing for pairwise comparisons of the traits of interest while adjusting for unwanted
biological/experimental variability. Significance of isomiR deregulation thereby corresponds to non-negligibility of
log fold changes (log2 FC) and is assessed by applying Wald tests to the coefficients of the GLM. For the Swedish
dataset we conducted 6 pairwise comparisons, incorporating untreated IBD (CD− and UC−) as well as controls
(SC and HC). For the German dataset, in turn, we conducted 4 pairwise comparisons, incorporating treated
IBD (CD+ and UC+) as well as controls (HC). Direct comparison between subsets of the Swedish and German
cohorts have not been performed. However, by employing HC as a mutual reference, exclusive features of isomiR
expression profiles (for CD−, UC−, CD+, UC+, SC) can be identified post hoc and regardless of the country
of origin. To illustrate the resulting expression signatures, heatmaps and quasi-proportional Venn diagrams [41]
have been generated.
2.5 Literature-based validation
There is an growing body of evidence for various miRNAs being deregulated in IBD (CD vs. HC, UC vs. HC as
well as CD vs. UC). However, the vast majority of studies used samples different from whole blood. We employed
rentrez::entrez search [50] to gather information available to date (for the corresponding PubMed query please see
Figure S2). Subsequent manual inspection of the retrieved papers resulted in a list of 25 recent articles reporting
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differentially expressed miRNAs in whole blood. The isomiRs being differentially expressed (Wald p < .05 and
log2 |FC| > 0) in the study presented here have been grouped with regard to the respective miRNA arms in order
to allow a comparison to these earlier studies not investigating miRNA isoforms. A previously published set of
deregulated miRNAs was assumed to support our findings in case it was overlapping with them. We performed
enrichment analysis employing Fisher’s exact test to evaluate these overlaps and by this the significance of our
findings. Note that, given the precise definition of the traits as well as composition and size of the respective
study populations varied, this approach might have a limited power, so the sizes of the overlaps are likely to be
underestimated.
2.6 Mathematical modeling
With this study we aim for the establishment of state-of-the-art machine learning methods for the mathematical
modeling of differential expression of isomiRs between the diagnoses under consideration, and to apply the resulting
models for in-silico predictions of these traits. In total, mathematical models for 9 distinct clinical classification
problems have been considered. This corresponds to all (4 · 3/2) = 6 binary comparisons incorporating the 4
Swedish (CD−, UC−, SC and HC) as well as all (3 · 2/2) = 3 binary comparisons incorporating the 3 German
phenotypes (CD+, UC+ and HC). It is worth noting that the considered classification problems vary with respect
to the importance for clinical practice. However, to answer more complex diagnostic questions by subsequent
construction of combined classification models, none of these can be neglected.
Each of the classification problems mentioned before has been solved by employing classical types of support
vector machines (SVMs), namely linear and radial SVMs as well as polynomial SVMs (R package e1071 [34]). In
addition, regularized incarnations of the SVM, including elastic net and SCAD (smoothly clipped absolute devia-
tion) SVM have been employed to generate distinguishing models of higher sparsity (R package penalizedSVM [3]).
For technical details on these models reference is made to Hu¨benthal et al. [17]. In order to increase stability and
sparsity of the models, only isomiRs exhibiting differential expression (p < 0.05 and | log2 FC| > 0) with regard
to the respective classification problem have been included in the modeling process. Each single model has been
evaluated using common metrics for the assessment of binary classifiers. Thus, for instance true positives and
negatives (TP and TN) as well as false positives and negatives (FP and FN), along with positive and negative pre-
dictive value (PPV and NPV) as well as sensitivity (SN), specificity (SP), balanced accuracy (BAC) and Matthews
correlation coefficient (MCC) have been calculated. Estimation of model parameters and model performance has
been performed based on randomly sampled subpopulations. Repetitions of the sampling have been performed to
determine distributional properties of each model’s performance. Optimization of the model’s hyperparameters
for each of these samples has been conducted based on nested cross validation (CV) and grid search as imple-
mented in R functions e1071::tune.svm and penalizedSVM::svm.fs. Models performing with highest classification
accuracy and stability (as estimated by median and interquartile range (IQR) of BAC) then have been chosen for
further investigation. According to the principal of majority voting [14], these models have been used to construct
combined classifiers that solve more complex diagnostic problems, such as the distinction between 3 (CD− vs.
UC− vs. HC, CD− vs. UC− vs. SC, CD+ vs. UC+ vs. HC) or even 4 traits (CD− vs. UC− vs. SC vs. HC ).
Combined classifiers’ performances have been estimated employing leave-on-out cross validation (LOO-CV).
Throughout the analysis the available data has been used based on the premise of good generalizability. Con-
struction of the atomic classification models has been conducted on a dataset of 500 samples, remaining after
random removal of 35 samples. The process of model construction thereby involved training (n=310) and evalua-
tion datasets (n=155) resulting from random splits into 1000 folds at an ratio of 2:1. Overall 45000 computational
experiments (model estimation and evaluation for 9 problems, 5 models and 1000 holdout samples) have been
performed. They all have been conducted employing the on-site high-performance computing (HPC) resources as
one job per holdout and phenotype group. After determination of the final models the 35 samples drawn initially
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have been used to evaluate the model’s prediction resulting from majority voting. Thereby the evaluation scheme
of LOO-CV has been followed. For a flowchart of the full setup of the classification experiment reference is made
to Figure 4.
3 Results
3.1 Explorative analysis reveals disease- and treatment-specific differences
We used plots based on multidimensional scaling to explore general features of the given isomiR expression data.
As evident from Figure 1, data points form homogeneous clusters for each trait under consideration. Judged
by visual appearance neither location nor dispersion differ considerably. This observation is further supported
by Kruskal-Wallis tests revealing no significant distributional differences for both, the Swedish and the German
cohort (data not shown). Likewise, this confirms that the adjustment for unwanted variation has been successful
(see Figure S1). Being hardly distinguishable on a global scale, samples of each trait show distinct expression
patterns for a subset of isomiRs. Thus, pairwise Wald tests (nominal p < 0.05 and | log2 FC| > log2 1.5) of all
substrata of the Swedish cohort reveal differential expression for a median number of 30 isomiRs (24 miRNA arms,
see Table S3A). The substrata of the German cohort, in turn, reveal differential expression for a median number of
155 isomiRs (85 miRNA arms, see Table S3B). To identify isomiRs being exclusively deregulated in a given trait
we examined the relationships between sets of differentially expressed isomiRs using Venn diagrams. However,
to allow for a comparison between the cohorts, we only considered pairwise comparisons with respect to HC. In
this way we identified 60 isomiRs (34 miRNA arms) as being exclusively deregulated in the untreated samples
(CD− vs. HC: 12 (9), UC− vs. HC: 23 (12) and SC vs. HC: 25 isomiRs (13 miRNA arms), see Figure 2A) as
well as 86 isomiRs (32 miRNA arms) as being exclusively deregulated in the treated samples (CD+ vs. HC: 38
(16), UC+ vs. HC: 48 isomiRs (16 miRNA arms), see Figure 2B). The signatures of untreated and treated CD
comprise 30 and 151 exclusively deregulated isomiRs (21 and 78 miRNA arms, see Figure 2C). The signatures of
untreated and treated UC, in turn, comprise 53 and 159 exclusively deregulated isomiRs (29 and 71 miRNA arms,
see Figure 2D). Expression patterns (in terms of logarithmized fold changes with respect to HC) of isomiRs being
exclusively differentially expressed in all the traits under consideration are depicted in Figure 3. For CD−, UC−,
CD+, UC+ and SC the heatmap comprises 11, 21, 34, 45 and 17 trait-specific isomiRs from 7, 8, 11, 11 and 7
trait-specific miRNA arms. Only 11 of these 128 miRNAs correspond to reference miRNAs being annotated in
miRBase release 22. Each of the remaining miRNAs exhibits at least one sequence modification (102 3’ trimming
and 32 5’ trimming modifications, along with 1 nucleotide substitution). Notably, not a single 3’ addition has
been detected as being trait-specific.
3.2 Study adds to the current knowledge gathered from literature
We consider the present study as a pilot assessing the capability of circulating isomiRs predicting inflammatory
bowel disease. Furthermore, it is the first study investigating IBD-associated blood-born miRNAs employing next
generation sequencing (NGS) technology. Nonetheless, previous publications reported alternative approaches
addressing the same question. Enrichment analysis (comparing our study to earlier studies) was performed to
assess the significance of our findings in terms of overlapping sets of differentially expressed isomiRs and miRNA
arms, respectively.
Several studies based their investigation on whole blood samples. Thus, Paraskevi et al. [39] and Schaefer et
al. [45], for instance, employed real-time quantitative PCR (RT-qPCR) to assay deregulation of miRNAs in CD
and UC with respect to the healthy state (HC). Enrichment analysis reveals non-random overlaps between each
of these studies and ours, for both, the untreated (p=3.66E-02 and 1.57E-03) as well as the treated (p=4.44E-11
and 2.65E-03) IBD cohort. Microarray studies by Wu et al. [52] and Hu¨benthal et al. [17] focusing on CD vs. HC,
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UC vs. HC and CD vs. UC confirm our results as well by likewise exhibiting a significant enrichment. Notably,
this only holds true for the treated cohort (p=4.17E-05 and 3.06E-03). Further studies by Iborra et al. [19] and
Zahm et al. [54, 55] based their investigation on serum-born miRNAs assayed by RT-qPCR. All three studies
focus on the comparison of CD and UC with the healthy state and support our results as well. Specifically, for the
untreated IBD cohort randomness as a source for overlapping sets of miRNAs has been ruled out with p=1.12E-04,
3.49E-02 and 2.32E-02. The same applies to treated the IBD cohort with p=7.18E-10, 2.63E-08 and 1.17E-02.
Table 2 briefly summarizes the enrichment analyses. A more comprehensive overview including identifiers of the
overlapping miRNA arms are provided in Table S5. For the underlying raw data resulting from the PubMed query
(Figure S2) reference is made to Table S4.
3.3 Mathematical modeling allows highly accurate trait prediction
Specific properties of isomiR expression profiles being detected in the course of explorative analysis have been fur-
ther used to build mathematical models for in-silico distinction of the traits under investigation. Thus, (penalized)
support vector machines have been generated to enable binomial classification of the clinical conditions. Distri-
butional features of each classifiers’ performance thereby has been evaluated based on 500-fold holdout sampling.
With median balanced accuracy of 0.9182 the overall performance (considering 5 model types and 9 classification
problems) has been estimated to be remarkably high. However, with an inter quartile range (IQR) of 0.2049,
it varied considerably. This variability illustrates the substantial differences in the difficulty of the classification
problems under consideration. Thus, for instance, the distinction between pairs of untreated phenotypes (Swedish
samples including HC but excluding SC) resulted in a median BAC of 0.9286 (IQR=0.2143). Distinguishing pairs
of treated phenotypes (German samples including HC), in turn, resulted in a comparably higher median BAC of
0.9655 (IQR=0.1812). This indicates treatment-dependent changes of the isomiR expression profiles, leading to
an improvement of diagnostic utility in treated patients. Irrespective of the treatment the distinction between
disease traits (CD, UC and SC) is estimated to be a bigger challenge than the distinction between disease and
health (HC). Figure 5 summarizes distributional features of the performance of all binomial classifiers built in the
course of this study.
The qualitative behavior of multinomial models solving more complex classification problems naturally depends
on the choice of the binomial models considered in the process of majority voting. Accordingly, each classifier has
been selected to optimize accuracy (as measured by median BAC) and stability of its votes (as measured by IQR
of BAC). Applying these criteria, classical SVMs (including linear SVM: BAC=0.9375, IQR=0.1989; radial SVM:
BAC=0.9375, IQR=0.2004; polynomial SVM: BAC=0.9375, IQR=0.2023) clearly outperform the penalized SVMs
(including elastic net SVM: BAC=0.8750, IQR=0.2261; SCAD SVM: BAC=0.8462, IQR=0.2160). Remarkably,
the least complex model (linear SVM) has been estimated to optimize both measures. However, to further increase
the predictive performance we allow the combined models to incorporate different types of binomial models (see
Figure 5).
Performances of the multinomial classifiers we report in Table 3. To increase reliability of the performance
measures their estimation has been based on independent samples neither used for training nor evaluation of the
underlying binomial models. To derive respective distributional properties LOO-CV has been employed. Increas-
ing complexity of a classification problem compromises the performance of the model solving it. Accordingly, it
is expected that multinomial classifiers are outperformed by individual binomial classifiers. However, with BACs
ranging from 0.7333 to 0.9000 the estimated performance of the combined classifiers under consideration is re-
markably high. Specifically, the model distinguishing CD−, UC− and SC has been estimated to perform with a
mean BAC of 0.7333. The model classifying CD−, UC− and HC incorporates the comparatively less demanding
distinction between IBD and HC. Accordingly, the classifier has been estimated to perform even better (mean
BAC=0.8667). This equally applies to the distinction between CD−, UC−, SC and HC (mean BAC=0.8667).
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However, these performances even have been exceeded while classifying CD+, UC+ and HC (BAC=0.9000), again
illustrating the dependency of the models’ utility on IBD treatment.
4 Discussion
With the here-presented study we, for the first time, report isomiR-based mathematical models for the distinction
of CD and UC among each other as well as from healthy (HC) and symptomatic controls (SC). We report
standard SVMs to be able to predict disease phenotypes with a remarkably high median balanced accuracy of
0.9375. Penalized SVMs showed comparably lower performance and/or stability and were therefore investigated
in less detail. However, they might provide a foundation for functional and clinical research due to their sparsity.
In contrast to the non-penalized SVMs they base phenotype predictions on isomiR signatures of minimal size. For
each binomial classification problem we provide candidate isomiRs that exhibit differential expression but also
allow accurate predictions in random subsamples of our data. This implies generalizability of both, the binomial
as well as derived multinomial models. Notably, assessing combined models based on a single random dataset
might result in optimistic or pessimistic estimates of classifier performance. However, employing LOO-CV reduces
the bias.
We show validity of the models by conducting enrichment analysis of signatures of miRNA arms (derived
from sets of differentially expressed isomiRs) with regard to previous work. We report non-random concordance
of signatures allowing the distinction between CD, UC and HC. Notably, highest consistency we observe for
classification problems incorporating treated IBD samples. This suggests that earlier studies neglected treatment
as a factor influencing disease-related deregulation of isomiR expression [19, 39, 54]. While such a sampling strategy
certainly corresponds to daily clinical practice, it impedes the identification of disease-specific signatures. However,
not all of the studies report the information needed to prove this hypothesis [9, 42, 48]. Beyond that, signature
validation by enrichment analysis assumes compatibility of underlying study cohorts. Since early biomarker studies
frequently employ small study cohorts of varying homogeneity, this assumption is likely to be violated. However,
by expectation this should lead to underestimation of enrichment. Accordingly, the here-reported estimates of
concordance should be rather conservative.
All comparisons between the treatment groups have been conducted with respect to healthy controls. This
approach enables the identification of treatment-induced differences specific for a given disease. In contrast,
differences being treatment-induced but unrelated to the diseases, have not been considered to ensure the neglection
of unwanted biological and technical variation. Accordingly, reliability of the results has been increased at the cost
of overall comprehensiveness of the study. Notably, the excluded comparisons are assumed to be of comparably
low clinical relevance. However, future investigations might consider them to elucidate the role of isomiRs with
respect to treatment response.
Serological markers, such as AMCA (anti-mannobioside carbohydrate antibody), ASCA (anti-saccharomyces
cerevisiae antibody) and ANCA (anti-neutrophil cytoplasmic antibody) represent common tools complementing
IBD diagnostics, particularly in case of diagnostic uncertainty. Nonetheless, their performance varies considerably.
In accordance to this, sole reliance on these biomarkers can not be recommended [15, 32]. AMCA and ASCA are
estimated to allow a distinction between IBD and HC with BACs of 0.5050–0.6150 and 0.6050–0.7250, respectively
(see [12, 47]). With median BACs of 1.0000 (for untreated CD or UC vs. HC) and 0.9828 (for treated CD or
UC vs. HC) the corresponding isomiR-based classifiers are clearly superior. ASCA+/ANCA− and ASCA+ allow
the more demanding distinction between CD and UC to be made with BACs of 0.7200–0.7900 and 0.5950–0.8600,
respectively (see [12, 47] among others). With a BAC of 0.7857 the here-presented models are competitive.
Notably, the most valid comparison of these performances certainly would have been based on biomarker levels
measured for the same samples. Unfortunately, the corresponding data was not available for both, the Swedish
and the German cohort.
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The multinomial models we propose represent a distinct feature of this investigation. Whereas previous studies
(with the exception of earlier work of our group [18]) focus in pairwise distinction of CD, UC, SC and HC, we
provide tools for a joint discrimination of arbitrary combinations of these traits. In the first place we present
models to solve 3-nomial (CD+ vs. UC+ vs. HC, CD− vs. UC− vs. HC and CD− vs. UC− vs. SC) as well as
4-nomial classification problems (CD− vs. UC− vs. SC vs. HC). With mean BACs of up to 0.9000 and 0.8667,
respectively, their performance likewise has been estimated to be remarkably high. In favor of generalizability,
we restricted the models to the given main phenotypes. However, extensions to multinomial models further
stratifying with respect to clinical parameters, such as disease location and disease activity, do not represent a
technical challenge.
Previously being dismissed as experimental artifacts, isomiRs are now considered to result from alterations in
miRNA biogenesis. Recent studies show these alterations to vary with respect to gender and ethnicity as well as
tissue and cell type [21, 29]. Here we ultimately provide evidence for the existence of blood-born isomiRs being
specific for IBD-related traits. This suggests sequence variation of miRNAs having an impact on the pathogenesis
of inflammatory bowel disease. On the other hand it questions the cell type specificity of our findings and therefore
motivates further investigation.
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Figures and tables
German cohort Swedish cohort
variable CD+ UC+ CD- UC-
general
female 92/50 [64.8/35.2] 65/57 [53.3/46.7] 13/17 [43.3/56.7] 21/23 [47.7/52.3]
age 39.0 (28.5-48.0) [66.9] 40.0 (28.0-48.0) [66.4] 34.0 (22.0-48.0) [100.0] 33.0 (26.0-44.0) [100.0]
weight 68.0 (60.0-83.5) [66.9] 79.0 (68.5-92.0) [65.6]
size 170.0 (166.0-178.0) [66.9] 175.0 (170.0-182.0) [66.4]
BMI 23.3 (21.2-26.4) [66.9] 25.5 (23.1-28.4) [66.4]
smoking 21/73 [14.8/51.4] 10/71 [8.2/58.2]
allergy 8/6 [5.6/4.2] 6/10 [4.9/8.2]
laboratory
leucocytes 80.5 (43.0-120.0) [66.2] 82.0 (41.0-118.0) [64.8]
erythrocytes 51.5 (27.0-75.0) [66.2] 61.0 (41.5-80.0) [64.8]
platelets 64.5 (35.0-102.0) [66.2] 63.0 (39.5-95.5) [64.8]
HB 33.0 (20.0-41.0) [66.2] 34.0 (22.0-43.0) [64.8]
hematocrit 40.0 (36.0-42.0) [66.2] 40.0 (37.0-42.0) [64.8]
CRP 2.5 (1.1-6.8) [66.2] 1.9 (1.0-7.2) [62.3] 32.0 (6.8-54.0) [43.3] 7.4 (2.1-9.1) [38.6]
calprotectin 1668.0 (337.0-4589.0) [20.0] 939.5 (459.5-1763.5) [9.1]
albumin 35.0 (31.5-38.0) [40.0] 37.0 (34.0-41.0) [38.6]
severity
CDAI 57.0 (23.0-78.5) [56.3]
Mayo (partial) 5.0 (3.0-6.0) [97.7]
Mayo (endoscopic) 2.0 (2.0-2.5) [100.0]
Mayo 7.0 (5.0-8.0) [97.7]
medication
azathioprin 21/73 [14.8/51.4] 19/61 [15.6/50.0]
adalimumab 17/77 [12.0/54.2] 0/80 [0.0/65.6]
infliximab 38/56 [26.8/39.4] 10/70 [8.2/57.4]
methotrexat 0/94 [0.0/66.2] 1/79 [0.8/64.8]
ciclosporin 0/94 [0.0/66.2] 0/80 [0.0/65.6]
mesalazin (systemic) 14/80 [9.9/56.3] 53/26 [43.4/21.3]
mesalazin (topical) 5/89 [3.5/62.7] 17/64 [13.9/52.5]
corticosteroids (topical) 2/92 [1.4/64.8] 7/72 [5.7/59.0]
corticosteroids (systemic) 25/69 [17.6/48.6] 28/52 [23.0/42.6]
Table 1: Clinical characteristics. Stratified by country-of-origin and trait the study population is summarized
with regard to clinical parameters, including measures of disease severity. Categorical variables (e.g. gender) are
reported in terms of absolute numbers as well as percentages of non-missing datapoints per category. Quantitative
variables (e.g. age) are reported in terms of median (M), lower quartile (LQ) and upper quartile (UQ) as well as
the percentage of non-missing datapoints.
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Figure 1: Visual inspection by multidimensional scaling. For both cohorts logarithmically transformed data
with correction for technical batches as well as gender is shown. MDS plots have been generated using distance
based on Spearman correlation. For each trait an ellipse tracing the bivariate normal density contour (with 25%
of the samples being excluded) has been added. Ellipses are colored according to the sample’s trait.
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Figure 2: Trait-specific DE miRNA arms. Quasi-proportional Venn diagrams [41] have been generated to
illustrate ovarlaps of signatures of DE miRNA arms for (A) CD−, UC− and SC, (B) CD+ and UC+, (C) CD−
and CD+ as well as (D) UC− and UC+, each with respect to HC.
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Figure 3: Expression profile of trait-specific miRNAs. For CD−, UC− and SC as well as CD+ and UC+
expression levels of isomiRs being significantly deregulated (p < 0.05 and | log2 FC| > log2 1.5) with respect to
HC are shown as a heatmap of logarithmized fold changes. The sidebars at the bottom of the panel indicate the
modification type of a given isomiR. Numbers of deregulated isomiRs per trait as well per modification type are
added in parentheses.
Swedish cohort German cohort
study technology comparison sample size mirnas overlap p-value overlap p-value
Paraskevi et al. [39] RT-qPCR CD vs. HC, UC vs. HC 378 32 5 3,66E-02* 23 4,44E-11*
Schaefer et al. [45] RT-qPCR CD vs. HC, UC vs. HC 90 7 4 1,57E-03* 5 2,65E-03*
Iborra et al. [19] RT-qPCR CD vs. HC, UC vs. HC 69 31 9 1,12E-04* 21 7,18E-10*
Zahm et al. [54] RT-qPCR CD vs. HC, UC vs. HC 78 21 4 3,49E-02* 16 2,63E-08*
Zahm et al. [55] RT-qPCR CD vs. HC, UC vs. HC 47 3 2 2,32E-02* 3 1,17E-02*
Wu et al. [52] microarray/RT-qPCR CD vs. HC, UC vs. HC, CD vs. UC 55 20 1 6,69E-01 11 4,17E-05*
Hu¨benthal et al. [17] microarray CD vs. UC, CD vs. HC, UC vs. HC 114 16 2 2,33E-01 7 3,06E-03*
Wu et al. [51] microarray/RT-qPCR CD vs. HC 24 3 0 1,00E+00 3 1,17E-02*
Duttagupta et al. [9] microarray/RT-qPCR UC vs. HC 40 39 4 1,72E-01 21 1,54E-08*
Takagi et al. [48] microarray/RT-qPCR UC vs. HC 24 2 0 1,00E+00 2 4,29E-02*
Polytarchou et al. [42] microarray UC vs. HC 67 4 2 3,36E-02* 2 9,50E-02
Table 2: DE miRNAs overlapping with the literature stratified by study. Two sets of miRNAs reported
as being DE (set A from the literature and set B from our study) are compared to each other. Comparisons CD vs.
HC, UC vs. HC and CD vs. UC have been investigated. In case study B was focusing on a particular subphenotype
(inactive or active CD or UC, respectively) the corresponding main phenotype (CD or UC, respectively) has been
considered. To assess whether or not the overlap with the literature was occurring by chance Fisher’s exact test
was applied (significance criterion p < 0.05, non-significant studies neglected). Overlaps are presented for both,
the untreated Swedish as well as the treated German cohort. For a more comprehensive table, including the list
of DE isomiRs per study, reference is made to Table S5.
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Figure 4: Setup of the classification experiment. The flowchart illustrates how isomiR count data has
been used throughout the individual analysis steps. (A) Differential expression analysis employs the complete
dataset to identify trait-specific isomiR signatures and to reduce dimensionality of the classification problems to
be tackled. Random splitting into subsets is then performed for construction of atomic classifiers (B) and their
subsequent combination aiming for solutions to more complex classification problems (C). Parameter estimation
and subsequent evaluation is based distinct datasets repeatedly drawn at random without replacement (1000-fold
holdout sampling). Selection of hyperparameters for each model being optimized thereby employs internal 5-fold
cross validation. To apply binary models to solve a given diagnostic task the classification results are combined
according to the principle of majority voting. Voting as well as subsequent evaluation of the final classification
result is based on leave-on-out cross validation (LOO-CV).
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Figure 5: Classifier assessment and selection. Performance of different types of SVMs in terms of balanced
accuracy (BAC) as resulting from the application to pairwise classification problems incorporating CD−, UC−,
SC and HC (upper panel) as well as CD+, UC+ and HC (lower panel). For each panel pairwise comparisons
have been ordered by median performance with respect to all models under consideration. Furthermore, for each
pairwise comparison the model type optimizing median performance has been marked in red.
classifier #tests TP FN FP TN MCC BAC SN SP PPV NPV
CD− vs. UC− vs. SC 3 11 1 6 6 0,5091 0,7333 0,9333 0,5333 0,6678 0,7785
CD− vs. UC− vs. HC 3 12 0 3 9 0,7611 0,8667 1,0000 0,7333 0,7900 1,0000
CD− vs. UC− vs. SC vs. HC 6 23 1 6 18 0,7487 0,8667 0,9667 0,7667 0,8060 0,9391
CD+ vs. UC+ vs. HC 3 10 2 1 11 0,8034 0,9000 0,8667 0,9333 0,9303 0,8921
Table 3: Details on selected combined classifiers. Performance in terms of Matthews correlation coeffi-
cient (MCC), balanced accuracy (BAC), sensitivity (SN), specificity (SP), positive predictive value (PPV) and
negative predictive value (NPV) binary classifiers applied to combined classification problems incorporating main
phenotypes (CD-, UC-, CD+, UC+, HC, SC). For each pairwise comparison the model type has been chosen to
maximize the median classification performance as measured by BAC. Accuracy estimates represent the mean
based on LOO-CV given 5 independent samples per trait.
14
2 Publications Hu¨benthal, Juze˙nas, Nikolaus et al. (in submission)
100
Supplementary figures and tables
batch CD- UC- SC HC
B0001 14 (14) 11 (11) 15 (14)
B0002 13 (13) 12 (11) 15 (15)
B0003 11 (10) 15 (15)
B0004 14 (13) 15 (15)
B0005 15 (13)
batch CD+ UC+ HC
B0006 15 (15) 78 (76)
B0004 24 (20) 25 (24)
B0007 80 (80) 58 (57)
B0008 27 (27) 30 (29)
B0009 12 (12)
B0010 16 (16)
Table S1: Experimental batches. This table summarizes the grouping of samples being investigated in regard
to sequencing technician, chemistry and run for both, the Swedish (top) and the German cohort (bottom).
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Figure S1: Visual inspection by multidimensional scaling. For both cohorts logarithmically transformed
data is shown. MDS plots have been generated using distance based on Spearman correlation. For each trait an
ellipse tracing the bivariate normal density contour (with 25% of the samples being excluded) has been added.
Ellipses are colored according to the sample’s trait.
Table S2: Sequencing and mapping characteristics. For each sample sequenced in the course of this study
sequencing parameters, such as the number of raw, preprocessed and filtered reads (raw reads, pre processed reads
and filtered reads), as well as mapping statistics, including the mapping efficiency are listed.
Table S3: Differential expression analysis. For each pairwise classification problem incorporating (A)
Swedish and (B) German phenotypes, summary statistics of DE analysis, including effect size (log2FC) and effect
significance (p-value), are reported.
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(microrna[Title/Abstract] OR mirna[Title/Abstract]
) AND (
(inflammatory bowel disease[Title/Abstract ]) OR (IBD[Title/Abstract ]) OR
(ulcerative colitis[Title/Abstract ]) OR (UC[Title/Abstract ]) OR
(crohn ’s disease[Title/Abstract ]) OR (CD[Title/Abstract ])
) AND (
min_date[Date - Publication ]: max_date[Date - Publication]
)
Figure S2: PubMed query. Employing rentrez::entrez search this query has been used to gather current
information on miRNAs/isomiRs being differentially expressed in regard to the traits under investigation.
Table S4: Differentially expressed miRNAs being previously reported in the literature. Publications
resulting from the PubMed query (Figure S2) have been screened to obtain information on miRNAs being reported
as DE and complemented with meta-information, such as samples type and disease/control cohort.
Table S5: DE miRNAs overlapping with the literature. Two sets of miRNAs reported as being DE (set A
from the literature and set B from our study) are compared to each other. Comparisons CD vs. HC, UC vs. HC
and CD vs. UC have been investigated. In case study B was focusing on a particular subphenotype (inactive or
active CD or UC, respectively) the corresponding main phenotype (CD or UC, respectively) has been considered.
To assess whether or not the overlap with the literature was occurring by chance Fisher’s exact test was applied
(significance criterion p < 0.05, non-significant studies neglected). This summary extends Table 2 by naming the
DE miRNA arms being replicated from each study.
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ABSTRACT
With this study, we provide a comprehensive ref-
erence dataset of detailed miRNA expression pro-
files from seven types of human peripheral blood
cells (NK cells, B lymphocytes, cytotoxic T lympho-
cytes, T helper cells, monocytes, neutrophils and ery-
throcytes), serum, exosomes and whole blood. The
peripheral blood cells from buffy coats were typed
and sorted using FACS/MACS. The overall dataset
was generated from 450 small RNA libraries using
high-throughput sequencing. By employing a com-
prehensive bioinformatics and statistical analysis,
we show that 3′ trimming modifications as well as
composition of 3′ added non-templated nucleotides
are distributed in a lineage-specific manner––the
closer the hematopoietic progenitors are, the higher
their similarities in sequence variation of the 3′
end. Furthermore, we define the blood cell-specific
miRNA and isomiR expression patterns and iden-
tify novel cell type specific miRNA candidates. The
study provides the most comprehensive contribution
to date towards a complete miRNA catalogue of hu-
man peripheral blood, which can be used as a ref-
erence for future studies. The dataset has been de-
posited in GEO and also can be explored interactively
following this link: http://134.245.63.235/ikmb-tools/
bloodmiRs.
INTRODUCTION
MicroRNAs (miRNAs) are fundamental regulators in
many cell biological processes. They represent a class of
short (∼22 nucleotides long), non-coding RNAs that reg-
ulate gene expression at the post-transcriptional level by
predominantly targeting the 3′ UTR region of target mes-
senger RNAs (1). To date, >2500 miRNA sequences are
known in humans (miRBase v21 (2)) and it has been pre-
dicted that 30–80% of human genes are influenced by at
least one miRNA (3,4). Numerous mature miRNAs have
been implicated in a wide range of physiologic and patho-
logic processes. Since the deregulation of miRNAs has been
demonstrated in a range of diseases, including several types
of cancer (5–8) and heart disease (9), there is a significant
focus on miRNAs in biomarker research to utilize them in
the prediction and early detection of diseases.
In recent years, the long-standing theory that each
miRNA precursor (more precisely each arm of the hair-
pin molecule) produces one constant mature miRNA se-
quence, was disproved by results from high-throughput se-
quencing and subsequent bioinformatics analyses. It has
been shown that a single miRNA hairpin arm can give rise
to multiple distinct isoforms (isomiRs) that are now re-
ferred to as the mature miRNA transcripts and that can
differ in their length and sequence composition (10). The
term ‘miRNA-arm’ is used to define the set of all ma-
ture transcripts deriving from one arm (5p or 3p) of the
miRNA hairpin molecule (11). IsomiRs are categorized
into three main classes: 5′ isomiRs, 3′ isomiRs, and poly-
morphic isomiRs. Additionally, 5′ and 3′ isomiRs are sub-
classified into templated or non-templated modifications
(12). Several studies have shown that isomiR expression
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profiles depend on tissue type, gender, population, ethnic-
ity, disease type and subtype (13–16), andmost importantly,
that isomiRs exhibit functional differences in comparison
to their archetype miRNAs (the miRNA sequences listed
in public database) (17,18). These findings provide solid ev-
idence that isomiRs have functional relevance and cannot
be dismissed as experimental artefacts.
In 2008, miRNAs were first characterized in blood and
described as circulating miRNAs (19–21). The detection
of miRNAs in circulation provided an opportunity to use
miRNAs as non-invasive biomarkers for the distinction of
biological/clinical conditions. Since then numerous studies
have reported circulating miRNAs as biomarkers for a vari-
ety of cancers and other diseases (22–24). However, the ori-
gin and especially the sequence variation of these miRNAs
has been poorly investigated. In a recent study, Pritchard
et al. (25) examined 79 solid tumor circulating miRNA
biomarkers reported in the literature and showed that 46
of 79 are highly expressed in different blood cells. This pro-
vided first insights that blood cells substantially contribute
to circulating miRNA levels, be it because of contamina-
tion by hemolysis or regular physiological processes. Since
then, only a few research projects focused on the miRNA
transcriptomes of either several or single separated blood
cell types (26–29) and even fewer focused on the miRNA se-
quence variations in distinct cell types (30,31). Yet, there is
still only scarce knowledge about the blood cell origin of cir-
culating miRNAs, their expression pattern with respect to
different cell types and especially about their sequence vari-
ations in different blood compounds. Therefore, it is impor-
tant to further study miRNA expression of different blood
cells in order to identify cell type specificity.
Because of its high availability in clinical practice, periph-
eral blood is also the most commonly collected body fluid.
The majority of non-invasive miRNA biomarker studies,
thus, currently focus on the measurement of blood miR-
NAs, although numerous other fluid compounds are also
under investigation. Methodologically, besides quantitative
PCR (qPCR) and array-based technologies, small RNA se-
quencing (sRNA-Seq) has become a popular technology
to establish miRNA-based transcriptional profiles. Inter-
pretation of results gained from those blood-based sRNA-
Seq studies, however, remains a challenging task (32–34).
Most sRNA-Seq protocols are PCR-based and depend on
adapter-ligation steps and often suffer from the limitation
that the measurement of a particular miRNA is not inde-
pendent from other miRNAs. The resulting introduction of
biases towards certain miRNAs may lead to discrepancies
in the overall abundance of sequencedmiRNAs. In addition
to the above-described technological problems, blood as liq-
uid tissue has only a relatively low abundance of miRNAs
compared to solid tissues, which decreases the signal-to-
noise ratio and renders the measurement of rare miRNAs
difficult. Moreover, due to the differential miRNA expres-
sion in different blood cell types and the uneven distribution
of cell types based on different conditions, e.g. diseases, it
is difficult to distinguish between true positive, false posi-
tive but also potential false negative signals in sRNA-Seq
datasets. Finally, depending on the treatment of the sample
material, hemolysis can occur and introduce another source
for altered measurements (34).
Given the above-described difficulties, when studying
sRNA-Seq-based miRNA profiles, it is crucial to first un-
derstand how miRNAs and their isoforms are distributed
in human blood before interpreting a deregulated state,
e.g. in the context of a disease. For this purpose, a com-
prehensive reference dataset for miRNA expression in the
different components of healthy human blood (cell types,
vesicles and fluid) is urgently needed but currently only
fragmentary in the public domain. The results presented
here thus summarize our (still non-exhaustive, but substan-
tial) contribution towards such a reference dataset. We re-
port the transcriptional profiles of miRNAs and isomiRs
from seven distinct peripheral blood cell populations of 43
healthy donors using sRNA-Seq. In addition, we also ex-
amined whole blood profiles (n = 77) as well as circulat-
ing miRNAs from serum (n = 38) and blood-borne exo-
somes (n = 38). The results can be interactively browsed at
http://134.245.63.235/ikmb-tools/bloodmiRs.
MATERIALS AND METHODS
Study samples
A total of 162 blood samples from healthy volunteers (rou-
tine blood donors from transfusionmedicine) were included
in this study. Of the 162 samples, 43 buffy coats remain-
ing from plasma donation were collected. Forty two serum
samples were collected into serum collection tubes (BD Va-
cutainer 366643) and 77 whole blood samples were col-
lected into PAXgeneRNAblood tubes (Qiagen).All donors
signed a written informed consent form. Approval for the
study was received from the Ethics Committee of the Med-
ical Faculty, University, Kiel.
Isolation and purification of cell types
Human peripheral blood cells were isolated from leukocyte
concentrates (buffy coats) of healthy donors by Ficoll den-
sity gradient centrifugation. Briefly, buffy coats (∼50 ml)
were dissolved in 100 ml phosphate-buffered saline (PBS)
and 15ml lymphocyte separationmedium/Ficoll (d= 1.077
g/ml) were carefully added and centrifuged at 2000 rpm
for 20 min (divided in four separate 50 ml tubes, with-
out using the brake function). After centrifugation, pe-
ripheral blood mononuclear cells (PBMCs) enriched in the
interface between plasma and Ficoll were carefully gath-
ered. After washing three times with PBS (1 × 5 min, 1600
rpm; 2 × 10 min, 1000 rpm), cells were resuspended and
an aliquot counted by fluorescence-activated cell sorting
(FACS). Granulocytes and RBCs, which are not within the
PBMC fraction, were extracted separately by pipetting 1000
l from the interface between Ficoll and red blood cells
(RBCs) or 100 l from the bottom of the tube, respectively.
Magnetic activated cell sorting (MACS, Miltenyi Biotec,
Bergisch-Gladbach, Germany) was used to purify CD56+
(NK cell), CD19+ (B cell), CD8+ (cytotoxic T cell), CD4+
(T helper cell), CD14+ (monocyte), CD15+ (neutrophil)
and CD235a+ (erythrocyte) cell populations, following the
manufacturer’s instructions. CD14+, CD15+, CD19+ and
CD235a+ cells were isolated by positive selection, whereas
CD4+, CD8+ and CD56+ cells were isolated by negative
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selection. Purity of the individual cell populations was as-
sessed using FACS.
Total RNA isolation and sRNA-Seq
Total RNA including small RNA from sorted cell types was
extracted using the mirVana RNA Isolation Kit (Ambion).
For whole blood, we used the PAXgene Blood miRNA Kit
(Qiagen). For serum samples miRNeasy Serum and Plasma
kit (Qiagen) was used and exosomes were processed using
the Total Exosome Isolation Reagent and the Total Exo-
some RNA and Protein Isolation Kit (Life Technologies).
All isolation protocols were conducted according to the
manufacturers’ instructions, without further modifications.
Extracted total RNAs were combined with a spike-in
cocktail (except whole blood samples) as previously de-
scribed by Hafner et al. (35). The products were then sub-
jected to Illumina TruSeq Small RNA Sample Preparation
protocol to generate small RNA libraries for each sample.
Subsequently, the libraries were randomized and pooled
with six samples per lane for serum and exosomes, and 24
samples per lane for cell types and whole blood. Sequenc-
ing was conducted on an Illumina HiSeq 2500 (1 × 50 bp
SR, v3). Raw sequencing reads and quantified read-count
data have been deposited at NCBI Gene Expression Om-
nibus (GEO) (36) under the accession number GSE100467.
Data analysis
Obtained raw reads were subjected to exhaustive adapter
trimming using cutadapt v1.3 (37). Low quality 3′ ends
of reads falling below Q20 (Phred score) were discarded.
Only the quality trimmed reads that were longer than 18
bp were retained. Subsequently, the reads mapping to viral
genomes, viral miRNAprecursors and human non-miRNA
short RNAs were filtered out. The remaining reads were
mapped to miRNA sequences from miRBase v21 (2) us-
ing mirAligner (38) with default parameters (1 mismatch,
3 nt in the 3′ or 5′ trimming variants and the 3 nt in 3′-
addition variants) and to spike-in sequences. As the lat-
ter were not available for all samples analysed, the respec-
tive read counts were neglected for further analysis. The
R package isomiRs (38) was used to generate counts of
miRNA-arms (read count sums of all isomiRs including
archetype miRNA which align to the same miRBase en-
try) and isomiRs. Samples with fewer than one million of
initial reads and those for which the number of expressed
miRNA reads on a logarithmic scale was falling below Q1
− 1.5 IQR were excluded from further analysis. miRNA-
arm and isomiR sequences that were expressed (expression
value ≥ 5) in at least 85% of the samples in at least one of
the cell types were normalized using DESeq2 (39). Normal-
ized counts were checked for potential confounding effects
such as age, gender, cell counts, cell purity, levels of hema-
tocrit, number of leukocytes and erythrocytes. The counts
were then subjected to pairwise comparisons between dif-
ferent cell types or combined cell type groups. The P-values
resulting fromWald tests were corrected for multiple testing
according to Benjamini and Hochberg (40). The miRNAs
with a correctedP-value≤ 0.001 and |log2FC| > 1 were con-
sidered to be significantly differentially expressed. ThemiR-
NAs which were uniquely significantly upregulated in one
of the cell types when compared to every other cell typewere
called as being cell type specific miRNAs. In order to de-
termine the genomic context of cell type specific miRNAs,
the Ensembl API was used to retrieve annotated features
(introns, exons and UTRs of coding and non-coding tran-
scripts) that overlapped miRNA precursors. The miRNAs
that did not intersect any transcript features were consid-
ered as intergenic. Furthermore, miRNA profiles from cell
types were qualitatively compared with those from whole
blood samples, serum and exosomes.
Statistical analyses and data processing were done in R
version 3.3.3 (41). Visualization of graphs and heatmaps
was performed with ggplot2 (42) and ComplexHeatmap
(43) packages, respectively.
Detection of novel miRNAs
In order to detect novel miRNAs, raw sequencing reads
from all samples were pooled into a single file to increase the
power of prediction (44). Subsequently, pooled data were
trimmed for adapters using cutadapt v1.3 and collapsed to
obtain unique sequences while saving the information about
read counts. The resulting data were mapped and filtered
against spike-ins, viral genomes (RefSeq (45)), viral miRNA
precursors (miRBase v21 (2)) and other human small RNAs
(rRNAs, tRNAs, snRNAs and sRNAs (Rfam (46)) using
BLASTN v2.2.30 (47). The remaining reads were mapped
to the human genome (version hg19) using Bowtie v1.1.1
(48) and only those reads that mapped to the reference
genome were passed down for novel miRNA prediction
employing miRDeep2 v2.0.07 (49) with default parameters
and as input for related species using known miRNAs from
Hominidae family (miRBase v21). In order to reduce the
number of false positively predicted miRNAs, several filter-
ing steps were applied to remove: (a) novel miRNA candi-
dates with miRDeep2 score < 1; (b) predicted precursors,
which overlapped with human coding sequences (CDS) and
non-coding RNAs (ncRNAs) (reference genome version
hg38, Ensembl (50)); (c) novel miRNA precursors which
were enriched with repetitive DNA element sequences from
Dfam (51); and d) predicted miRNAs, which had outly-
ing values based on quantiles (lower quantile = 0.01, up-
per quantile = 0.99) of GC content of known miRNA ma-
ture sequences belonging to Hominidae family (miRBase
21). Filtered novel miRNA candidates were ranked accord-
ing to their distance to the features in the early miRBase
(v1–v7) versions using novo-miRank (52).
Sample-wise quantification of candidate novel miRNAs
was performed using quantifier.pl module from mirDeep2
v2.0.07 with default parameters. Normalization and statis-
tical analysis of novel miRNA candidate count dataset was
performed as described in the previous section.
Web-page implementation
To make our results easily accessible to researchers in the
field, we implemented a web-tool for interactive browsing of
miRNA expression results of peripheral blood cell popula-
tions. It contains miRNA-arm and isomiR expression data
which can be explored by cell type or by miRNA of inter-
est. The differential expression analysis can be performed
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in real time by selecting different cell types or combined
cell type groups for pairwise comparisons. The web-tool
was implemented using shiny web application framework
for R (53), as well as R packages such as DESeq2 (39),
dplyr (54), plotly (54) and iheatmapr and is available at
http://134.245.63.235/ikmb-tools/bloodmiRs.
RESULTS
Overview of the small RNA transcriptome data
Illumina deep sequencing was conducted to profile miRNA
expression in major peripheral blood cell populations, as
well as serum, exosomes and whole blood of healthy indi-
viduals. We used magnetic activated cell sorting (MACS)
to purify blood cells (see Figure 1) from the lymphoid lin-
eage (CD56+ (NK cells), CD19+ (B cells), CD8+ (cytotoxic
T cells), CD4+ (T helper cells)) and the myeloid lineage
(CD14+ (monocytes), CD15+ (neutrophils) and CD235a+
(erythrocytes)). Purity of the sorted cells was tested using
FACS analysis. Most cell populations were rather homo-
geneous with purity over 90%. Neutrophils, however, dis-
played considerable heterogeneity with a mean sorting pu-
rity of 79% (see Supplementary Figure S1A). Overall, 298
samples were sorted; however, we failed to sort erythrocytes
for three samples, and T helper cells for one sample.
Subsequent total RNA isolation and small RNA se-
quencing of the above-mentioned cell fractions and blood
compounds resulted in approximately 2.56 billion (B) raw
sequencing reads, ranging from 212.7 thousand (K) to 32.7
million (M) reads per sample (Supplementary Figure S1B).
This wide range in the raw sequences was expected and
could occur due to individual variability (health, blood
counts etc. of the donor) and due to variability in exper-
imental factors such as different RNA isolation methods
(i.e. mirVana, PAXgene, miRNeasy etc.), and/or differ-
ent amounts of small RNAs in distinct blood compounds,
which lead to unequal adapter dimer contamination and
unequal spike-in distribution when preparing libraries (55).
Figure 1. Simplified human hematopoietic tree of different cell compounds
(modified from Ha¨ggstro¨m (69)). The miRNA expression profiles were
generated for natural killer (NK) cell (CD56+), B lymphocyte (CD19+),
cytotoxic T cell (CD8+), T helper cell (CD4+), monocyte (CD14+), neu-
trophil (CD15+) and erythrocyte (CD235a+) populations (highlighted in
red).
After the adapter and quality trimming step, we retained
91.3% (2.34B) of the initial sequencing reads, which shows
the high quality of the dataset. The bulk of those reads
were 19–24 nt length which corresponds to the length range
of mature miRNA sequences (Supplementary Figure S1C).
The filtering steps (seeMethods section for details) retained
81.4% (2.09B) of the initial sequencing reads. The major-
ity of filtered reads belonged to human non-miRNA short
RNAs from Rfam database (Supplementary Figure S1D).
The remaining high quality reads were mapped to known
miRNA (miRBase v21) and spike-in sequences (see Mate-
rials and Methods section for details). The overall compo-
sition of the initial reads per sample in distinct blood com-
pounds is presented in Supplementary Figure S1E. Quan-
tification of filtered reads yielded 719.4M sequences to be
mapped to 2106 unique known miRNA sequences from
miRBase v21. As expected, the lowest numbers of miRNA
counts were observed in transcriptionally non-active blood
compounds such as RBCs, exosomes and serum (Supple-
mentary Figure S1F). However, low miRNA read counts
were also observed in neutrophils (CD15+)whichwas prob-
ably due to the lower cell sorting purity. After applying our
QC threshold, 19 low read and/or outlying samples were re-
moved, leaving 431 samples for downstreamanalysis. On av-
erage, wemapped 540 uniquemiRNAspecies per peripheral
blood cell type, 162, 267 and 645 unique miRNA species
per exosomes, serum and whole blood, respectively (Sup-
plementary Figure S1F).
Sequencing andmapping statistics for all libraries used in
this study can be found in Supplementary Table S1.
Anucleate blood harbors a substantial miRNA repertoire
Triggered by earlier reports about miRNAs being also
present in RBCs (25, 27), we first qualitatively character-
ized the RBC miRNA content. Only miRNAs having at
least five reads in at least 85% of the samples were consid-
ered in our analysis. Surprisingly, as anucleate cells should
not be transcriptionally active, we identified 271 miRNA
species within RBCs––several of them with considerable
read counts (>1000/sample, see also Figure 2). In addition,
we generatedmiRNAdata from serum samples (n= 38) and
exosomal vesicle preparations for 38 samples (34 of which
are paired samples) of healthy donors, which resulted in an-
other 90 and 51 miRNA species, respectively. When com-
paring the miRNA content of RBCs to those of serum and
exosomes, we found a considerable overlap between all three
fractions pointing towards a common miRNA repertoire
of those blood compounds. We found 38 miRNA species
present commonly in serum, exosomes and RBCs, whereas
19 miRNA species were found to be uniquely present in
serum, 2 and 21 miRNA species in exosomes and RBCs, re-
spectively (Figure 2). In total, we were thus able to detect 93
unique miRNA species outside the transcriptionally active
cellular components of healthy human blood.
Sequence variation analysis reveals lineage specific 3′ end
modification patterns of isomiRs
The growing evidence of constitutive variability in miRNA
biogenesis across human tissues encouraged us to exam-
ine the sequence variation patterns of mature miRNAs
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Figure 2. The presence of miRNAs in erythrocytes (RBCs), exosomes and serum. The barplot shows the log2 transformed median read counts of the most
abundant miRNAs in RBCs. The heatmap represents presence (blue) or absence (red) of miRNAs in specific blood compounds. Only the miRNAs which
were detected (expression value > 5) in at least 85% of the samples in at least one of the blood compound were considered as being present.
within different peripheral blood compounds. Accordingly,
we used mirAligner to identify trimming variations at
the 5′ and 3′ ends, nucleotide (nt) substitutions and non-
templated 3′ additions in miRNA sequences. In order to
avoid sequencing errors, we consider a mismatch as a real
substitution, when the fraction of reads having that sub-
stitution was >2% within the mapped reads to a certain
miRNA sequence. Additionally, we only kept those substi-
tutions which mapped uniquely to one miRNA molecule.
By comparing miRNA sequences obtained from our
dataset to the archetype sequences deposited in miRBase,
we identified sequence variations in 69.0% (1454/2106) of
detected miRNAs. The most common miRNA sequence
variation types were non-templated 3′ addition and 3′
trimming, which were observed in 77.0% (27539/35769)
and in 75.6% (27032/35769) of isomiR sequences, respec-
tively. Conversely, 5′ trimming (33.6%, 12025/35769) and
nt-substitutions (6.2%, 2229/35 769) within the mature
miRNA sequence were the least common variants. About
one third (33.9%, 755/2229) of nt-substitutions occurred in
the seed sites of miRNAs. More than one type of sequence
variation was observed in 74.0% (26482/35769) of isomiRs.
To get deeper insights into isomiR variation preferences,
we looked at variation distributions in our investigated
blood compounds. The unique miRNA sequences having
5′ trimming variations were similarly distributed across the
blood compounds, except that in neutrophils (CD15+),
serum and exosomes this variation at position –1 with re-
spect to reference sequences was more prevalent than in
other cell types (Figure 3A). Surprisingly, 3′ trimming dis-
tributions showed clear lineage-specific patterns across the
cell types. The frequency of unique sequences having 3′
trimming modification at positions –3 and –2 was higher
in lymphoid than in myeloid lineage, whereas from posi-
tion –1 to 3 it changed, and unique sequences having 3′-
trimming variation became more abundant in the myeloid
lineage. Meanwhile, the 3′ trimming distributions in serum
and exosomes showed similar patterns, and in most of the
positions were distinct from RBCs and whole blood sam-
ples (Figure 3B). The nt-substitutions were distributed sim-
ilarly across the blood compounds, except for serum at po-
sitions 1 and 4 and for exosomes from position 12 to 14. In-
terestingly, the overall distribution of substitutions within
miRNA sequences revealed a consistent pattern of posi-
tions in which nucleotides are less frequently substituted,
pointing toward the nucleotides which are the most im-
portant in the base-pairing during miRNA–target inter-
action, i.e. the ones within the seed site (2–8 nt) of miR-
NAs (Figure 3C). The fractions of unique sequences hav-
ing 3′ non-templated nucleotides were similar in neutrophils
(CD15+), RBCs, serum and exosomes. Unique sequences
having this modification were highly frequent at position 1
and vice versa at position 2 of the above-mentioned com-
pounds when compared to all the others (Figure 3D).
We were interested to further explore whether the anu-
cleate compounds such as RBCs, serum and exosomes
could also share the similar composition of the added nu-
cleotides, therefore we decided to look at the non-templated
3′ additions more closely. Remarkably, the composition of
3′ added nucleotides, the same as 3′ trimming preference,
was lineage-specific. The composition of non-templated nu-
cleotide additions clustered into three distinct groups, cor-
responding to myeloid lineage, lymphoid lineage and non-
cellular blood compounds, including serum and exosomes
(Figure 4). These results suggest that most of the RBC-
miRNAs probably originate from RBCs (or their progeni-
tors) and that the majority of miRNAs found in serum and
exosomes are not the products of hemolysis.
Differential expression analysis identifies blood cell specific
miRNA transcription signatures
To determine whethermiRNA expression profiles (precisely
miRNA-arms) could distinguish cell types, we first per-
formed multidimensional scaling analysis which revealed
a consistent clustering within and between cell types with
only a very small proportion of outliers (see Figure 5).
Even the distinction of lymphoid and myeloid blood cells is
clearly visible with the red blood cell fraction forming a sep-
arated cluster. Also, the already mentioned heterogeneous
neutrophil cells form a consistent cluster pointing towards
a consistent sorting result.
Analysing the repertoire of previously known miRNAs
listed in miRBase v21, 382 of the currently annotated 2578
miRNAs were found to be expressed in >85% of the sam-
ples in at least one of the cell types. Pairwise differential
expression analysis between different cell types revealed
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Figure 3. The distributions of isomiR modification types across different blood compounds. (A) 5′ end trimming modification distribution; (B) 3′ end
trimmingmodification distribution; (C) nucleotide substitutionmodification distribution; (D) 3′ end additionmodification distribution. Each dot represents
individual sample colored by group. The size of dots indicates the abundance which corresponds to the relative number of molecule copies per modification
type and position present in a given sample. The dash (–) symbol indicates the mean frequency of unique sequences per group. The smoothing in figure C
was performed using the generalized additive model (GAM) method.
224 of the 382 arms being significantly differentially ex-
pressed (FDR corrected P-value < 0.001; |log2FC| > 1)
between the two major blood cell lineages (lymphoid ver-
sus myeloid). We excluded the RBC data from this expres-
sion analysis, as RBCs per definition are anucleate and
do not express genes. As depicted in Figure 6A, 77 out
of 224 differentially expressed miRNAs are up-regulated
in lymphoid cells, whereas 167 miRNAs are up-regulated
in the myeloid lineage. Furthermore, by focusing on the
subtypes of lymphoid and myeloid cells, we found that
149 miRNAs were significantly different between natural
killer cells (CD56+) and small lymphocytes (CD4+, CD8+
and CD19+), 119 miRNAs between T-lymphocytes (CD4+
and CD8+) and B-lymphocytes (CD19+) and 193 between
CD14+ andCD15+ cells. Formore details reference ismade
to http://134.245.63.235/ikmb-tools/bloodmiRs.
We next focused on miRNAs that were significantly
higher expressed in one given cell type when compared
to every other cell type (see Figure 6B). Those miRNAs
could be considered part of the cell type-specific miRNA-
arm expression signature. Of the 382 miRNAs that were
expressed in at least one of the investigated cell types, 136
miRNAs followed the above pattern (FDR corrected P-
value < 0.001 and log2FC > 1). For CD4+ (T helper cells),
CD8+ (cytotoxic T cells), CD19+ (B cells) andCD56+ (NK
cells) we identified 9, 3, 10 and 18 specific miRNAs, respec-
tively, whereas for CD14+ (monocytes) and CD15+ (neu-
trophils) we detected 25 and 50 specific miRNAs, respec-
tively. The majority of these miRNAs were derived from
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Figure 4. The composition of 3′ added nucleotides across the blood compounds. A hierarchical average linkage clustering was used to generate a dendro-
gram based on relative frequencies of bases per position of the unique sequences, which then were visualized as sequence logos.
intronic regions of protein coding genes. Genomic con-
text and miRNA family information of cell type specific
miRNA-arms can be found in Supplementary Table S2.
To get an overview on miRNAs that are present in hu-
man blood but have not been covered by our cell sort-
ing approach, we additionally generated miRNA expres-
sion data for whole blood samples. We found 417 miRNAs
that were expressed in 85% of the samples in at least one
of the cell types or whole blood samples. Compared to the
Figure 5. The similarity structure of human blood cell miRNA transcrip-
tomes. MDS plot showing three clearly resolved clusters corresponding
to lymphoid cells (NK cells, B cells, T cells and Th cells), myeloid cells
(monocytes and neutrophils) and anucleate erythrocytes. The analysis was
performed onmiRNA count data using Spearman’s correlation distance (1
– correlation coefficient). The dots represent samples coloured by group,
while the centre of ellipses corresponds to the group mean and the shapes
are defined by the covariance within group.
above-mentioned 382 miRNA species of the cell type spe-
cific datasets, we detected additional 35 miRNAs which are
either specific for other blood cell types or originate from
other sources (Supplementary Table S3).
Distinct isomiRs yield higher cell type specificity than
miRNA-arms
Taking into consideration that isomiRs can make a sig-
nificant contribution to miRNA representation, we re-
peated the pairwise differential expression analysis be-
tween different cell types and/or cell type groups by using
isomiR counts. Applying the previously described thresh-
old, we identified 2538 expressed isomiRs arising from
309 distinct miRNA-arms. Pairwise comparison between
lymphoid and myeloid lineages revealed 1862 differen-
tially expressed isomiRs deriving from 281 arms, 912 of
those isomiRs being up-regulated and 950 being down-
regulated. Analogous comparisons of the subtypes of lym-
phoid and myeloid cells displayed 1204 (derived from 211
miRNA-arms) differentially expressed isomiRs between
natural killer cells (CD56+) and small lymphocytes (CD4+,
CD8+ and CD19+), 773 (from 179 arms) isomiRs between
T-lymphocytes (CD4+ and CD8+) and B-lymphocytes
(CD19+) and 1420 (from 246 arms) between CD14+ and
CD15+ cells. For detailed information reference is made to
http://134.245.63.235/ikmb-tools/bloodmiRs.
As expected, when looking at higher resolution we were
able to detect considerably higher number of cell type spe-
cific isomiRs than by looking only at the miRNA-arms. In
total, we identified 800 isomiRs which were uniquely sig-
nificantly up-regulated in one of the cell types when com-
pared to every other cell type. For lymphoid lineage CD4+
(T helper cells), CD8+ (cytotoxic T cells), CD19+ (B cells)
and CD56+ (NK cells) we identified 31, 5, 57 and 212 cell
type specific isomiRs, respectively, whereas for myeloid lin-
eage CD14+ (monocytes) and CD15+ (neutrophils) cells
we detected 206 and 289 cell type specific isomiRs, respec-
tively (Supplementary Figure S2). The number of identified
isomiRs per cell type was highly correlated with the number
of identified cell type specific miRNA-arms (Pearson’s r =
0.9).
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Figure 6. (A) Differentially expressed miRNAs between lymphoid and myeloid cell lineage; (B) expression levels of blood cell lineage-specific miRNAs.
Each row of the heatmaps represents a sample corresponding to the one of the blood cell types, and each column represents an individual miRNA-arm.
All miRNAs were statistically differentially expressed (FDR ≤ 0.001 and |log2FC| > 1). The Z-score in the heatmaps represents standardized normal-
ized expression values. The unsupervised (agglomerative) hierarchical clustering of miRNAs was performed using Spearman’s correlation distance (1 –
correlation coefficient) as metric and average linkage clustering as linkage criterion.
Modification types of cell type specific isomiRs were sim-
ilarly distributed as in the general population of identified
isomiRs. The most common were 3′ trimming and 3′ ad-
dition modifications, and the least common were 5′ trim-
ming and nucleotide substitutions (Table 1). Interestingly,
on average, only∼56% of isomiRs per cell type were arising
from previously identified cell type specific miRNAs, mean-
ing that the rest were not captured when only looking at
the miRNA-arm level. The complete list of cell type spe-
cific miRNA-arms and isomiRs identified in this study is
provided in Supplementary Table S4.
Identification of novel, blood cell specific miRNAs
In addition tomeasuring the expression of knownmiRNAs,
we also investigated whether novel miRNAs are hidden in
the generated sRNA-Seq data. For that purpose, pooled
data for each blood cell type were analyzed using the de
novo prediction functionality ofmiRDeep2.Overall, we ob-
tained 716 novel miRNA candidates predicted by miRD-
eep2. After removing false positives and performing several
filtering steps (Supplementary Figure S3), we retained 413
most probable novel miRNA candidates and ranked the se-
quences according to their similarity of knownmiRNA fea-
tures using novo-miRank. Of these 413 novel miRNA can-
didates, 52 molecules shared the same seed sequence with
known miRNAs from the taxonomic family of primates
(Hominidae). Characteristics such as genome context (in-
tronic, UTR or intergenic), nucleotide composition, min-
imum free energy (MFE) structure etc. of the novel can-
didates are provided in the Supplementary Table S5. Ad-
ditionally, precursor structures, read signatures and predic-
tion scores of novel candidates are provided in the Supple-
mentary File S1. Moreover, 50 out of 197 common novel
miRNAs were validated by the hybridization method in re-
cent study by Fehlmann et al. (56).
Next, we focused on differential expression of novel miR-
NAs in cell types and quantified novel miRNA candidates
in a sample-wise manner. We detected 76 out of 413 candi-
dates in at least 85% of the samples in at least one cell type,
and 26 of those were identified as cell type specific (Supple-
mentary Figure S4). Interestingly, with our thresholds, un-
like in previous reports, we were not able to identify novel
miRNA candidates within the RBC fraction.
DISCUSSION
Most sRNA-based biomarker studies today investigate
archetype miRNA or miRNA-arm expression in either
serum, exosomes or whole blood, while only a small num-
ber of studies focus on sub-compartments of blood, such as
the peripheral mononuclear cell fraction (PBMCs) or even
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Table 1. Summary of cell type specific isomiRs modification types
Cell type
Number of
isomiRs
5′-trimming
isomiRs
Seed
substituted
isomiRs
3′-trimming
isomiRs
3′ nt-added
isomiRs
nt-
substituted
isomiRs
Multi-
modified
isomiRs
Monocytes (CD14+) 206 44 (21.4%) 1 (0.5%) 112 (54.4%) 82 (39.8%) 1 (0.5%) 70 (34%)
Neutrophils (CD15+) 289 52 (18%) 0 (0%) 166 (57.4%) 142 (49.1%) 4 (1.4%) 99 (34.3%)
B cells (CD19+) 57 7 (12.3%) 0 (0%) 42 (73.7%) 39 (68.4%) 0 (0%) 32 (56.1%)
T helper cells (CD4+) 31 0 (0%) 0 (0%) 26 (83.9%) 15 (48.4%) 0 (0%) 14 (45.2%)
NK cells (CD56+) 212 52 (24.5%) 0 (0%) 161 (75.9%) 135 (63.7%) 0 (0%) 136 (64.2%)
Cytotoxic T cells (CD8+) 5 0 (0%) 0 (0%) 4 (80%) 1 (20%) 0 (0%) 1 (20%)
Total 800 155 (19.4%) 1 (0.1%) 511 (63.9%) 414 (51.7%) 5 (0.6%) 352 (44%)
single cell types. Moreover, even fewer studies are focusing
on isomiR expression in the aforementioned compounds.
Nearly all studies, including our own, report differentially
expressed miRNAs characteristic for a certain condition
or a disease, but in most of the cases it is not further in-
vestigated what are the variations in their sequences, and
which tissues or cell types contribute to the expression pat-
tern. The herein presented detailed miRNA expression cat-
alogue for different cellular and non-cellular components
of healthy human peripheral blood enables the researcher
to assign expression-signatures of single or groups of miR-
NAs and isomiRs to cell types and, thus, gather hypothe-
ses about putative functionality of the respective miRNA
(or its predicted target genes) in the study context. While
previous reports on miRNAs in sorted human blood cells
are mostly based on very few samples (n ≤ 5, see below)
or focused on developmental aspects such as hematopoiesis
(57), a comprehensive miRNA expression catalogue for a
broad range of mature blood cell types currently only exist
for mice (58). Moreover, all of the mentioned studies were
focusing only on archetypemiRNAs and did not explore the
sequence variations and modifications of mature miRNAs.
Given our data, we were able to detect a substantial num-
ber of miRNAs outside transcriptionally active blood com-
pounds. We identified 271 known miRNA species within
RBCs. The results of a paper by Doss et al. (27) are nicely
mirrored in our RBC profiles, although we are able to ex-
pand the catalogue of highly abundant miRNAs in RBCs
with the most abundant miRNAs being present with me-
dian read counts >1000 reads per sample.
Analysis of miRNA sequence heterogeneity showed that
a vast majority of mature miRNAs, which were found to
be expressed in the peripheral blood compounds, are carry-
ing different and often composite sequence modifications.
Within our dataset, we identified sequence variations in
69.0% of detected miRNAs. As already indicated by previ-
ous studies in various human tissues, 3′-end modifications
were the predominant category (10,13,59–61).
Comparing the distributions of different types ofmiRNA
modifications across the studied blood compounds, we
found that 3′ trimming modifications were distributed in a
lineage-specific manner – the closer the hematopoietic pro-
genitors are, the higher are their similarities in the prefer-
ence of 3′ trimming modification. This phenomenon was
not observed in 5′ trimming distributions of isomiRs se-
quences, where the frequencies of modification were dis-
tributed similarly across the cell types, except for neu-
trophils (CD15+) and RBCs (CD235a+) in which the
isomiRs having earlier trimmed nucleotide were more fre-
quent than in another cell types. Similar findings of 5′ trim-
ming preference were observed in serum and exosomes.
These results support the assumption that, in contrast to
isomiRs with 3′ variability, 5′ isomiRs because of seed-
shifting have effects on target selection and the choice of
miRNA-5p/-3p strand for AGO binding (12,18), and pos-
sibly due to that, the intra-group variability of 5′ sequence
variation is lower than in the 3′ end.
One particularly interesting finding is that the overall dis-
tribution of nt-substitution modification within isomiR se-
quences showed a consistent pattern of positions in which
the nucleotides are less frequently substituted, thus, high-
lighting the nucleotides at positions 2–8 (seed site) and 15–
19, respectively, which are known to be important for tar-
get site recognition (62,63). All together this explains the
reduced heterogeneity at those sites.
Another surprising observation relates to our finding
that compositions of 3′ added non-templated nucleotides
in the blood compounds are also lineage-specific. The fre-
quencies of non-templated nucleotides clustered into three
main groups, corresponding to myeloid, lymphoid and
non-cellular compartments (serum and exosomes). Non-
templated additions of isomiRs found in whole blood clus-
tered together with RBCs, which is meaningful because
RBCs are the most abundant cells in blood. It is worth
pointing out that 3′ end uridylated isomiRs are relatively
more common in serum and exosomes than in cells––this
finding is consistent with results by Koppers-Lalic et al.,
where they showed that 3′ end adenylatedmiRNAs are rela-
tively enriched in B-lymphocytes, whereas 3′ end uridylated
isoforms appear overrepresented in exosomes (30). Another
study by Gutie´rrez-Va´zquez et al. demonstrated that 3′ ad-
dition of uridine promotes degradation of these uridylated
miRNAs after T-lymphocytes activation (31). Moreover, it
has been reported that non-templated nucleotide additions
can affect miRNA stability, target identification and target-
ing power (30,60).
Several recent studies already reported miRNA expres-
sion data on single blood cell types, such as natural
killer cells (64), B-lymphocytes (65), T-lymphocytes (29)
and RBCs (27). Two other projects screened the miRNA-
transcriptome usingmicroarray technology in several blood
cell types (26,28). Comparing the results of both studies to
our miRNA-arm expression data, the previously reported
cell type specific miRNA signatures could only be partially
confirmed, as many miRNAs previously reported to be cell
type specific are actually found in other blood cell types
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in our data. All of six cell type specific miRNAs from Al-
lantaz et al. were confirmed within our dataset (26). The
miRNA profile of monocytes and B-cells reported by Lei-
dinger et al. were also completely verified by our find-
ings. The other profiles (T-cells,NK-cells and granulocytes),
however, contained only about half of cell type specificmiR-
NAs that could be confirmed in our data. These differences
most probably arise from distinct miRNA profiling plat-
forms (66) or even different blood cell purification tech-
niques (67). In addition, our data complements the already
knownmiRNAprofiles with numerous other miRNAs, pre-
viously unknown to be specific for certain blood cell types.
The same holds true for studies investigating only a single
blood cell type. Although these reports do not compare dif-
ferent cellular blood compounds, but rather cells in acti-
vated and resting states, thus, they do not report cell type
specific miRNAs; however, a considerable fraction of the
namedmiRNAs is reflected by our cell type specific profiles.
As nearly one half of miRNAs that have previously been re-
ported to be cell type specific are actually present in more
than one cell type in our data, the best explanation for these
discrepancies is the sample size and profiling platform. All
recent studies were conducted on n ≤ 5 samples using mi-
croarrays compared to n > 40 samples using NGS in our
case, which increases the statistical power substantially and
overcomes possible inter-individual variability.
Finally, we determined cell type specific isomiRs of the
human peripheral blood cells. In comparison to miRNA-
arms, we found a substantially higher number of cell type
specific isomiRs. The modification types of these molecules
were commonly distributed as in the general isomiR popu-
lation.An interesting observation is that almost a half of cell
type specific isomiRswere arising frommiRNA-armswhich
previously, in our dataset, were not assigned as cell type spe-
cific, showing that a big proportion of molecules is diluted
when looking only at the miRNA-arm level. However, up
to now there are no reports referring to differential expres-
sion of isomiRs within different blood cells, thus making it
impossible to compare and draw conclusions about these
results.
Taken together, we do not claim that our results are ex-
haustive or cover the entire miRNA-repertoire of healthy
human blood, but they provide the most comprehensive
contribution to date (with n> 40 individuals) toward a com-
plete miRNA inventory of human peripheral blood. Up-
coming reports from bigger research initiatives such as the
international human epigenome program (68) will hope-
fully amend the data with additional cell types and more
exhaustive data on miRNA and especially, on isomiRs
in circulation and exosomes. Moreover, recent techno-
logical developments enabling analyses on the single-cell
level will––as soon as they are applicable for miRNA
analysis––likely also make a significant contribution to-
wards completing the miRNA map of human blood.
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Supplementary Figure S1: Overview of the small RNA transcriptome data. A) The purity of blood cell pop-
ulations after sorting by MACS; B) Raw reads per sample within di↵erent blood compounds; C) Read length
distribution of pre-filtered sequencing reads; D) Composition of filtered reads within di↵erent blood compounds.
The reads were filtered against non-miRNA small RNAs from Rfam (green), viral genomes from RefSeq (yellow)
and viral precursors from miRBase (orange); E) Overall composition of the initial reads per sample in distinct
blood compounds. Due to a small fraction of novel miRNAs, their proportions within most of the samples are
not visible in graphs; F) Number of reads mapped to known miRNAs per distinct blood compound; G) Number
of mature miRNAs detected per individual blood compound. Note: Samples in graphs B, D and E are aligned
in the same order.
Supplementary Figure S2.9: Overview of the small RNA transcriptome data. A) The purity of
blood cell populations after sorting by MACS; B) Raw reads per sample within different blood compounds;
C) Read length distribution of pre-filtere sequencing reads; D) Composition of filtered rea s within ifferent
blood compounds. The re ds were filtered against non-miRNA small RNAs from Rfam (gre n), vira genomes
from RefSeq (yellow) and viral precursors from miRBase (orange); E) Overall composition of the initial reads
per sample in distinct blood compounds. Due to a small fraction of novel miRNAs, their proportions within
most of the samples are not visible in graphs; F) Number of reads mapped to known miRNAs per distinct
blood compound; G) Number of mature miRNAs detected per individual blood compound. Note: Samples
in graphs B, D and E are aligned in the same order.
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Supplementary Figure S2: Heatmap representing the expression levels of blood cell lineage-specific isomiRs. Each
row of the heatmap corresponds to the one of the samples per blood cell types, and each column corresponds to
an isomiR. All molecules were significantly up-regulated (FDR p-value<0.001; |log2FC|>1) exclusively in one of
the cell types. The unsupervised hierarchical clustering of isomiRs was performed using Spearman’s correlation
distance as metric and average linkage clustering as linkage criterion.
Supplementary Figure S2.10: Heatmap representing the expression levels of blood cell
lineage-specific isomiRs. Each row of the heatmap corresponds to the one of the samples per blood
cell types, and each col mn corresponds to an isomiR. All molecules were significantly up-regulated (FDR
p-value < 0.001; |log2FC| > 1) exclusively in one of the cell types. The unsupervised hierarchical clustering
of isomiRs was performed using Spearman’s correlation distance as metric and average linkage clustering as
linkage criterion.
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miRDeep2 predicted miRNAs
716
Novel miRNAs with signal-to-noise ratio   1
624
Novel miRNAs after filtering against human CDS,
ncRNAs (GRCh38) and repetitive sequences (Dfam)
512
Novel miRNAs after filtering based on GC content of known miRNAs
446
Novel miRNAs after filtering out highly correlating candidates
413
Supplementary Figure S3: Filtering pipeline of novel miRNA candidates.
Supplementary Figure S2.11: Filtering pipeline of novel miRNA candidates.
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Supplementary Figure S4: Expression of blood cell specific novel miRNA candidates in di↵erent blood cells.
In the heatmap, rows represent samples and columns represent novel miRNA candidate transcripts which are
exclusively significantly up-regulated (FDR p-value<0.001; |log2FC|>1) in one of the cell types. The Z-score
represents standardized normalized expression values. The unsupervised hierarchical clustering was performed
using Spearman’s correlation distance as metric and average linkage clustering as linkage criterion.
Suppl mentary Figure S2.12: Expression of blood cell specific novel miRNA candidates in
different blood cells. In the heatmap, rows represent samples and columns represent novel miRNA
candidate transcripts which are exclusively significantly up-regulated (FDR p-value < 0.001; |log2FC| > 1)
in one of the cell types. The Z-score represents standardized normalized expression values. The unsupervised
hierarchical clustering was performed using Spearman’s correlation distance as metric and average linkage
clustering as linkage criterion.
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The diagnosis of inflammatory bowel disease still remains a clinical challenge and the most accurate di-
agnostic procedure involves a combination of clinical, endoscopic, histological and radiological parameters.
At present, neither genetic nor serological testing is recommended for routine clinical practice. However,
a multitude of biomarkers has been proposed to complement diagnostics, particularly in case of diagnostic
uncertainty. In the scope of this work we evaluated whether systematic miRNA or miRNA variant expres-
sion profiling, in conjunction with state-of-the-art machine learning techniques, is suitable as a non-invasive
tool for diagnostics of IBD.
Based on microarray technology, expression levels of 863 miRNAs have been determined for whole blood
samples from patients (40 CD and 36 UC, repectively) as well as healthy and inflammatory controls (108 HC
and 130 IC, repectively; see Article II). Subsequently, we identified comprehensive profiles of miRNA expres-
sion patterns being distinctive for each of the traits under consideration. Then we conducted mathematical
modeling to generate computer-based tools utilizing these profiles for diagnostic phenotype prediction. In
this way we were able to reveal highly accurate classification models that distinguish CD and UC among
each other as well as from different types of controls. Relying on a minimal set of not more than 16 miRNAs
being sufficient for sensitive and specific classification, these models hold great promises and should be
further evaluated in independent sample panels.
We employed support vector machines (SVMs) to solve the given diagnostic problems. Regularized instances
of these models, such as the elastic SCAD SVM, incorporate penalties for model complexity to prevent
overfitting and to provide sparse solutions. In the scope of the here-presented study this property has been
used to obtain small sets of miRNAs being suitable for diagnostic application. It is expected that miRNAs
being informative for a particular classification problem are likewise selected when utilizing another modeling
strategy. In this work the miRNA signature selected using the elastic SCAD SVM has been confirmed by
comparably high classification performance of random forests as an independent classification approach. To
obtain more even comparable results, future studies might consider regularized random forests as proposed
by Deng and Runger [1].
To obtain a model applicable with high accuracy to independent data, for each of the given diagnostic
problems we chose the sparsest median performing elastic SCAD SVM along with the corresponding miRNA
signature. Both, the regularization approach and the comprehensive holdout sampling decrease the model’s
probability of being overfitted to the dataset generated for this study. However, due to correlating expression
profiles it is expected that models with matching accuracy potentially incorporate differing miRNAs. For
the same reason more complex signatures may exist which merely incorporate additional highly correlated
miRNAs.
To derive hypothetical biological functions of the here-presented miRNA signatures, we screened current
databases for experimentally validated miRNA-target interactions. Notably, a considerable fraction of the
target genes has been implicated in intestinal diseases. Many of these targets have been identified in recent
IBD GWAS. However, most of the genetic variation detected does not correlate (and thus not interfere)
with miRNA regulatory binding sites. Solely binding sites of hsa-mir-99b, located within the 3’-UTRs of
RAVER2, represent good candidates for further experimental investigation. More complete data on genetic
variation, particularly within the 3’-UTRs of IBD-related genes, is needed for more comprehensive analyses
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of miRNA target genes. In a recent article reviewing genetic studies in IBD, Liu and Anderson conclude that
most of the identified GWAS loci reside in non-coding regions of the human genome [2]. A vast number of
these non-coding variants is assumed to affect gene regulation, which miRNAs play an crucial role in. Future
studies on the here-presented miRNA signatures might therefore give valuable insights into the etiology of
inflammatory bowel disease.
Relying on predefined annealing probes, microarray technology solely allows the detection of annotated
miRNAs and isomiRs, respectively. Next generation sequencing (NGS) technology, instead, enables the
quantification of the entire set of isomiRs being expressed in a given sample. With our biomarker study
utilizing NGS we provide the first discriminative analysis of global sequencing-based isomiR expression in
the context of IBD (see Article III). We examined isomiR expression profiles of 515 individuals, including
75 cases of untreated IBD, 271 cases of treated IBD, 124 healthy (HC) and 45 symptomatic controls (SC).
Based on the resulting data, we identified isomiRs that exhibit differential expression and likewise allow
accurate distinction between the investigated traits. We report standard SVMs to be able to predict disease
phenotypes with a remarkably high accuracy. Penalized SVMs showed comparably lower performance and/or
stability and were therefore investigated in less detail. Due to their sparsity, however, they might provide a
foundation for further functional research.
Previously being dismissed as experimental artifacts, isomiRs are now considered to result from alterations in
miRNA biogenesis. Recent studies show these alterations to vary with respect to gender and ethnicity as well
as tissue and cell type. With our NGS-based study we ultimately provide evidence for the existence of blood-
born isomiRs being specific for IBD-related traits. We furthermore show altered isomiR expression being
dependent on the patients’ treatment regimen. All comparisons between the treatment groups have been
conducted with respect to healthy controls. This approach enables the identification of treatment-induced
differences specific for a given disease. In contrast, differences being treatment-induced but unrelated to the
diseases, have not been considered to ensure the neglection of unwanted biological and technical variation.
Accordingly, reliability of the results has been increased at the cost of overall comprehensiveness of the
study. However, future investigations might consider them to elucidate the role of isomiRs with respect to
treatment response.
Current research on circulating biomarkers usually focuses on miRNAs in either whole blood, plasma or
serum, while only a small number of studies investigates hematopoietic cells. Moreover, even fewer studies
are investigating isomiR expression in these particular cells. As part of this work we present the currently
most comprehensive miRNA expression catalogue of cellular (NK cells, B lymphocytes, cytotoxic T lympho-
cytes, T helper cells, monocytes, neutrophils and erythrocytes) and non-cellular fractions of healthy human
peripheral blood (serum, exosomes; see Article IV). Therewith, we provide a foundation for decomposing
blood-born miRNA expression patterns into its cell-type-specific components.
Moreover, the availability of this unique resource facilitated comprehensive analysis of the cell-type-specific
features of hematopoietic miRNA landscape. We identified sets of miRNAs being specifically DE in each
of the investigated blood compounds. Notably, only subsets of these miRNA signatures could replicate
previous findings. They rather complement reported signatures by adding miRNAs, previously unknown
to be specific for a certain blood cell type. The same holds true for earlier studies investigating only a
single blood cell type. Although these reports do not compare different cellular blood compounds and
therefore do not investigate cell-type-specific expression, a considerable fraction of the named miRNAs is
reflected by our cell-type-specific profiles. Discrepancies between all the studies, however, can probably be
explained by varying miRNA profiling platforms [3] as well as varying blood cell purification techniques [4].
Furthermore, they mirror differences in size and homogeneity of the investigated study samples. Completing
our catalogue of expression profiles, we identified 271, 90 and 51 miRNA species in RBCs, serum and
exosomes, respectively. With these findings we finally confirm previous reports on miRNAs being detectable
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outside the transcriptionally active components of human blood [5, 6].
Cell-type-specific signatures established on the basis of isomiRs instead of archetype miRNAs turn out to
be significantly larger in size. This suggests that considering sequence variation adds significantly to the
distinguishability of cell-type-specific miRNA profiles. However, the description of isomiRs within different
blood cells represents a unique feature of our study. We detected sequence modifications in 69.0% of the
miRNA variants. A combination of more than one type of sequence variation has been observed in 74.0%
of the isomiRs. We identified non-templated 3’ additions (observed in 77.0% of isomiR sequences) to be
distributed in a lineage-specific manner. Thus, the frequency distribution of added nucleotides clustered
into three main groups, corresponding to myeloid, lymphoid and non-cellular compartments. Non-templated
additions detected in RBCs, in turn, formed an additional cluster with whole blood. The observed frequencies
are in line with previous reports on nucleotide distribution in B and T lymphocytes [7, 8]. It has been
reported that non-templated nucleotide additions modulate miRNA stability as well as targetin efficiency.
According to the clustering, these modulations likewise are expected to show a lineage-specific pattern [7, 9].
Additional lineage specificity we discovered for the frequencies of 3’ trimming modifications (detectable in
75.6% of isomiR sequences). Particularly, the fraction of unique sequences at positions -3 and -2 has been
estimated to be higher in lymphoid than in myeloid cells. The fraction at positions -1 to 3, in turn, has
been estimated to be higher in myeloid than in lymphoid cells. Elucidating the functional significance of
these observations needs further investigation. One particularly interesting finding relates to the overall
distribution of nt-substitution (detectable in 6.2% of isomiR sequences). We observe decreased frequencies
of this modification type at positions 2–8 and 15–19, respectively, known to play a crucial role in the
recognition of miRNA target sites [10, 11].
Certainly, the clinically most relevant objectives of this work include the accurate distinction of the major
IBD phenotypes among each other as well as from healthy controls. Employing microarray-based miRNA
expression profiling we estimated these tasks to be solvable with median balanced accuracies of up to 91.70%
(CD vs. UC) and 98.10% (CD or UC vs. HC), respectively (see Article II). For sequencing-based isomiR
expression profiling, we generated solutions performing with median balanced accuracies of 78.57%/78.83%
(untreated/treated CD vs. UC) and 100.00%/98.28% (untreated/treated CD or UC vs. HC), respectively
(see Article III). Hence, performance estimates for the distinction from healthy controls by far exceed
those available for established biomarkers (ACCA, ASCA, ALCA, AMCA, anti-C and anti-L). The same
holds true for our performance estimates for the distinction of CD from UC being compared to established
biomarkers (ACCA, ALCA, AMCA, anti-C, anti-L, anti-OmpC and pANCA). Remarkably, they deceed
the performance of ASCA or ASCA+ANCA. However, in contrast to our findings, the estimates provided
by literature about these biomarkers exhibit substantial instability (balanced accuracy ranging from 59.50
to 86.00%, see Article I). Notably, conducting a valid comparison of performance estimates assumes the
availability of a representative study cohort of asymptotic size for which every biomarker of interest has
been evaluated. The lack of such a dataset introduces uncertainty while classifying the clinical value of the
here-presented candidates. Accordingly, a conclusive assessment needs further investigations.
Pairwise distinction of the traits under consideration has been implemented utilizing different types of
support vector machines (SVMs). Aiming for sparse solutions incorporating miRNA signatures of minimal
size, the microarray-based study (Article II) employed penalized models, such as ridge, LASSO, elastic net,
SCAD and elastic SCAD penalized SVMs. Allowing for more comprehensive signatures, the sequencing-
based study (Article III) then focused on unpenalized models, including linear, radial and polynomial SVMs.
We provide evidence for SVMs being a valuable tool for non-invasive prediction of inflammatory phenotypes,
irrespective of the penalty and kernel function being used. However, the most accurate models are not
sparse.
Unlike earlier studies the here-presented investigations have not been restricted to binomial classification
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problems (see Article I). We rather evaluated joint discrimination of arbitrary combinations of the given
traits (Article II: CD, UC, IC and HC; Article III: CD, UC, SC and HC). The predictive performance of
the resulting multinomial classification models thereby has been estimated to be remarkably high, for both
the microarray- as well as the sequencing-based analysis. In favor of generalizability, we only considered the
main phenotypes. However, extensions to multinomial models further stratifying with respect to clinical
parameters, such as disease location and disease activity, do not represent a technical challenge.
Cortes and Vapnik introduced SVMs as binomial classifiers [12]. Other groups introduced formulations of the
model that allow multinomial classification problems to be solved in a single constrained optimization [13,
14]. However, we employed the classical strategy of reducing single multinomial classification problems
to sets of binomial classification problems, providing the basis for subsequent majority voting [15]. This
method features numerous favorable properties. Thus, it enables the reuse of single binomial models for the
construction of a multitude of multinomial models. Furthermore, it does not restrict the binomial models
to be of a particular type. In the course of this work we combined SVMs employing different kernels.
However, the chosen strategy allows a combination of models of arbitrary nature and thereby introduces
the possibility for post-hoc improvement of here-presented phenotype predictions. Notably, our approach
likewise allows an improvement by incorporation of unrelated explanatory variables. These might include
genomic, epigenomic or metagenomic information.
The model-based approach to (multinomial) prediction of inflammatory phenotypes represents a unique
feature of this work. Direct comparisons to earlier studies are aggravated for this reason. However, miRNA
expression patterns being replicably observed in independent datasets are expected to allow for the derivation
of models of comparable quality. In accordance to this assumption we rely on consistency of expression
patterns in regard to previous work to evaluate the validity of our models. Thus, our microarray data
confirms 45.0%, 71.4% and 75.0% of deregulated miRNAs being reported by Wu et al. [16], Duttagupta et
al. [17] and Chen et al. [18]. Agreement of expression patterns observed by Zahm et al. [19] and Paraskevi
et al. [20], in turn, amounts to 100%. The significance of our sequencing-based findings we evaluate in terms
of overlapping sets of differentially expressed isomiRs and miRNA arms, respectively. Based on enrichment
analysis we provide evidence for non-random overlaps between our study and earlier works, including Zahm
et al. [19], Paraskevi et al. [20] and Schaefer et al. [21]. Employing the same methodology we confirm our
biomarker studies with one another (see Article II and III).
Nearly all biomarker studies, including our own, employ varying abundance of miRNAs as an indicator
for differential expression being associated with disease. However, accumulating evidence suggests those
differences likewise being attributable to the cell type composition of the tissue under investigation. Whereas
the extent of cell-type-specific miRNA expression varies depending on the tissue type, it certainly can
not be neglected. First evidence for the blood cell composition contributing to the levels of miRNAs in
circulation has been provided by Pritchard et al., questioning the validity of a substantial fraction of proposed
cancer biomarkers [5]. Since then, only a few research projects elaborated on the miRNA transcriptomes of
cellular components of human peripheral blood [6, 22–24]. Ultimately, our group presented a catalogue of
miRNA/isomiR expression pattern being specific for blood cell lineages (lymphoid and myeloid) as well as
individual blood cell types (CD4+, CD8+, CD14+, CD15+, CD19+, CD56+ and CD235a+) (see Article
IV). Still, this resource represents the most comprehensive contribution toward a complete miRNA inventory
of the blood. Along with cell count data it will facilitate the discrimination between expression changes being
attributable to blood cell composition and disease. Models incorporating this additional layer of information
might have increased clinical utility. However, further studies are needed to verify this hypothesis.
All the data presented throughout this thesis has been designed, sampled, reviewed and analyzed based on
the premise of obtaining generalizable results. Depending on availability of the corresponding meta-data,
known sources of technical and biological variability have been accounted for. However, unknown sources
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of variability might exist. This holds true especially for inflammatory, auto-immune diseases as being
investigated in the scope of this work, since intra- and inter-individual miRNA-expression variability might
be altered by numerous comorbidities. Further research is likewise needed to investigate environmental
factors affecting miRNA expression. Cohorts being characterized in even more detail on both, the data
and the meta-data level, might enable the identification of these sources and alleviate translation to clinical
practice.
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Conference attendances
[1] “International Symposium on Integrative Bioinformatics, August 20–22, 2008, Lutherstadt Witten-
berg, Germany”.
[2] “German Conference on Bioinformatics 2009, September 28–30, 2009, Halle (Saale), Germany”.
[3] “International symposium ”Predictive Genetic Testing, Risk Communication and Risk Perception”,
November 21–22, 2011, Robert Koch Institute, Berlin, Germany”.
[4] “Annual Meeting of the AGD 2012, October 12–13, 2012, Potsdam, Germany”.
[5] “International 4th Cluster Symposium ”Inflammation at Interfaces”, February 22–23, 2013, Hamburg,
Germany”.
[6] “Dritter Workshop zur Genetischen Epidemiologie ”Genetic Variants, Omics, and Individualized Pre-
vention”, April 10–12, 2013, Grainau, Germany”.
[7] “ASHG 2013 Annual Meeting, October 22–26, 2013, Boston, Massachusetts, USA”.
[8] “Annual Meeting of the AGD 2014, October 10–11, 2014, Potsdam, Germany”.
[9] “UEG Week 2014, October 18–22, 2014, Vienna, Austria”.
[10] “International 5th Cluster Symposium ”Inflammation at Interfaces”, February 26–28, 2015, Kiel, Ger-
many”.
[11] “International RTG Symposium ”Genes, Environment and Inflammation”, June 1–3, 2015, Kiel, Ger-
many”.
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[12] “ASHG 2015 Annual Meeting, October 6–10, 2015, Baltimore, Maryland, USA”.
[13] “DAGStat 2016, March 14–18, 2016, Go¨ttingen, Germany”.
[14] “e:Med Meeting 2016 on Systems Medicine, October 4–6, 2016, Kiel, Germany”.
[15] “ISMB/ECCB, July 21–25, 2017, Prague, Czech Republic”.
Activities and memberships
[1] “Associate membership, Cluster of Excellence 306 “Inflammation at Interfaces””.
[2] “Peer reviewing, “Genomics, Proteomics & Bioinformatics””.
[3] “Peer reviewing, “Human Mutation””.
Workshop attendances
[1] “Agfa ORBIS, December 13, 2011, UKSH Akademie, Kiel, Germany”.
[2] “3. Workshop der Deutschen i2b2-Usergroup, February 27, 2012, TMF e.V., Berlin, Germany”.
[3] “Training in Genetischer Epidemiologie, April 19–21, 2012, University of Lu¨beck, Lu¨beck, Germany”.
[4] “TMF school extra “Logical Reasoning in Human Genetics”, September 24–28, 2012, TMF e.V.,
Berlin, Germany”.
[5] “Inflammation at Interfaces Indian Summer School “A Comprehensive View of Experimental Ap-
proaches in Inflammation Research”, November 19–21, 2013, Kiel, Germany”.
[6] “Workshop Theoretical Biology, February 28, 2014, Plo¨n, Germany”.
Trainings and coachings
[1] “Feedback culture. Helga Ha¨nsler, Kiel, Germany”.
[2] “Oral presentation skills. Carla Westerheide, ProSciencia, Lu¨beck, Germany”.
[3] “Coaching. Helga Ha¨nsler, Kiel, Germany”.
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